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Bone tissue engineering has been proposed as a more effective and efficient
alternative option for bone repair and regeneration. Here, we propose a two-pronged
approach for enhance scaffold-guided bone regeneration. Second to developing optimized
PLGA optimally-porous scaffolds, we will pre-vascularize our constructs in vitro in order
to reduce vascularization time, and enhance bone formation in vivo. We will prevascularize our constructs by seeding and culturing them with a combination of two cell
populations required for angiogenesis and osteogenesis: peripheral blood derived endothelial progenitor cells (EPCs) and bone marrow derived -mesenchymal stem cells
(MSCs). Previous studies have demonstrated EPCs and MSCs promote enhanced bone
regeneration via the stimulation of neo-vascularization. We will systematically examine
of the combination of these two required cell populations and the optimally-porous
PLGA scaffolds, and the resultant effects on healing critically sized segmental bone
defects. We hypothesize that our pre-vascularized, optimally-porous PLGA scaffolds will
substantially improve the performance of PLGA microsphere scaffolds by promoting
angiogenesis, and significantly enhancing bone formation in vivo.
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Life takes you to unexpected places,
Love brings you home.
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1.

INTRODUCTION

Oral/maxillofacial and orthopaedic surgeons perform over two million bone
replacement procedures annually, a figure lending bone as the second most transplanted
tissue after blood (1, 2).

Bone replacements/grafts are necessitated when patients

experience bone loss due to high-energy trauma, tumor resection, revision surgery,
developmental deformities, infection and non-union fractures, in addition to dental bone
loss as a result of missing teeth and periodontal disease (3, 4). However, all currently
available treatment options for bone repair or regeneration (i.e., autografts, allografts and
synthetic materials) may present very serious risks. Although autografts are considered
the “gold standard” and represent over half of bone substitutes, they are limited by the
amount of available patient bone volume, and are also associated with donor site
infection

and

morbidity

(5-7).

Allografts,

isolated

from

cadavers,

involve

immunogenicity and disease transmission risks (8, 9). Also, synthetic materials (i.e.,
metals, plastics and ceramics) often require follow-up surgeries due to fatigue, fracture,
and toxicity of the material (10). Thus, there is a warranted search for superior bone
replacement methods to overcome the drawbacks of the current treatment options.
Bone tissue engineering (BTE) has been proposed as a more effective and
efficient alternative option for bone repair and regeneration. BTE involves the
combination of biodegradable and porous scaffolds, with or without the use of boneforming cells and growth factors, to regenerate bone (11-14). The success of the scaffoldbased bone regeneration approach critically depends on the effectiveness of the
biodegradable scaffold used, as it serves as a temporary, mechanically-stable matrix for
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cells to infiltrate and proliferate. Scaffold pore structure (i.e., pore size and
interconnectedness) is an essential consideration in the development of scaffolds to
ensure proper cell growth, migration and nutrient flow (15). Scaffolds currently designed
with small pore sizes (i.e., approximately 100 µm) display in vitro and in vivo osteoblast
survival and bone formation limited to the periphery, due decreased oxygen and nutrient
diffusion throughout the scaffolds (16-22). On the other hand, studies have demonstrated
scaffolds with large pore sizes (i.e., >400 µm) increase osteoblast proliferation and
differentiation throughout the entire scaffold, due to enhanced mass transport of oxygen
and nutrients and neo-vascularization (17, 23-26). However, scaffolds with larger pores
are mechanically less stable than small-pored scaffolds, and are not mechanically
compatible with human bone (27-30). Hence, sizing pores to achieve the necessary
balance of cell growth and mechanical support is critical.
This work focuses on poly(85 lactide-co-15 glycolide) (PLGA) microsphere
scaffolds. PLGA has been recognized for its biocompatibility, as well as its recent
approval by the United States Food and Drug Administration (FDA) as a biodegradable
material for certain biomedical devices (31, 32). For BTE applications, current PLGA
scaffolds developed via a microsphere sintering technique have a unique advantage as
they display mechanical properties in the range of human cancellous bone (31).
However, the current PLGA microsphere scaffolds with small pore sizes (i.e. ~100 µm)
fail to provide the prerequisites required for optimal bone regeneration (i.e. a stable
oxygen and nutrient supply), limiting bone regeneration only to the scaffold surfaces (33,
34). We propose the generation of optimal PLGA microsphere scaffolds with optimallysized pores to balance the positive and negative features of the previously mentioned pore
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size ranges, and also allow for homogenous bone regeneration and neo-vascularization,
while still retaining human bone-mechanical compatibility.
In addition to the fabrication of an effective BTE scaffold, establishing a
sufficient vascular network in a timely manner is a crucial requirement for optimal bone
tissue growth (35). This is clearly demonstrated in large BTE constructs that fail to
support neo-vascularization throughout the construct, as seeded cells do not survive due
to hypoxia and insufficient nutrition (36, 37). Thus, the rate and range of vascular growth
determines the efficiency of new bone formation (38, 39). Although the objective of
fabricating our PLGA optimally-porous scaffolds with increased interconnectivity and
optimal engineering pore size is to enhance bone growth by improving neovascularization, this approach presents limitations. In situ neo-vascularization of tissue
engineered bone is very slow to meet the nutritional requirements of osteoblasts, as it
occurs over a course of several days to weeks for the center of the implanted constructs to
become perfused (35).
Thus, we propose a two-pronged approach for enhance scaffold-guided bone
regeneration. Second to developing optimized PLGA optimally-porous scaffolds, we will
pre-vascularize our constructs in vitro in order to reduce vascularization time, and
enhance bone formation in vivo. We will pre-vascularize our constructs by seeding and
culturing them with a combination of two cell populations required for angiogenesis and
osteogenesis: peripheral blood derived -endothelial progenitor cells (EPCs) and bone
marrow derived -mesenchymal stem cells (MSCs) (40-48).

Previous studies have

demonstrated EPCs and MSCs promote enhanced bone regeneration via the stimulation
of neo-vascularization (47, 49, 50). We will systematically examine of the combination
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of these two required cell populations and the optimally-porous PLGA scaffolds, and the
resultant effects on healing critically sized segmental bone defects. We hypothesize that
our pre-vascularized, optimally-porous PLGA scaffolds will substantially improve the
performance of PLGA microsphere scaffolds by promoting angiogenesis, and
significantly enhancing bone formation in vivo. Upon the completion of the proposed
specific aims, we will have addressed a significant challenge in the field of scaffoldbased BTE and its clinical applicability towards bone defect repair and regeneration in
oral/maxillofacial and orthopaedic surgery.
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2.

BACKGROUND

Bone grafts are utilized in a wide array of clinical settings to augment bone repair
and regeneration. Bone defect repair via tissue engineering approach is perceived as a
better approach as the repair process may leave with the patient own tissue by the time
the regeneration is complete (11, 51, 52). Currently, the United States, as well as other
countries worldwide, are experiencing an exceedingly high demand for functional bone
grafts, as the statistics have risen above half a million recipent patients and costing over
$2.5 billion annually in the United States. This figure not only doubles on a global basis,
but is also expected to double by 2020 due to a variety of factors, including the growing
baby boomer population and increased life expectancy (53).
Extensive studies have reported on considerable shortcomings, limitations and
complications of current clinical treatments for bone repair and regeneration, which
include autologous and allogeneic transplantations by using autografts and allografts
(Table 2-1) (5, 7, 53-57). To date, autografts serve as the gold standard for bone grafts as
they are histocompatible and non-immunogenic, and offer all the imperative properties
required of a bone graft material.

Specifically, autografts possess the essential

components to acheive osteoinduction (i.e., bone morphogenetic proteins (BMPs) and
other growth factors), osteogenesis (i.e., osteoprogenitor cells) and osteoconduction (i.e.,
3D and porous matrix). However, autografts involve harvesting bone from the patient’s
iliac crest, and thus, requires a second operation at the site of tissue harvest (58).
Autologous bone transplants are very expensive procedures, and may result in significant
donor site injury and morbidity, deformity, scarring, as well as surgical risks, including
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bleeding, inflammation, infection and chronic pain (6, 59, 60). Autografts, further, may
be a null treatment option in cases where the defect site requires larger volumes of bone
than is feasible or available. Allografts represent the second most common bone grafting
technique and involves transplanting donor bone tissue, often from a cadaver. Allogeneic
bone is also likely histocompatible, and is available in various forms, including
demineralized bone matrix (DBM), morcellised and cancellous chips, cortico-cancellous
and cortical grafts, and osteochondral and whole-bone segments, depending on the host
site requirements. In comparison to autografts, allografts carry risk of immunoreactions
and transmission of infections, and reduced osteoinductive properties and no cellular
component, since donor grafts are devitalized via irradiation or freeze-drying processing
(8-10). Although less than autografts, allogenic grafts come with substantial cost issues.
Further, the bone grafting market is experiencing an obvious unmet supply and demand
as there is currently a shortage in allograft bone graft material (61). Other commonly
used bone repair techniques may involve distraction osteogenesis, bone cement fillers and
bone morphogenic proteins.

Although the previously mentioned clinical interventions

have been shown to improve repair of bone, none possess all the ideal characteristics:
high osteoinductive and angiogenic potentials, biological safety, low patient morbidity,
no size restrictions, ready access to surgeons, long shelf life, and reasonable cost.
The field of bone tissue engineering (BTE) was initiated nearly three decades ago.
As seen in Figure 2-1, interest and progress in the BTE field has seen tremendous growth
over the years, with and exponentially increasing number of studies and reviews
published on the PubMed database since the mid-1980s. The field of BTE is aimed to
create an alternative treatment option that would ideally eliminate the previously
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described issues of current clinically used treatments (i.e., donor site morbidity, limited
availability, immune rejection and pathogen transfer) (62).

BTE requires the

collaborative efforts of scientists, engineers and surgeons alike in order to achieve this
ultimate goal of creating bon
bone grafts that enhance bone repair and regeneration.
regeneration

The

classic BTE paradigm highlights several key players; (i) a biocompatible scaffold that
closely mimics the natural bone extracellular matrix niche, (ii) osteogenic cells to lay
down the bone tissue matrix,
atrix, (iii) morphogenic signals help direct the cells to the
phenotypically desirable type, and (iv) sufficient vascularization to meet the growing
tissue nutrient supply and clearance needs. Specifically, as seen in Figure 2-2, upon
implantation, the construct may influence the host by releasing osteogenic and/or

Figure 2-1. (A) Published articles on bone tissue engineering since mid-1980s
mid
on
PubMed. (B) Break-down
down of the articles published in 2011 according to bone tissue
engineering focus (i.e., biomolecules, cells, matrices, and other, including
vascularization approaches and bioreactors).
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Table 2-1. Bone graft options for bone repair.
Bone
Graft

Structural
Strength

Osteoconduction

Cancellous
Cortical

No
+++

+++
++

Osteoinduction
Autograft
+++
++

Osteogenesis

Disadvantages

+++
++

- considered gold standard
for repairs of bone defects
- contains osteoprogenitor
cells capable of synthesizing
new bone, and a structural
matrix that acts as a scaffold
- limited supply
- donor-site pain, infection,
morbidity can be as high as
25%
- required secondary surgery

Cancellous
Cortical

No
+++

++
+

Allograft
+
+

No
No

+

No

- imunogenic response by
the host to the foreign tissue
of the graft
- potential for disease
transmission
- plentiful supply
- prepared from cadaveric
human bone
- contains noncollagenous
proteins: type 1 collagen
(provides the
osteoconductive scaffold for
osseous in-growth), and
osteoinductive growth
factors (BMPs, fibroblast
growth factor, insulin-like
growth factor, plateletderived growth factor, and
TGF-β)
- available in several forms,
including freeze-dried
powder, granules, gel, putty,
and strips

Demineralized
Bone
Matrix
(DBM)

No

+

Coralline
HA

+

++

Bone graft substitutes
No
No
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- FDA approved in 1992
- produced from marine
coral exoskeleton that have
pore structures resembling
cancellous bone
- effective for managing
metaphyseal defects
- not highly resorbable:
blocks of implanted coralline
HA remain for 10 years

Collagenbased
matrices

No

+

No

No

Calcium
phosphate

+++

++

No

No

Calcium
sulfate

No

+

+

+

Bioglass

+

++

++

++

Biodegrada
ble
Polymers
(i.e.,
PLGA)

+

++

No

+
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- approved by FDA in 1991
- xenografts consisting of
sponge-like strips of bovine
collagen combined with
hydroxyapatite
- Collagraft (Collagen / HA /
Tri-calcium phosphate,
Zimmer), Healos (Collagen /
HA, Depuy)
- capable of
osteoconduction and
osseointegration
- injectable calcium paste
has 4 to 10 times the
compressive strength of
cancellous bone
- calcium phosphate cement
has the highest mechanical
compression strength of any
of the osteoconductive bonegraft substitutes
- 95% of calcium phosphate
is resorbed in 26-86 weeks
- approved by FDA in 1996
- calcium sulfate resorbs in
4-12 weeks, making it the
quickest of any of the
osteoconductive products
currently available
- wound drainage
occasionally is noted and is
hypothesized to be the result
of the osmotic effect of the
calcium sulfate
- osteoconductive void filler
- available from numerous
companies (Osteoset,
Calceon 6, Bone Blast, etc.)
- mimics mineral
composition in bone
- tunable porosity and
mechanical strength
depending on form
- various polymers (PLGA,
PLLA) release acidic
byproducts
- abundant supply
- no risk of disease
transmission

vasculogenic growth factors (i.e., growth factor-releasing scaffold, scaffold with growth
factor analogs, or seeded with platelet-enriched plasma), or by housing cells that are
genetically engineered to or naturally release growth factors. In turn, accelerated cell
homing, vascularization and bone regeneration of the defect site results. Although much
progress has been made, there still are many crucial hurdles yet to be cleared on the way
to BTE becoming a true clinical reality.

The following is a review of critical

consideration, advances and obstacles for functional BTE.

Figure 2-2. Schematic illustration of bone tissue engineering paradigm. Factors
from the implanted graft at the defect site that influence the host response may
include growth factors (or their analogs, or from platelet-enriched plasma), and
cells (genetically- modified to release factors, or naturally produce factors). In
response, cell homing and enhanced vascularization and bone regeneration will
occur.
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2.1.

Fundamentals of Bone And Developmental

Biology
Bone tissue engineering (BTE) is based on the understanding of bone structure,
mechanics and tissue formation as it aims to induce new functional bone tissues.

In

other words, in order to successfully regenerate or repair bone, knowledge of the bone
biology and its development is quite essential.
Bone possesses the ability to perform a wide array functions, and respond to a
variety of metabolic, physical and endocrine stimuli. Bones represent (1) the foundation
for our bodily locomotion, (2) provide load-bearing capacity to our skeleton and
protection to our internal organs, (3) house the biological elements required for
hematopoiesis, (4) trap for dangerous minerals (i.e., lead), as well as (5) maintain the
homeostasis of key electrolytes via calcium and phosphate ion storage. In addition, it is
engaged in a constant cycle of resorption and renewal, undergoing continual chemical
exchange and structural remodeling due to both internal mediators and external
mechanical demands (11). Bone has been previously, and most appropriately referred to
as the ultimate smart material for its scar-less regenerative capacity. Functional bone
tissue engineering requires that the newly restored bone to be fully integrated with the
neighboring host bone, and importantly, possess the ability to perform the previously
mentioned functions of native bone.
Bone is a highly dynamic and diverse tissue both, structurally and functionally.
Macroscopic structure and mechanical properties of the various two hundred plus bones
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in the human skeletal system are largely influenced by distinct loading conditions.
Skeletal structures range from being long (i.e., tibia, ulnar, etc.), short (i.e., phalanges,
etc.), flat (i.e., skull, sternum, etc.) and irregular (i.e., pelvic, vertebrae, etc.). Bone
functions range from locomotion, to vital organ protection. Bone tissue may also either
take on a compact (i.e., cortical bone) or trabecular (i.e., cancellous bone) pattern
arrangement, ranging in mechanical strength and modulus.

Despite these complex

features and forms, it has a relative simplicity in terms of its microscopic, hierarchical
architecture. Specifically, bone extracellular matrix (ECM) is comprised of both a nonmineralized organic component (predominantly type-1 collagen) and a mineralized
inorganic component (composed of 4 nm thick plate-like carbonated apatite mineralites).
The nano-composite structure (tough and flexible collagen fibers reinforced by
hydroxyapatite crystals) is integral to the requisite compressive strength and high fracture
toughness of bone (63).

2.1.1.

Bone Development

Bone formation occurs via two very distinct pathways (intramembranous and
endochondral). In either case, mesenchymal cellular condensation first occurs and serves
as a template for the subsequent bone formation.

Intramembranous bone formation

involves mesenchymal progenitor cells differentiating directly into osteoblasts, and the
subsequent development of parts of the mandible and clavicle, and many cranial bones.
Most bones in the body (i.e., all long bones and vertebrae), however, are formed through
endochondral bone formation. This process involves mesenchymal progenitor cells first
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differentiating into chondrocytes, which are responsible for depositing a cartilaginous
template that is later, mineralized and replaced by bone.
Although there are distinct differences in the bone composition and structure
formed via endochondral and intramembranous ossification, several molecular regulators
are shared (64, 65). For instance, several key molecules including Indian Hedgehog
(Ihh), parathyroid hormone related peptide (PTHrP), bone morphogenetic proteins
(BMPs), vascular endothelial growth factor (VEGF) and fibroblastic growth factors
(FGFs) are critical regulators in both processes (66). In endochondral ossification, BMPs
are responsible for the initiation of mesenchymal condensations, and Ihh and PTHrP form
a critical feedback loop that mediate the balance between chondrocyte proliferation and
hypertrophy and regulate the thickness of the growth plate. Likewise, during
intramembranous bone formation, these key players are required to induce uncommitted
mesenchymal progenitor cells along the osteogenic pathway as pre-osteoblasts, which coexpress chondrocytic and osteoblastic markers simultaneously. Furthermore, in both
processes, bone remodeling is required for the maintenance of all normal healthy bone,
which involves a balance between osteoclastic bone resorption and osteoblastic bone
formation (67).

2.1.2.

Bone Defect Repair

Interestingly, upon fracture, bone is repaired by a process that recapitulates many
of the events of both intramembranous and endochondral bone formation, and uniquely
heals without the formation of scar tissue (Figure 2-3) (68, 69). Initially, hematoma
formation is accompanied by an inflammatory response, and the recruitment of many of
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the signaling molecules involved in the regulation of new bone formation (i.e., ILs, TNFα, FGFs, BMPs, PDGF, VEGF, etc.). At the cortex and periosteum, intramembranous

Figure 2-3. Schematic illustration of steps involved in bone defect repair.

bone formation immediately occurs. The external soft tissues stabilize the fracture by the
formation of a callus, which subsequently undergoes chondrogenesis, and then a process
highly similar to endochondral ossification. More specifically, after the callus forms,
chondrocyte proliferation decreases, as they begin to mature (i.e., hypertrophy) and
calcify the matrix.

In-growing blood vessels carry in chondroclasts, which are

responsible for resorbing the calcified cartilage, and osteoblastic progenitors, which begin
the process of new bone formation. The mechanical continuity of the cortex is achieved
via subsequent remodeling of the newly formed bone.
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The question remains, what is the optimal method for bone regeneration? Should
BTE focus more of on bone development processes or bone defect repair?

In my

opinion, BTE should not exclusively focus on one or the other, but instead both. In
situations requiring bone regeneration, the initial events always involve hematoma
formation and an early inflammatory response, which is largely responsible for the
recruitment of host cells and release of critical signaling molecules.

From there,

emulation of some aspects of normal bone tissue development and remodeling may hold
the key to the future success of BTE. Seminal developmental biology principles that may
help the future success of BTE include:
(1) the use of pluri- or multi- potent stem cells;
(2) the identification of critical genes, growth factors, and signal
transduction cascades that mediate bone formation;
(3) the physical process of bone formation;
(4) complex interactions between epithelium and mesenchyme within the
underlying connective tissue;
(5) the understanding of mesenchyme encoding tissue-specific patterns;
(6) the understanding that normal tissue healing involves progressive
remodeling and restructuring of pre-existing tissue structures,
(7) the importance of the tissue microenvironment’s physical properties
(i.e., “mechanotherapy”) and
(8) angiogenesis and neo-vascularization of the newly formed bone tissue.

Incorporation of developmental biology insights will critically impact future
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tissue engineering approaches. For instance, inclusion of appropriate extracellular matrix
molecules or adhesive ligands that target stem cells mediating earlier stages of tissue
remodeling and regeneration (70). Also, for the promotion of angiogenesis, development
of scaffolds that incorporate growth factors and possess the necessary porosity for
vascular ingrowth (16). Further, engineering micro- and nano- meter featured surface
topography of these scaffolds is critical for directing cellular adhesion, spreading, and
proliferation. On a broader scale, for successful BTE, it is critical to develop a scaffold
that is inspired by the natural processes of developmental biology and promotes tissue
remodeling, and not just simply supports final tissue form and function.

2.2.

Recent Advances in Bone Tissue Engineering

(BTE)

Although bone is a highly vascularized tissue and has the ability to regenerate,
beyond a critical point, clinical intervention measures are required. It is the hope that
bone tissue engineering will be the future treatment of choice, as it will likely eliminate
many of the pitfalls and concerns of current treatments. Here, I discuss the status and key
issues for BTE components (i.e., scaffolds, cells and vascularization).

2.2.1.

Biodegradable Scaffolds

2.2.1.1.

Scaffold Mechanical Integrity
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A key feature of BTE scaffolds is to provide temporary mechanical integrity at
the defect site, until the bone tissue is repaired or regenerated, and normal biomechanical
function is restored. It is established that in order for the bone tissue engineering scaffold
to be “functional” immediately upon implantation, its biomechanical properties must
match the physical demand of the healthy surrounding bone (71).

In addition,

mechanical strength of the scaffold affects the mechanotransduction of the adherent bone
cells on the scaffold, which plays a critical role in the bone repair and remodeling
processes. It has been proposed that, generally, the structural biomechanics of the BTE
scaffold is related to the osteoconductive properties of the scaffold, while
mechanotransduction is related to its potential osteoinductive properties (72).
Biomechanical stimuli on cells due to the scaffold deformation largely influences
osteoinduction (i.e., bone ingrowth from the host). Therefore, as suggested by Sikavitsas
et al., a mechanotransduction strategy may be used to control the function of bone cells in
vivo by designing a scaffold with mechanical properties that allow ‘osteoinductive fluid
flow’ in the scaffold.

By combining 3D imaging and numerical simulation of scaffold

physical properties, it was verified that a threshold permeability of ~3 x 10-11 m2 was
necessary for inducing vascularization and mineralization in the bone graft (73, 74).
The BTE biomechanical paradigm has been well described in a step-wise fashion,
where each step holds the mechanical aspects of the scaffold central to insure the safety
of the surgical procedure using a BTE scaffold (Figure 2-4) (72). The first step, which
involves the bone mechanical properties and loading conditions, are analogous to the
primary fixation of the scaffold. At this point, the BTE scaffold should not induce a
stress-shielding effect, resulting in peri-scaffold bone resorption as seen in the metallic
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joint implants. Also, the elastic property of the BTE scaffold should not exceed that of

Figure 2-4. Illustration of a three-step biomechanical paradigm in BTE. In the first
step, upon implantation, it is critical that the mechanical properties of the BTE
scaffold should closely match that of the surrounding host bone tissue and loading
conditions to reduce the stress-shielding effect. The second step involves interface
biomechanics, and should allow for interface scaffold-bone mechanotransduction
for enhanced osteointegration of the scaffold. Lastly, as the scaffold degrades,
ingrowing bone tissue will begin to support the mechanical load of BTE scaffold.
Adapted from Pioletti et al. (72).
bone in order to maintain a proper mechanical stimulation on the peri-scaffold bone,
which is driven by the loading conditions.

The second step involves interface

biomechanics, and may be identified as the secondary fixation. Here, the mechanical
properties of the BTE scaffold may be adapted to generate interface scaffold-bone
mechanotransduction, which has been shown to influence tissue differentiation and
osteointegration of the scaffold (75). For the third step, which may be termed ‘final
fixation,’ involves scaffold evolution, and the ingrowing bone offering support to the
mechanical load as the BTE scaffold degrades.

Thus, each step revolves around

mechanical aspects, which induce a biological reaction in and around the BTE scaffold
via mechanotransduction. It has been suggested that the separations between these steps
may be utilized as an engineering approach in the mechanical design of bone scaffolds.
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Ideally, if mechanical considerations can be used to confer osteoinductivity to a BTE
scaffold, the dependency of using osteogenic factors and bioreactors may be reduced, and
an off-the-shelf product could be obtained (76).
Mechanical properties of human bone vary tremendously according to location
and function (i.e., load or non-load bearing). Again, the restorative scaffold’s mechanical
properties should be modulated or tailored to match the demands of that at the defect site,
in order to decrease or avoid complications, such as stress shielding, implant-related
osteopenia and subsequent re-fracture (77).

2.2.1.2.

Scaffold Porosity

Micro-porosity is a critical element for the scaffold’s osteoconductive properties,
and the resultant bone tissue ingrowth and vascularization. Scaffold pore structure (i.e.,
pore size, volume and interconnectedness) is an essential consideration to ensure proper
cell growth, cell migration, nutrient flow, vascularization, and better spatial organization
for cell growth and ECM production (15, 19). Although there is still some ambiguity
surrounding the optimal porosity and pore size for a 3D bone scaffold, studies suggest
that scaffolds currently designed with small pore sizes (i.e., < 200 µm) display in vitro
and in vivo osteoblast survival and bone formation limited to the periphery, due decreased
oxygen and nutrient diffusion throughout the scaffolds (16). On the other hand, scaffolds
with a mean pore size above 200 µm display increased osteoblast proliferation and
differentiation throughout the entire scaffold, due to enhanced neo-vascularization and
mass transport of oxygen and nutrients (17, 23-25). For instance, Tsuruga et al.
demonstrated enhanced bone formation, as well as alkaline phosphase and osteocalcin
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levels in constructs with mean pore sizes of 300 to 400 µm four weeks post-implantation
in a rat subcutaneous mouse model (17). In addition, Klenke et al. demonstrated a
positive relationship between the scaffold’s mean pore size and vascular invasion,
volume of newly-formed bone, and bone volume density. After 4 weeks, implantation of
scaffolds with pore sizes 200-300 µm resulted in significantly enhanced vascular and
bone formation than that with pore sizes less than 200 µm in a mouse critical-size cranial
defect model (78).
A combination of various factors may attribute to the observed enhanced
performance of scaffolds with pore sizes greater than 200 µm. Scaffolds with larger
pores result in decreased cell aggregations developed along the scaffold’s periphery.
Specifically, Murphy et al. observed that scaffolds with pore sizes greater than 300 µm
demonstrate improved cell migration, which overcome the scaffold-surface cell trapping
phenomenon in vitro (79).

Instead, scaffolds with larger pore sizes allow for

homogenous cell proliferation through the construct, of which is not limited to the
scaffold periphery. Minimizing the cell sheet formation at the scaffold’s periphery may
also allow for enhanced diffusion of oxygen and nutrient.

Hypoxia, which defines the

lack of oxygen, is well associated with osteoblastic cell death. Therefore, it is critical to
fabricate scaffolds with proper pore sizes to allow for oxygen diffusion throughout the
scaffold.

Together, these factors allow for enhanced cell survival throughout the

scaffold, and not central necrosis that is often observed in scaffolds with small mean pore
sizes.
The cruciality of increasing pore size of scaffolds is well recognized, and a variety
of scaffold fabrication techniques have been proposed to achieve scaffolds with increased
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pore sizes. Porogen leaching was used in combination with several traditional scaffold
fabrication techniques, such as gas foaming (80, 81), freeze drying (82), and phase
separation (83) to fabricate highly porous scaffolds. However, as porosity and mean pore
sizes increase, mechanical strength is scarified; determination of a balance between
mechanical strength and porosity is crucial.
2.2.2.

Cellular Approaches

Though there remains an unresolved debate on the most effective cell type for
clinical bone regeneration, it has been established that cellular-based bone regeneration
approach is indeed effective. Cellular-based approaches in BTE primarily target the early
stages of bone repair when the recruitment of skeletal progenitors may be impaired.
Proposed mechanisms by which implanted cells enhance bone regeneration in BTE
involve (1) early release of key osteogenic and vasculogenic molecules and growth
factors, and (2) formation of a template to recruit host osteogenic and vasculogenic cells,
and (3) actively laying down bone matrix and vascularizing the bone construct.
The major challenge in making these cellular therapies more efficient is the
identification of the cell sources that can be implanted to the bone defect site, and will
differentiate into osteoblasts and form neo-vasculature (84, 85). Thus far, studies have
investigated several cell types including mesenchymal stem cells (MSCs), embryonic
stem cells (ESCs), induced pluripotent stem cells (iPSCs), adipose derived stem cells
(ADSCs) and stem cells from human exfoliated deciduous teeth (SHED) for their abilities
to promote bone repair and regeneration. This variety of possible candidates for cell
transplantation can be explained by the finding that cells involved in the reconstruction of
osseous

tissue

undergo

a

progression
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from

undifferentiated

progenitors

to

Table 2-2. Cell Choices for Bone Tissue Engineering.
Cell Type
Embryonic Stem
Cells (ESCs)
Induced
Pluoripotent Stem
Cells (iPSCs)
Adult Stem Cells

Source
Embryonic Bodies
(EBs)
Any cell type that
could be induced to
become osteoblasts
- Bone marrow

-

Adipose tissue

-

Peripheral
Blood
Teeth (pulp,
exfoliated
teeth)
Cord blood
Amniotic
Fluid
Stem Cells
derived from
ESCs and
iPSCs

-

-

Clinical Use
N/A
N/A

•
•
•
•
•
•
•
•

Segmental defects of long bones
Large bone diaphysis defects
Maxillary sinus augmentation
Posterior spinal fusion
Bone tumor resection
Large calvarial defect
Osteonecrotic Femoral Heads
Hip osteonecrosis
N/A
N/A

N/A
N/A
N/A

N/A
Any cell type that
could be genetically
modified
Platelet Rich Plasma
Autologous Cells
•
Necrosis of femur head, Avascular
Bone marrow
and Growth
necroses, Non-unions
Aspirate
Factor Cocktail
•
Sinus graft
biosynthetically mature cells; therefore therapeutic strategies can approach supporting the
Genetically
Modified Cells

healing process at different stages of bone tissue development (86). For successful
clinical application in the regeneration of bone, the properties of choice include isolation
and expansion efficiency, expression and stability of osteogenic markers, “bona fide”
bone tissue formation, and long-term safety (i.e., immunorejection, graft-versus-host
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disease, tumorigenicity). Table 2-2 summarizes the cell types that have been utilized for
clinical bone defect repair thus far. Here, I focus on mesenchymal stem cells (MSCs) and
endothelial progenitor cells (EPCs) as they have demonstrated to be highly effective in
promoting bone and vascular regeneration at bone defects.

2.2.2.1.

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) have been long recognized for their potential in
engineering bone grafts since they differentiate and form bone during the natural bone
development process. Their great potential in BTE has led to their characterization and
the identification of a plethora of sources for their isolation. MSCs have been defined
through the expression of various CD markers (i.e., negative for CD34, CD45, CD14,
CD11a, CD19 and HLA-DR and positive for STRO-1, CD29, CD73, CD90, CD105,
CD106, CD166, CD146 and CD44). Also, MSCs have been isolated from a number of
adult sources including bone marrow (87), peripheral blood (88), umbilical cord blood
(89), synovial membrane (90), deciduous teeth (91), dental pulp (92), amniotic fluid (93),
adipose tissue (94), brain, skin, heart, kidneys and liver (95) through a relatively simple
protocol that primarily relies on their ability to adhere to tissue culture plastic (96). In
addition, their high proliferative potential combined with ability to withstand the freezing
conditions allows for their in vitro expansion in order to obtain clinically relevant cell
numbers (87).
In addition to adult sources, MSCs have recently been derived from embryonic
stem cells, as well as iPS cells (97). These embryonic- and iPSC-derived MSCs have the
same in vitro and in vivo multi-potent characteristics as MSCs derived from other adult
sources (i.e., bone marrow). However, unlike MSCs derived from adult sources, iPSCs41

derived MSCs may be indefinitely expanded without senescence. Their enhanced
survival potential, both in vitro and in vivo, may be attributed to higher telomerase
activity (97). In any case, MSCs of embryonic and iPSC origin have to be further tested
to rule out the possibility of teratoma formation before considering them for clinical
applications.
The incorporation of MSCs into bone tissue engineering biomaterials is a widely
studied strategy for accelerated bone formation and osteointegration during bone defect
repair and regeneration.

Mechanisms by which enhanced bone regeneration occurs

involves directly providing mesenchymal stem cells for osteogenic differentiation and
bone formation, as well as enhanced osteoinductivity of the biomaterial via the release of
osteogenic growth factors and stimulation of the migration and differentiation of host
osteoprogenitors. In addition, pre-differentiating MSCs into the osteogenic lineage before
implantation has been shown to further accelerate defect repair and osteointegration of
the construct in vivo via delivering a more mature osteogenic population capable of
immediate bone formation. Pre-clinical trials with MSC-seeded constructs have proven
effective in accelerating bone repair in various scenarios including critical-size femoral
defects, cranio-maxillofacial deformities, and spinal fusions (98).
Although seemingly a great cellular option for enhanced bone tissue engineering,
several issues with their usage have been identified. Firstly, several studies have shown
that a maximum of 24–40 population doublings are reached before it comes to a
senescence-associated growth arrest. Also, osteogenic differentiation potential in vitro
and bone forming efficiency in vivo significantly decreases with the increasing donor age
and systemic disease.

Additionally, the lack of knowledge about common markers for
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MSCs isolated from different sources make it difficult to define MSCs (99, 100). These
factors significantly limit the actual amount and the quality of MSCs obtainable for
clinical application. Approximately four to six weeks is required for cell expansion
before possible patient treatment. Furthermore, long-term culture may lead to forced
selection under artificial culture conditions, which increases the possibility of abnormal
karyotype development and malignant cell transformation. Lastly, the use fetal bovine
serum (FBS) during in vitro expansion poses a risk of transmitting zoonotic or prionrelated diseases, which may induce an immune response triggered by xenogenic proteins.
The option of using synthetic serum with range of recombinant growth factors, or serumfree media are being explored as alternatives (86).
At present, a number of strategies have been reported that are capable of
augmenting the loss of both proliferative capacity and osteogenic differentiation potential
of MSCs after extensive population doublings ex vivo. These methods include cultivation
of MSCs in the presence of basic fibroblastic growth factor (FGF-2), and maintenance of
MSCs on several extracellular matrices (i.e., basement membrane-like extracellular
matrix produced by bovine corneal endothelial cells, denatured collagen type I matrix)
instead of conventional tissue culture plastic during progressive number of passages (98).
The mechanism of how various ECMs may influence the retention of MSC osteogenic
differentiation potential after ex vivo expansion is still ambiguous; however, it has been
suggested that the physical interactions between MSCs and certain ECM motifs (i.e.,
integrins and their ligands) may play a significant role.
The variability of colony formation and culture conditions necessary to sustain
proliferative capacity have led to an interesting proposal of the creation of a universal
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allogenic human MSC cell line serving as “of-the-shelf” or “ready to use” cells (15).
Though it may not seem possible without requiring the use of immunosuppressive drugs
to reduce associated risks of rejection, it has recently been shown that cultured MSCs
exhibit a poorly immunogenic phenotype (i.e., evidenced by MHC class I+, MHC Class
II-, and low level of expression of co-stimulatory molecules, CD40, CD80, and CD86).
Also, MSCs have been shown to be immune suppressive (i.e., immune privileged).
Specifically, MSCs do not induce the proliferation of lymphocytes, and suppress the
proliferation of T-cells and cytokine production in response to alloantigens or
insignificant mitogens, as well as inhibiting the function of B cells, dendritic cells and the
natural killer cells. This data greatly enhances the therapeutical appeal of MSCs in bone
tissue engineering.
2.2.2.2.

Endothelial Progenitor Cells

Endothelial cell-mediated vascularization is an absolute pre-requisite for bone
tissue formation, repair, and remodeling. Currently, endothelial progenitor cells (EPCs)
represent an attractive, if not the most attractive endothelial cell source involved in the
repair and angiogenesis of damaged or ischemic bone tissues. In addition, EPCs have
been recognized as an attractive autologous endothelial cell population that may easily
isolated from peripheral blood or bone marrow in clinic.
EPCs were first characterized in 1997 by Asahara et al. (48). EPCs were defined
as bone marrow-derived vascular endothelial cell growth factor-receptor 2 (VEGF-R2)
positive, CD43-positive monocyte like cells with the ability to differentiate into
endothelial cells in vitro and in vivo based on expression of CD31, eNOS, and E-selectin.
EPCs posses a very high and long-term proliferative potential (more than 1,000
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population doublings), and may be quickly expanded for clinical use. EPCs display the
typical cobblestone morphology of endothelial cells when culture in vitro, and have good
angiogenic ability, as demonstrated by complex and intricate network when cultured on
and within Matrigel in vitro, and angiogenic abilities in vivo.
Numerous subsequent studies were published attempting to further elaborate on
the molecular characterization on EPCs. Other studies demonstrated EPCs to express
VEGF-R2, CD133, CXCR-4 receptor, and to posses migrational ability to VEGF and
stromal cell derived factor-1 (SDF-1) (101). Other studies suggest that monocyte-like
cells expressing CD14, Mac-1 and the dendritic cell marker CD11c demonstrate EPC
activity (i.e., uptake of acetylated LDL and binding of ulex-lectin (102, 103). Ingram et
al. reported EPC-derived cells express KDR, CD31, and Tie-2 (angiopoietin 1 receptor)
(104).

Thus, there is still controversy surrounding an accurate molecular definition of

EPCs.
The reason for such discrepancy in the molecular definition of EPCs lies in the
fact that there is not a universal isolation method being utilized by these studies. There
are three common methods that exist for the isolation of EPCs (105). In the first method,
peripheral blood mononuclear cells are isolated and plated on fibronectin- or collagencoated tissue culture plates with a variety of endothelial growth factors. After several
days, the non-adherent cells are removed and the adherent cell population remaining,
which expresses the ability to ingest acetylated low density lipoprotein and to bind
certain plant lectins, is considered to represent EPC.

The second method utilizes

monoclonal antibodies and fluorescence activated cell sorting (FACS) analysis to
enumerate specific cell populations. Asahara et al. reasoned that putative EPC may
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express cell surface markers shared by hematopoietic stem cells (HSC) since endothelial
and blood cells share a similar mesodermal origin during embryonic development. Thus,
Asahara et al. cultured CD34+ cells (15.7% enriched) on fibronectin-coated dishes and
observed emergence of spindle shaped cells that expressed a variety of proteins generally
expressed by primary endothelial cells. However, EPCs (commonly identified by three
cell markers CD133, CD34, and the vascular endothelial growth factor receptor 2) may or
may not express CD34, depending on their differentiation state. Specifically, as EPCs are
mobilized from the bone marrow into the peripheral blood they begin to lose
CD133/CD34 and start to express CD31, vascular endothelial cadherin, and von
Willebrand factor (vWF). Therefore, it is critical to identify specific cell markers for
EPCs for this method to be effective. The third method involves in vitro colony forming
cell assays (i.e., colony forming unit-Hill (CFU-Hill) and endothelial colony forming cell
(ECFC) assays). In the CFU-Hill assay, adult peripheral blood or cord blood gives rise to
cells that do express many proteins similar to primary endothelial cells, but the CFU-Hill
also express numerous myeloid progenitor cell markers and mature into macrophages.
Furthermore, CFU-Hill and their progeny fail to spontaneously form human blood vessels
when implanted into immunodeficient mice. In contrast, ECFC express cell surface
antigens like primary endothelium, clonally propagate and re-plate into secondary and
tertiary ECFC, form capillary-like structures in vitro, but most remarkably, form human
blood vessels in vivo and inoculate with murine vasculature to become part of the murine
systemic circulation. Thus, ECFC display all of the properties of an EPC while the CFUHill assay identifies hematopoietic cells.
Although there is still controversy surrounding an accurate molecular definition
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and precise phenotype of EPCs, their ability to promote enhanced vascularization and
bone formation at bone defects are certain (104). For instance, Yu et al. demonstrated
that pre-seeding scaffolds with EPCs effectively promoted neovascularization in grafts,
prevented the ischemic necrosis, and improved osteogenesis in a mouse femur bone
defect model after 6 weeks post-implantation (47). Zhou et al. and Tan et al. also
demonstrated EPC-mediated enhanced vascularization and bone formation in a rabbit
bone defect models post-implantation of pre-seeded EPC constructs (45, 49).

This

observation was also observed in various other animal models including in rats, and
sheep (41, 42, 106). Thus, EPCs clearly represent an attractive cell source for promoting
bone and vascularization in bone tissue engineering.

2.2.3.

Vascularization Techniques

The importance of vascularization to the development and repair of bone tissue
has been extensively documented in BTE investigations (107). The greatest amount of
newly formed bone occurs in the most vascularized areas, whereas inadequate
vascularization at bone defect sites is associated with decreased bone tissue repair and
regeneration, and has been identified as the major pitfall to successful BTE.
Specifically, until the timely onset of construct vascularization, which is typically on the
order of hours to days (i.e., less than 1 mm/day), seeded cells in an implanted BTE
construct rely on diffusion for the uptake of nutrients (i.e., oxygen, glucose, etc.) and
clearing of metabolic byproducts (i.e., carbon dioxde, lactic acid, etc.), a transport
mechanism that is only efficeint over short distances (i.e., less than 200 µm) (37). These
diffusional constraints result in viable cells located only superficially (i.e., periphery of
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the constructs), and thus, limiting the success of the engineering bone tissue throughout
the entire thickness of the defect. Although in vitro delivery of nutrients to engineered
constructs may be alleviated via bioreactor systems, this only delays the diffusional
constraint problem to when it is implanted in the host defect site. There is a critical
obstacle in maintaining the survival of large masses of cells upon transfer from the in
vitro culture conditions into the host defect site in vivo (108). For this, scientists have
proposed several methods to accelerate the onset of neo-vascualization for survival and
integration of BTE grafts with host tissue including (1) scaffold design, (2) inclusion of
angiogenic growth factors, (3) in vitro pre-vascularization (i.e., co-culture of endothelial
and osteogenic cells), and (4) in vivo pre-vascularization. Although it is still unclear
which method is the best for successful in vivo application, a combination of these
methods may prove to be most effective. The following is a brief review of each method
and its challenges.

2.2.3.1.

Scaffold Design

Scaffold design has a profound effect on the rate of vascularization after
implantation. Specifically, mean pore size of the scaffold is a critical determinant of
blood vessel ingrowth. BTE studies suggest pore sizes greater than 300 µm to be required
for vascular ingrowth (16). Interconnectivity of pore is also critical, as it significantly
affects cell migration, and in turn, vascularization.

Scaffold fabrication techniques

including gas foaming, phase separation and freeze drying are employed in association
with porogen leaching for the generation of increasingly porous scaffolds. Recently, the
authors developed thermal sintering and porogen leaching method and fabricated
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scaffolds with the desired pore size and volume. These scaffolds are proven to be
superior because they not only support vascular in growth but also meet the mechanical
requirements for bone regeneration (109, 110). On the other hand, methods such as layerby-layer deposition (i.e., solid free-form fabrication) are now commonly used to actively
design scaffold porosity and interconnectivity.

With these fabrication systems,

production of complex scaffolds with well-defined architecture and optimized pore
interconnectivity is possible (111).

2.2.3.2.

Inclusion of Angiogenic Growth Factors

The local delivery of angiogenic growth factors certainly accelerates
vascularization of an implanted graft. Angiogenic growth factors may be incorporated
into the BTE construct design either by way of the scaffold or seeded cells. In the first
scenario, the growth factor may be incorporated onto the scaffold by (1) simple soaking
for resultant fast release, (2) encapsulated in scaffolds, or (3) covalent immobilization for
controlled and extended release. Otherwise, growth factors may be incorporated into the
seeded cells via genetic modification.
Several critical considerations should be taken into account for success in this
method. Firstly, the choice of growth factors is crucial. Several commonly studied
angiogenic growth factors in BTE include vascular endothelial growth factor (VEGF),
platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF).
Secondly, the proper dosage of the growth factor has been shown to affect the quality of
the neo-vasculature. For instance, excess amounts of VEGF have been shown to cause
severe vascular leakage and hypotension (112). Lastly, it should be considered that

49

multiple growth factors along spatial and temporal gradients may allow for even
enhanced results as bone tissue development is controlled by the interaction of multiple
growth factors. Studies have shown that the incorporation of VEGF and bFGF results in
accelerated vascularization of engineered tissues via the mobilization and recruitment of
endothelial progenitor cells (EPCs), though the resulting vessels are often disorganized,
leaky and hemorrhagic (113).

For this reason, the addition of growth factors that

stimulate the recruitment of smooth muscle cells or pericytes for the stabilization and
maturation of the vessels may be considered, and include PDGF, transforming growth
factor-β (TGF-β) and angiopoietin 1 (Ang1) (114, 115).
The addition of growth factors to scaffolds is a relatively easy and widely studied
approach. Since this type of growth factor delivery is either driven by passive diffusion
or coupled to the rate of biomaterial degradation, the growth factor release may be altered
only to some extent by the amount of growth factor added or varying the degradation rate
of the material. The release profile for this method is, therefore, often not in tune with
the actual healing process and cellular demands (116).

On the other hand, growth

factors covalently linked to the scaffolds may be released according to the cellular
demands. It was demonstrated that the vasculature formed in this manner via controlled
release of VEGF formed organized vasculature, in comparison to the vasculature that
arose from an uncontrolled VEGF release (117).
The incorporation of growth factors into the scaffolds is not an efficient process.
Adding the high price associated with the human recombinant growth factors make the
growth factor-loaded scaffold approach not an attractive one. On the other hand, the
incorporation of genetically modified cells, such as VEGF releasing ADSCs, has
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demonstrated enhanced vascular formation (118).

In addition, cells releasing the

combination of osteogenic and angiogenic factors (i.e., BMP-4 and VEGF, respectively)
together have been shown to increase not only vascular formation, but also the quantity
of regenerated bone, compared to the when each factor was alternatively delivered alone
(119). However, gene therapy in general has safety concerns, and it is not yet approved
for clinical use.

2.2.3.3.

In Vitro Pre-Vascularization

Current in vitro pre-vascularization strategies of BTE involve the prior seeding
and co-culture of endothelial cells and osteogenic cells in BTE constructs in vitro. The
mechanism underlying this strategy depends on the direct and indirect communication of
these two cell types, and the formation of premature vessels by the endothelial cells in
vitro, which may later mature, and anastomose with the host vasculature upon
implantation. As seen in Figure 2-5, there is a definite cross-talk between endothelial and
osteogenic cells (120).

This approach has not only demonstrated accelerated

vascularization in vivo, but also enhanced osteogenic differentiation in vitro and bone
formation in vivo (43, 121). With this method, anastomoses occurs more quickly in
comparison to non pre-vascularized constructs, as host vessels only need to grow into the
outer region of the constructs to meet the pre-vascular structures. This method may
decrease the time needed for vascularization from weeks to days.
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Figure 2-5.. Diffusible factors involved in crosstalk between osteoblastic cells and
endothelial cells. Growth factors, as well as systemic hormones, can have effects on
endothelial functions (purple) and/or on osteoblastic functions (blue). These factors
act through activation of specific receptors (black arrows) that in turn stimulate the
expression of other proteins after activation of intracellular sign
signaling
aling pathways
(green arrows) Adapted from Grellier et al. (120).
An important consideration for in vitro pre-vascularization is the type of utilized
cells, and identifying an abundant source of effective autologous endothelial cells.
Although mature endothelial cells, isolated from biopsies of skin or saphenous veins may
be used, they present with m
major drawbacks, including insufficient numbers with limited
proliferative abilities (i.e., limited in vitro expansion) (122). In contrast, various stem
cells, namely endothelial progenitor cells (EPCs) have recently been the topic of
discussion. When co-culturedd with mesenchymal stem cells and implanted at defect sites,
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and constructs demonstrate enhanced levels of vascularization and bone formation. Yu et
al. also noted that central necrosis is avoided when scaffolds are seeded with EPCs and
MSC-derived osteoblasts, which is not the case when only osteoblasts are seeded alone
and implanted (47).

Perhaps the most desirable cell source is one that contains both

osteogenic and vasculogenic progenitor cells. For instance, mesenchymal stem cells,
which may be isolated from bone marrow for osteoprogenitor cells, also have been shown
to have the potential to differentiate toward endothelial lineage (123). Another attractive
autologous source that may be used to isolate both osteo- and endothelial- progenitors is
the stromal vascular fraction (SVF) of adipose tissue, which abundantly available, easy to
harvest, and associated with minimal donor site morbidity. In addition, in comparison to
bone marrow, it has a much higher frequency of clonogenic mesenchymal progenitors
compared (124).
Several issues regarding in vitro pre-vascularization still remain uncertain. For
instance, it is unclear whether it is better to maintain the pre-vascularization in vitro long
term for establishment of a premature vascular network formation, or to implant the
construct shortly after seeding the cells in order to allow the in vivo environment help in
the establishment of a functional vasculature. Also, even though endothelial cells have
the potential to form new vessels within the scaffolds that may anastomose with host
vasculature when implanted in vivo, it is important to consider the presence of other cell
types (i.e., smooth muscle cells, pericytes) to ensure the formation of functional
vasculature, and so a tri-culture approach should be further investigated (125). Lastly,
the potential benefits of this approach have been doubted since it involves cell-containing
constructs, which like others require immediate supply with nutrients and oxygen after
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implantation.

One approach to solve this problem may involve the engineering of

vascular axis within the in vitro construct, which can be surgically connected to the host
vasculature as it is when vessels are surgically implanted.
2.2.3.4.
In Vivo (Surgically Induced) PreVascularization
In vivo pre-vascularization may be performed to allow for vascularization of bone
constructs. The “flap pre-fabrication” approach utilizes an “extrinsic” mode of
vascularization, and involves two main stages. First, the BTE construct is implanted in
axially vascularized tissue (i.e., in subcutaneous, intramuscular, or intraperitoneal sites),
where microvascular network formation within the constructs occurs within several
weeks. The construct is then harvested, and transferred as free bone flap to the bone
defect site, where the vascular axis is connected via microsurgical vascular- anastomosis
techniques, resulting in instantaneous perfusion of the entire construct.

Several

drawbacks with this technique include the obvious requirement of two required surgeries,
cost, the formation of a random vascularization pattern, degree of vascularization is based
on host’s tissue vascularity, as well as donor site morbidity (126). In another method, an
“intrinsic” mode of vascularization is used where vessels that are suitable for
microsurgical transfer (i.e., carotid artery, jugular vein saphenous bundle, or
arteriovenous (AV) loop) are incorporated into the construct (127).

Though this

procedure has clear advantages over the “flap pre-fabrication” approach, including that it
does not require two separate operations like the “flap pre-fabrication” approach, is not
dependent upon local vascular conditions and the included vasculature is not randomly
oriented, this method is still very challenging since most load-bearing osteogenic
constructs are not able to be molded or shaped around the AV loops.
54

2.3.

Functional Bone Tissue Engineering

The term, functional bone tissue engineering, was coined over a decade ago, and
is defined as approach that allows for full functional ability of the graft immediately
following their surgical implantation. In this approach, the bone graft to be implanted is
required to have carefully defined biomechanical properties to allow its immediate usage
upon completion surgery. However, functional bone tissue engineering entails more than
just the ability for immediate mechanical usage.

Instead, functional bone tissue

engineering approaches involve those that allow for the newly restored bone to be fully
integrated with the neighboring host bone, and importantly, possess the ability to perform
all the functions of native bone.

The quality of the new regenerated tissue should

seamlessly match that of the host bone. In the future, effective quality assessment tests
should be developed to ensure truly functional engineered bone for patients.

2.4.

Overall Objective and Specific Aims

Oral/maxillofacial and orthopaedic bone grafts and substitutes represent a
combined $2.5 billion market in the United States, a rapidly rising figure due to the aging
baby boomer population. Yet, currently available treatment options, including autografts
and allografts, are far from ideal. Bone tissue engineering (BTE) is considered one of the
most promising treatments on the horizon. Successful BTE critically depends on three
components, (i) a three-dimensional, biodegradable scaffold, (ii) an appropriate cell
population, and (iii) an adequate vascular supply. We propose the development of an
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optimized biodegradable scaffold, seeded with the appropriate cells to promote enhanced
bone regeneration and vascularization.
Poly(85 lactide-co-15 glycolide) (PLGA) microsphere scaffolds have attracted
significant attention due to their display of better osteocompatibility and human bone compatible mechanical properties, and the recent approval of PLGA by the US FDA as a
biodegradable material for certain biomedical devices. Unfortunately, bone regeneration
with these microsphere scaffolds (pore size ~100 µm) is limited to the scaffold surfaces,
due to failure to support sufficient mass transport of oxygen and nutrients, osteoclast
activity, and neo-vascularization. Recent studies have demonstrated other scaffold types
with higher pore sizes (i.e., > 400 µm) can ease these limitations, increase cell
infiltration, and ultimately, allow for bone formation and vascularization throughout the
entire scaffold. However, as pore size increases, the scaffold’s mechanical strength, a
critical BTE factor for load-bearing bones, is sacrificed. Thus, we propose the generation
of optimal PLGA microsphere scaffolds with optimally-sized pores (i.e., ~300 µm) to
balance the positive and negative features of the previously mentioned pore size ranges,
allowing for increased bone regeneration and neo-vascularization, while still retaining
human bone-mechanical compatibility.
In addition to an effective biodegradable scaffold, BTE also requires a suitable
cell population and sufficient neo-vascularization to accomplish complete bone
regeneration.

Our proposal includes culturing our optimized scaffolds with two

clinically-relevant cell populations for enhanced bone formation and vascularization,
specifically peripheral blood derived - endothelial progenitor cells (EPCs) and bone
marrow derived - mesenchymal stem cells (MSCs). Previous studies have demonstrated
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EPCs and MSCs promote enhanced bone regeneration via the stimulation of neovascularization. We will systematically examine the combination of these two cell types
and our optimized PLGA scaffolds, and their resultant effects on healing bone defects.
We hypothesize that our approach will substantially improve the performance of PLGA
microsphere scaffolds, and may offer a practical and effective solution to important
clinical problems facing BTE in oral/maxillofacial and orthopaedic surgery.

SPECIFIC AIM 1: To design, fabricate and characterize optimally-porous,
mechanically compatible biodegradable microsphere scaffolds.

It is hypothesized that thermal sintering combined with NaCl salt-leaching will generate
consistent and reproducible optimally-porous, human bone-mechanically compatible
PLGA microsphere scaffolds. In this aim, we will design optimally-porous scaffolds,
analyze the porosity via MicroCT, and evaluate mechanical strength via Instron 5544
testings.

SPECIFIC AIM 2: To study the ability of clinically-relevant cell populations to
support enhanced mineralization and vascularization on optimally-porous scaffolds
in vitro and in vivo.
It is hypothesized that cell seeded - optimally-porous scaffolds will exhibit increased cell
survival, proliferation and differentiation of two clinically relevant cell types (i.e., rabbit
MSCs and EPCs) as compared to control scaffolds. In this aim, we will seed and culture
rabbit MSCs and EPCs, which have been shown to enhance bone and vascular formation,
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on the control and optimally-porous at pre-determined ratios in vitro. We will examine
the cell survival via a cell viability assay, as well as cellular localization and phenotypic
expression via immunofluorescence and confocal microscopy. Also, we will also study
the mineralization and vascularization potential of these constructs in mouse
subcutaneous model 8 weeks post-implantation.

SPECIFIC AIM 3: To assess the ability of optimally-porous biodegradable scaffolds to
promote enhanced bone formation and vascularization in vivo.

It is hypothesized that optimally-porous scaffolds will achieve homogeneous bone tissue
regeneration via increased neo-vascularization. In this aim, we will implant optimallyporous scaffolds seeded with rabbit MSCs and EPCs in a rabbit ulnar critically-sized
bone defect model. At week 12, we will evaluate the explanted grafts via MicroCT to
measure bone tissue volume, and histology to assess the enhanced osteogenesis and
angiogenesis.

With these specific aims, we aim to develop pre-vascularized, optimally-porous, human
bone-mechanically compatible biodegradable scaffolds for effective bone defect
regeneration.
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3.

FABRICATION AND IN VITRO EVALUATION OF

OPTIMALLY-POROUS MICROSPHERE-BASED
SCAFFOLDS

3.1.

Introduction

Bone tissue engineering (BTE) has been proposed as a more effective alternative
option for bone defect repair/regeneration.

BTE involves the combination of

biodegradable and porous scaffolds, with or without the use of bone-forming cells and
growth factors, to regenerate bone (13, 128). The success of the scaffold-based bone
regeneration approach critically depends on the effectiveness of the biodegradable
scaffold (129).

Important design considerations for BTE scaffolds include

biocompatibility, mechanical compatibility, osteoconductivity (i.e., ability of bone cells
to grow on scaffold surface and form bone), osteoinductivity (i.e., ability to recruit and
stimulate differentiation of progenitor cells into osteoblasts) and osteointegration (i.e.,
ability to achieve direct bone-to-implant contact) (130). Of these, osteoconductivity of a
scaffold is a critical, since cell survival and proliferation in the scaffold’s interior relies
on mass transport upon initial implantation until the onset of vascular invasion (131).
Methods to achieve cellular conduction involve scaffold pore structure
optimization (16, 17). Scaffolds currently designed with decreased accessible volume
and/or small pore sizes (i.e., < 200 µm) display osteoblast survival and bone formation
limited to the periphery, due to decreased oxygen and nutrient diffusion throughout the
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scaffolds (16). On the other hand, studies have demonstrated that scaffolds with increased
accessible volume and/or large pore sizes (i.e., macro-porous, > 200 µm) display
increased osteoblast proliferation and differentiation throughout the entire scaffold, due
to enhanced mass transport of oxygen and nutrients, and neo-vascularization (23-25).
There have been many efforts to improve scaffold overall osteoconductivity by
fabricating macro-porous scaffolds that support osteoblast survival and growth
throughout the scaffold. Various scaffolding methodologies have been utilized to
fabricate macro-porous scaffolds, including gas foaming (28), freeze drying (29, 82),
phase separation (30, 83) and porogen leaching (27, 132-134). However, in comparison
to scaffolds with smaller pore sizes, these macro-porous scaffolds display a significant
decrease in mechanical strength.

For instance, Martin et al. demonstrated poly(85

lactide-co-15 glycolide) (PLGA) foam scaffolds to display uniform mineralization
throughout, but have inferior mechanical strength (i.e., average compressive modulus of
1.3 MPa) (135). Therefore, there is a clinical need to develop biodegradable scaffolds
with optimal pore characteristics and adequate mechanical strength required to support
large area bone regeneration.
PLGA microsphere scaffolds have attracted much attention for BTE, because they
display human cancellous bone-compatible mechanical properties and have demonstrated
bone formation in vivo (31, 32). However, the current PLGA microsphere scaffolds, like
other scaffold types with limited accessible volume and pore sizes, fail to provide the
prerequisites for optimal bone regeneration (i.e. a stable oxygen and nutrient supply),
limiting bone regeneration only to the scaffold surfaces (16, 34). Though Boschetti et al.
has reported the fabrication of mechanically-stable macro-porous microsphere scaffolds,
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this study included only preliminary cellular biocompatibility studies using fibroblasts
(136). In the present study, we systematically examined a novel set of PLGA microsphere
scaffolds using pre-osteoblastic cells, and performed comprehensive analyses on the
effects of increased porosity and oxygen tension in respect to cell seeding, proliferation,
survival, and mineralization. Through this study, we established optimally-porous
biodegradable scaffolds that are load-bearing, fully osteoconductive and suitable for large
area bone defect repair.

3.2.

3.2.1.

Materials and Methods

Preparation of PLGA Microspheres

PLGA microspheres were prepared by an oil-in-water method as reported
previously (31). In brief, PLGA 85/15 (Lakeshore Biomaterials, Birmingham, AL) was
dissolved in methylene chloride (L-14119, Fisher Scientific, Pittsburgh, PA) in a 1:5
dilution ratio (i.e., 4 g PLGA: 20 milliliters of methylene chloride).

The

PLGA/methylene chloride solution was added slowly to 1 liter of 1% polyvinyl alcohol
(PVA, Sigma-Aldrich, St. Louis, MO) solution under a stirring speed of 250 RPM. The
stirring continued for 24 hours to allow the methylene chloride to evaporate. The
resultant PLGA microspheres were washed with distilled water, filtered, air-dried, sieved
into different sizes, and stored in a desiccator until further use.
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3.2.2.

Fabrication of Optimally-Porous Microsphere

Scaffolds
3.2.2.1.
Paraffin-Leached PLGA Microsphere
Scaffolds
We attempted to fabricate porogen-leached PLGA microsphere scaffolds with
paraffin microspheres as the porogen. We created paraffin microspheres using a similar
method as that for PLGA microspheres. Briefly, 5 grams of paraffin was melted at 90oC,
and then added slowly to 1 liter of 1% polyvinyl alcohol (PVA, Sigma-Aldrich, St. Louis,
MO) solution under a stirring speed of 300 RPM. The speed of stirring was increased to
a stirring speed of 350 RPM, and ice was added to the mix to decrease the temperature of
the stirring solution. The stirring continued for 24 hours. The resultant paraffin
microspheres were washed with distilled water, filtered, air-dried, sieved into different
sizes, and stored in a desiccator until further use. To fabricate paraffin-microsphere
PLGA microsphere scaffolds, we mixed PLGA microspheres (diameter 425-600 µm) and
a porogen, paraffin (diameter 200-300 µm), were mixed at specific weight ratios (i.e.,
PLGA:paraffin ratios of 100:0, 90:10, 80:20, 70:30, 60:40 and 50:50).

The

PLGA/paraffin mixture was then placed into a steel mold, and thermally sintered at
100oC. At this time, we observed collapsed scaffold forms since the paraffin melted
during the sintering process. We then turned to NaCl crystals for a superior porogen for
the fabrication of PLGA microsphere scaffolds with increased porosity.

3.2.2.2.
Salt-Leached, Optimally-Porous PLGA
Microsphere Scaffolds
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A new scaffolding method of “Thermal Sintering and Porogen Leaching”
developed in this study was used to fabricate microsphere scaffolds with increased
porosity. A schematic illustration of this method is shown in Figure 1a. In brief, PLGA
microspheres (diameter 425-600 µm) and a porogen, NaCl (diameter 200-300 µm), were
mixed at specific weight ratios (i.e., PLGA:NaCl ratios of 100:0, 90:10, 80:20, 70:30,
60:40 and 50:50). The PLGA/NaCl mixture was then placed into a steel mold, and
thermally sintered at 100oC.The NaCl porogen was leached out by soaking the composite
PLGA/NaCl scaffolds in distilled water for 2 hours, resulting in scaffolds with increased
porosity compared to control scaffolds. The scaffolds with 0% NaCl are referred to as
control PLGA scaffolds, while the rest as macro-porous scaffolds. We fabricated discshaped scaffolds (10 mm diameter, 2 mm height) for porosity measurements and the
majority of cellular studies, and cylinder-shaped scaffolds (5 mm diameter, 10 mm
height), which were utilized for mechanical testing, live/dead study, and part of
mineralization studies. Scaffolds were air-dried and stored in a desiccator until future
use. Scanning electron microscopy (SEM) was used to image the morphology of the
microsphere scaffolds and visually examine the increased number of large pore sizes after
NaCl-leaching.

3.2.3.

Morphology of Optimally-Porous PLGA

Microsphere Scaffolds

3.2.3.1.

Scanning Electron Microscope Analysis

Scanning Electron Microscope (SEM, FEI Strata 400s Dual Beam FIB) analysis
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was utilized to examine the morphology of the fabricated PLGA microsphere scaffolds
(i.e., control scaffold, composite PLGA microsphere/NaCl scaffold before and after salt
leaching). Samples were prepared by coating with gold/palladium and examined under
SEM.

3.2.3.2.

Micro-Computed Tomography Analysis

Scaffold specimens were imaged using cone beam micro-focus X-ray computed
tomography to render three-dimensional models for direct quantitation of porosity
(µCT40, Scanco Medical AG, Bassersdorf, Switzerland). Serial tomographic images
were acquired at 45 kV and 177 µA, collecting 2000 projections per rotation at 300 msec
integration time. Three-dimensional 16-bit grayscale images were reconstructed using
standard convolution back-projection algorithms with Shepp and Logan filtering, and
rendered within a 12.3 mm field of view at a discrete density of 4,629,630 voxels/mm3
(isometric 6 µm voxels).

Segmentation of solid scaffold from open porosity was

performed in conjunction with a constrained Gaussian filter to reduce noise, applying a
threshold of -220 Hounsfield units (water = 0, air = -1000). Direct measurements of
internal porosity included volume fraction, size, connectivity, accessible internal pore
volume, and accessible solid surface area of scaffold (as a function of pore dimension).
The accessible volume and surface parameters provide direct measurements of the pore
volume and surface available to cell infiltration as a function of minimum pore
dimension, using a distance transformation algorithm similar to Moore et al. (137)
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3.2.4.

Mechanical Evaluation of Optimally-Porous PLGA

Scaffolds

Compressive testing of cylindrical PLGA microsphere scaffolds (5 mm diameter
x 10 mm height, n=6/group) was performed at 2 mm/min (model 5544, Instron Corp.,
Norwood, MA) following the standard protocol of ASTM 1621 (138). Compressive
strength was defined as the maximum stress magnitude.

Apparent modulus was

measured as the tangential slope of the linear region of the effective stress-strain curve at
50% of compressive strength magnitude.

3.2.5.

In Vitro Evaluation of Optimally-Porous PLGA

Scaffolds

3.2.5.1.
Pre-Osteoblast MC3T3-E1 Cell Culture and
Evaluation on Optimally-Porous PLGA Scaffolds
3.2.5.1.1. MC3T3-E1 Cell Seeding and Culture on OptimallyPorous PLGA Scaffolds

The pre-osteoblast immortalized cell line MC3T3-E1 (American Type Culture
Collection, Manassas, VA) were cultured in α-minimal essential medium (α-MEM)
containing 10% fetal bovine serum and 1% penicillin/streptomycin at 37°C, 5% CO2 and
95% humidified air. Cells were maintained in sub-confluent cultures until needed for in
vitro scaffold studies.
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PLGA microsphere scaffolds were sterilized by immersing the scaffolds in 70%
ethanol for twenty minutes. Scaffolds were then washed three times in sterile PBS before
exposing them to UV radiation for one hour. After cell trypsinization, a MC3T3 cell
suspension containing 4 x 104 cells was uniformly seeded onto the scaffolds. The discshaped scaffolds were placed flat on the culture plate, and a 20 µl cell suspension was
uniformly added to the top of the scaffold. The cylinder-shaped scaffolds were placed
along the length of the scaffold on the culture plate, and a 40 µl cell suspension was
added to the lengthwise surface as the scaffold was slowly rotated (i.e., along the long
axis of the scaffold) to maintain uniform cell seeding. The cell-seeded scaffolds were
incubated for two hours at 37oC to allow for cell adhesion onto the scaffolds. The cellscaffold constructs were cultured in osteogenic media (i.e., α-MEM supplemented with
10% FBS, 1% penicillin-streptomycin, 3mM β-glycerophosphate and 50 µg/ml ascorbic
acid), and maintained for 7, 14, 21, and 28 days in an incubator at 37°C, 5% CO2, and
95% humidified air.

3.2.5.1.2. MC3T3-E1 Cell Seeding Efficiency on OptimallyPorous PLGA Scaffolds

After 6 hours of cell seeding, scaffolds were transferred to new wells. Cells at the
bottom of the original wells were trypsinized, resuspended and counted with a
hemacytometer. Cell seeding efficiency (i.e., the number of cells that adhered to the
scaffolds) was determined by the difference between the number of cells initially seeded
(i.e., 4 x 104 cells) and the number of cells that were counted at the bottom of the well.
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3.2.5.1.3. MC3T3-E1 Cell Proliferation on Optimally-Porous
PLGA Scaffolds

DNA concentration of the pre-osteoblast MC3T3 cells cultured on control PLGA
scaffolds and PLGA scaffolds with increased porosity (n=3) was evaluated quantitatively
using Quant-iT PicoGreen dsDNA assay (Invitrogen, Carlsbad, CA) following
manufacturer’s instructions. After culturing the samples (scaffold dimensions 8 mm
diameter x 2 mm height) for 7, 14, and 21 days in osteogenic media, the cell-scaffold
samples (n=3) for each experimental group were harvested. Samples were washed with
PBS, incubated in lysis buffer (i.e., 1% Triton X-100 solution), and subjected to freeze–
thaw cycles. DNA concentration from the cell lysates was determined according to the
manufacturer’s protocol. Experimental groups included control scaffolds (i.e., 0:100 ratio
of NaCl:PLGA), and scaffolds with increased porosity (i.e., 10:90, 20:80, 30:70, and
40:60 ratio of NaCl:PLGA).

3.2.5.1.4. MC3T3-E1 Cell Viability on Optimally-Porous
PLGA Scaffolds

The live-dead cell viability assay we used (Invitrogen, Carlsbad, CA) includes
calcein AM and ethidium homodimer-1 probes to label live and dead cells green and red,
respectively. We used this live-dead assay to compare MC3T3 cell survival on the
surface and in the interior of scaffolds. Cylindrical scaffolds (5 mm diameter, 10 mm
height) were cultured for 4, 7, and 14 days in osteogenic media, at which point the
scaffolds (n=3) for each experimental group were harvested. Samples were bisected
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lengthwise from each scaffold group to allow for the examination of cell viability in the
sample’s interior. Live-dead cell viability assay was performed according to the
manufacturer’s protocol, using confocal microscopy to image cells at the surface and
interior of the scaffolds.

3.2.5.1.5. MC3T3-E1 Cell Localization and Expression on
Optimally-Porous PLGA Scaffolds

To

visualize

cellular

localization

and

expression

via

histology

and

immunohistochemistry, samples were paraffin-embedded and sectioned (139). Briefly,
cell-scaffold constructs were washed with PBS, and then fixed in formalin overnight at
4oC. Samples were dehydrated sequentially using an isopropyl alcohol series (i.e., 70%,
90% and 100%) for one hour each, at room temperature.

Samples were directly

transferred to molten paraffin (Tissue Path Paraplast Tissue Embedding Media, Fisher
Scientific, Pittsburgh, PA) at 55oC for 10 minutes and then embedded in fresh molten
paraffin. Paraffin-embedded samples were cut into serial sections (20 µm thick) using
Cryofilm (Section-Lab Co. Ltd., Hiroshima, Japan) and a microtome sectioning machine.
Sections were placed on glass slides for histological analysis. Sections were stained with
Gill’s 3 hematoxylin (Sigma-Aldrich, St. Louis, MO) to visualize MC3T3 cell
localization within the PLGA scaffolds after culturing the constructs for 28 days in
osteogenic media. Immunostaining of two bone markers, osteopontin (OPN) and collagen
Type I (Col I) was performed via a rabbit polyclonal anti-human osteopontin (Abcam,
Cambridge, MA, ab8448) antibody and a rabbit polyclonal anti-human collagen type I
antibody (Abcam, Cambridge, MA, ab292), respectively. Briefly, sections were de68

paraffinized in HistoClear (National Diagnostics, Atlanta, Georgia), taken through a
descending series of ethanol concentrations, rehydrated in distilled water, and then placed
in 3% hydrogen peroxide (Sigma-Aldrich, St. Louis, MO) in PBS to quench endogenous
peroxidase activity. To improve antigen exposure, the sections were boiled in Target
retrieval (Dako, Carpinteria, CA) and washed in distilled water. Samples were incubated
with blocking solution (i.e., 0.5% (w/v) bovine serum albumin in PBS) for one hour.
Primary antibodies were diluted in 0.5% (w/v) bovine serum albumin in PBS at
concentrations of 1:200 for OPN or 1:300 for Col I. Samples were incubated with the
primary antibody for two hours at room temperature. Sections were washed free of
primary antibody and incubated with SignalStain® Boost IHC Detection Reagent, HRP,
Rabbit (Cell Signaling, Boston, MA, #8114) followed by an incubation with 3,3'diaminobenzidine (DAB, Vector Laboratories, Burlingame, CA) for thirty seconds. The
slides were rinsed three times in water, and mounted using mounting media (Electron
Microscopy Sciences, Hatfield, PA) for thirty minutes.

3.2.5.1.6. MC3T3-E1 Cell Mineralization on OptimallyPorous PLGA Scaffolds

Matrix mineralization or calcium deposition was evaluated via Alizarin Red
staining. This colorimetric analysis is based on solubility of the red matrix precipitate
with cetylpyridinium chloride (CPC, Sigma-Aldrich, St. Louis, MO) to yield a purple
solution. Briefly, after 14, 21 and 28 days of culturing in osteogenic media, cell-scaffold
constructs were washed with distilled water and fixed with 70% ethanol at 4°C for one
hour. Ethanol was removed and samples were air-dried for ten minutes. Samples were
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incubated with alizarin red dye (Sigma-Aldrich, St. Louis, MO) for ten minutes at room
temperature. Following washes to remove excess alizarin red dye, the samples were
incubated with 10% CPC at room temperature for thirty minutes. The absorbance of the
resulting solution, which is proportional to the amount of calcium deposited, was read on
a TECAN plate reader at 562 nm.

3.2.5.1.7. Oxygen Tension Measurements on OptimallyPorous PLGA Scaffolds

After culturing the MC3T3-E1 cells on control and optimally-porous PLGA
scaffolds for 21 days in osteogenic media, the cell-scaffold samples were quantitatively
evaluated for the oxygen tension in the interior region of each sample group using needletype fiber optic oxygen microsensors (501656, World Precision, Saratoga, FL), as
previously described by Volkmer et al. () (25). Specifically, we examined scaffold
groups with 0%, 10%, 20%, 30%, and 40% NaCl, and cultured 100,000 cells on each
scaffold (dimensions 5 mm diameter, 10 mm height). The oxygen sensors were mounted
on optic fibers with a tip diameter of 50 µm. To protect these fragile sensors, they are
fixed within a standard hollow 27 gauge needle of 0.4-mm diameter. A 25 gauge needle
was utilized to pre-form a 2.5 mm deep channel on the side of the scaffold for which the
probe would then be inserted (305127, Becton Dickinson). Oxygen tension measurements
in the medium were carried out by inserting a probe in the medium next to all
experimental scaffold groups. Prior to sample measurements, the oxygen microsensor
was calibrated following a conventional two-point calibration protocol described by the
manufacturer. Briefly, oxygen-free water and water-vapor saturated air were used as
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calibration standards.

The oxygen-free water standard was prepared by dissolving one

gram of sodium sulfite (S430, Fisher Scientific) in 100 milliliters of water in a sealed
vessel, and the water-vapor saturated air was prepared by placing a wet piece of cotton in
a sealed vessel. The oxygen tension measurements were obtained by inserting the probe
mid-length and mid-diameter (Figure 3-1). Measurements are expressed as the mean of
three samples per scaffold group ± standard deviation.
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Figure 3-1. A) Photograph of needle-type fiber optic oxygen / pH microsensors setup. (B) Photograph of needle-type fiber optic micro-sensors inserting into the
interior region the cell-scaffold construct.

3.2.5.2.
Mesenchymal Stem Cell (MSC) Culture and
Evaluation on Optimally-Porous PLGA Scaffolds
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3.2.5.2.1. MSC Isolation

Mesenchymal stem cells (MSCs) were isolated from the bone marrow of one New
Zealand white rabbit (4-5 kg). The mononuclear cell fraction was isolated via layering
over a Percoll density gradient, and centrifuging at 600 rpm for 20 min at room
temperature. The mononuclear cell fraction was seeded and expanded in Dulbecco's
Modified Eagle Medium (DMEM, Invitrogen) supplemented with 10% FBS and 1%
Penicillin/Streptomycin (P/S, Gibco) at 37oC and 5% CO2. Passages 3-5 were used for
experimentation.

3.2.5.2.2. MSC Seeding and Culture on Optimally-Porous
PLGA Scaffolds

PLGA microsphere scaffolds (10 mm x 5 mm) were sterilized by immersing the
scaffolds in 70% ethanol for twenty minutes. Scaffolds were then washed three times in
sterile PBS before exposing them to UV radiation for one hour. After cell trypsinization,
a MSC cell suspension was uniformly seeded onto the scaffolds. The cylinder-shaped
scaffolds were placed along the length of the scaffold on the culture plate, and a 40 µl
cell suspension of 1 x 105 cells was added to the lengthwise surface as the scaffold was
slowly rotated (i.e., along the long axis of the scaffold) to maintain uniform cell seeding.
The cell-seeded scaffolds were incubated for two hours at 37oC to allow for cell adhesion
onto the scaffolds. The cell-scaffold constructs were cultured in osteogenic media (i.e., αMEM

supplemented

with

10%

FBS,
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1%

penicillin-streptomycin,

3mM

β-

glycerophosphate and 50 µg/ml ascorbic acid), and maintained for 7, and 21 days in an
incubator at 37°C, 5% CO2, and 95% humidified air.

3.2.5.2.3. MSC Cell Viability on Optimally-Porous PLGA
Scaffolds

Live-dead cell viability assay (Invitrogen, Carlsbad, CA) was used to analyze cell
survival in the interior of cell-seed constructs. We seeded and cultured 100,000 MSCs on
scaffolds (0% NaCl/100% PLGA, and 20% NaCl/80% PLGA) in osteogenic media media
(i.e., α-MEM supplemented with 10% FBS, 1% penicillin-streptomycin, 3mM βglycerophosphate and 50 µg/ml ascorbic acid) for 7 and 21 days 37oC and 5% CO2.
Samples were bisected lengthwise from each scaffold group (n=3) to allow for the
examination of cell viability in the sample’s interior. Live-dead cell viability assay was
performed according to the manufacturer’s protocol to label live cells green with calcein
AM, and dead cells red with ethidium homodimer-1 probes. Confocal microscopy (Zeiss
LSM ConfoCor2, 20X magnification) was utilized to image cells interior of the scaffolds.

3.2.5.2.4. Oxygen Tension Measurements on OptimallyPorous PLGA Scaffolds

Needle-type fiber optic oxygen microsensors (501656, World Precision, Saratoga,
FL) were utilized to analyze oxygen levels in the interior of MSC-seeded control and
macro-porous scaffolds (25). Briefly, 100,000 MSCs were seeded on each scaffold type
(i.e., 0% NaCl, 10% NaCl, 20% NaCl, 30% NaCl, 40% NaCl), and cultured for 21 days
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in osteogenic media (DMEM, 10% FBS, 10 nM dexamethasone, 50 µg/ml ascorbic acid,
5 mM β-glycerophosphate) 37oC and 5% CO2. At this point, a 25 gauge needle was
utilized to pre-form a 2.5 mm deep channel on the side (mid-length) of the scaffold for
which the probe would then be inserted (305127, Becton Dickinson). Prior to sample
measurements, the oxygen microsensor was calibrated following a conventional twopoint calibration protocol described by the manufacturer. Briefly, oxygen-free water and
water-vapor saturated air were used as calibration standards.

The oxygen-free water

standard was prepared by dissolving one gram of sodium sulfite (S430, Fisher Scientific)
in 100 milliliters of water in a sealed vessel, and the water-vapor saturated air was
prepared by placing a wet piece of cotton in a sealed vessel. Oxygen tension
measurements in the medium were carried out by inserting a probe in the medium next to
all experimental scaffold groups. Oxygen tension measurements of the interior of the
cell-seeded scaffolds was carried out by placing the probe tip in the center of the scaffold
by way of the pre-formed channel made in the constructs. Oxygen tension measurements
are expressed as the mean of three samples per scaffold group ± standard deviation.

3.2.5.2.5. pH Measurements on Optimally-Porous PLGA
Scaffolds

Needle-type fiber optic pH microsensors (World Precision, Saratoga, FL) were
utilized to analyze pH levels in the interior of MSC-seeded control and macro-porous
scaffolds (25). Cell seeding on scaffolds and culture in vitro was performed in same
manner for the oxygen tension measurement samples. Prior pH measurements, the pH
microsensors were calibrated with buffer solutions of pH 5.0, 6.0, 7.0 and 8.0. pH
measurements in the medium were carried out by inserting a probe in the medium next to
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all experimental scaffold groups. pH measurements of the interior of the cell-seeded
scaffolds was carried out by placing the probe tip in the center of the scaffold by way of
the pre-formed channel made in the constructs. pH measurements are expressed as the
mean of three samples per scaffold group ± standard deviation.

3.2.6.

Statistical Analysis

For scaffold porosity analysis, cell seeding efficiency, cell proliferation,
mineralization, and oxygen tension and pH measurement analyses, a two-way
way analysis of
variance (ANOVA) was preformed to compare data. Three scaffolds per group were
analyzed at each time point. Error is reported in figures as the standard deviation (SD)
and significance was determined using a probability value of p < 0.050.

3.3.
3.3.1.

Results
Microsphere Scaffolds with Increased Porosity

Figure 3-2. (A) Schematic diagram illustrating the fabrication process of PLGA
microsphere scaffolds with increased pore sizes. SEM image of (B) PLGA
microspheres after thermal sintering, (C) PLGA/NaCl composite scaffold after
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sintering, and (D) PLGA scaffold with increased pore sizes created after thermal
sintering and porogen leaching.
PLGA microsphere sintering often results in three-dimensional scaffolds with
limited pore volume.

However, we developed a novel method to fabricate PLGA

microsphere scaffolds with increased pore volume and average pore size, as shown in
Figure 3-2. Through mixing a porogen (i.e., NaCl crystals, 200-300 µm diameter) with
PLGA microspheres (425-600 µm diameter), thermal sintering, followed by porogen
leaching, we successfully created PLGA microsphere scaffolds with increased pore
volume. Thermal sintering, and particulate leaching are well known methods for
fabricating three-dimensional and porous scaffolds (31, 132). Here, we combined them
into a single method “Thermal Sintering and Porogen Leaching” to design PLGA
microsphere scaffolds with the desired pore characteristics. SEM imaging demonstrated
that after porogen leaching (Figure 3-2D), there was visually an increase in number of
large pore sizes compared to scaffolds fabricated with PLGA microspheres alone. (i.e.,
control PLGA scaffolds).

3.3.2.

Scaffold Porosity via Micro-CT

MicroCT imaging was used to reconstruct 3D models of scaffolds for
nondestructive measurements of porosity. Computational assessment of all MicroCT
images confirmed that the internal porosity is one interconnected space comprising
99.9% of the total pore volume.

The porosity and accessible volume of the PLGA

microsphere scaffolds corresponded to porogen size and amount used.

PLGA

microsphere scaffolds that were not fabricated with NaCl (i.e., control scaffolds),
displayed a void volume of approximately 39 mm3, whereas scaffolds fabricated with
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20% NaCl and 40% NaCl (percent by weight) displayed a void volume of 50 mm3 and 59
mm3, respectively (Figure 3-3).

Also, by mixing 40% NaCl and 60% PLGA

microspheres (by dry weight), percent accessible pore volume increased 337% in relation
to control scaffolds at an average pore size of 200 µm (Figure 3-4B). Data and images
describing scaffold pore volume are presented as a function of pore size, providing direct
measurements of externally accessible pore space through the full range of diametral pore
dimension (Figure 3-4A, C). Although the range of pore size dimensions remained
constant, the volume of porosity increased with higher concentration of porogen. For
example, blue areas signify the accessible volume in the scaffolds to objects with a
diameter in the range of 100-200 µm, and red in the range of 400-500 µm. Thus, as
porogen concentration increased, the accessible interconnected volume also increased
(Figure 3-4A).

In control scaffolds, a sphere with a diameter of 200 µm can access

approximately 10% of the total pore volume, whereas the same sphere can access
approximately 40% of the pore volume of the 40% NaCl/60% PLGA scaffold (Figure
3-4B).

This is illustrated in Figure 3-5C, which again shows that the experimental

scaffolds fabricated with a porogen have a higher percentage of accessible pore volume
in the 300-500 µm range in comparison to control scaffold. Thus, we effectively
increased the accessible volume for cell infiltration throughout the scaffold. In addition,
as seen in Figure 3-5, scaffolds fabricated with altleast 20% NaCl demonstrated
significantly enhanced pore sizes in the range of 300-400 µm as compared to control
matrixes (i.e., 0% NaCl).
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Figure 3-3. Increasing porosity (i.e., void volume (mm3)) in PLGA microsphere
scaffolds fabricated with a porogen (NaCl).
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Figure 3-4. Scaffold pore interconnectivity and percent accessible volume obtained
via micro-computed tomography imaging and analysis. (A) Accessible volume space
images generated by imposing specific pore diameter parameters (scale 100–500
mm) on 0% NaCl/100% PLGA, 20% NaCl/80% PLGA, and 40% NaCl/60% PLGA
scaffolds from a top-view, mid-view, and cross-sectional view. (B) Graph comparing
the effect of increasing porogen to accessible volume in the PLGA scaffolds. Dashed
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line illustrates percent accessible volume of PLGA/0% NaCl and PLGA/40% NaCl
scaffolds for an object with a diameter of 200 mm. (C) Increasing scaffold accessible
volume in optimally- porous PLGA scaffolds. Interconnected volume accessible to
spherical objects with a specific diameter range (i.e., 100
100–200, 200–30
300, 300–400,
and 400–500
500 mm) in PLGA/0% NaCl, PLGA/ 20% NaCl, and PLGA/40% NaCl
scaffolds.

Figure 3-5. (A) Percent accessible volume of each scaffold group in the range of
200-400
400 µm. (B) Histogram of percentage of pores in increments of 100 µm for each
scaffold group. (C) Graphs illustrating percentage
age of pores within each pore size
range.
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3.3.3.

Scaffold Mechanical Characterization

By using an increasing amount of porogen in the scaffold fabrication process,
compressive strength and modulus of the scaffolds were sacrificed (Figure 3-6).
Scaffolds with increased porosity (i.e., 40% NaCl/60% PLGA by dry weight) displayed
significantly less compressive strength and modulus than control scaffolds (i.e., 0%
NaCl/100% PLGA). Scaffolds with optimally-sized pores (i.e., 20% NaCl/80% PLGA)
displayed a significant decrease, 63.2%, in compressive strength, and a 29.8% decrease in
compressive modulus in comparison to control scaffolds. 20% NaCl/80% PLGA
displayed significantly higher compressive strength, 140%, and modulus, 240%, than
scaffolds with the highest porosity (i.e., 40% NaCl/60% PLGA).

The compressive

modulus and strength for the scaffolds with increased porosity (i.e., 10-40% NaCl/9060% PLGA), although lower than the control scaffold, are in the range of human
trabecular bone mechanical properties (i.e., compressive modulus 50-800 MPa and
compressive strength 1-10 MPa. Thus, we termed the 20% NaCl/80% PLGA scaffold
group as optimally-porous scaffolds, since they display significantly higher pore volume
than control, while retaining mechanical strength.
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Figure 3-6. Mechanical characterization of PLGA microsphere scaffolds with an
increased porogen content. Analysis of (A) compressive strength and (B)
compressive modulus.

3.3.4.

Effect of Scaffold Accessible Pore Volume on In

Vitro Cell Performance
3.3.4.1.
MC3T3-E1 Cell Performance on OptimallyPorous PLGA Scaffolds
3.3.4.1.1. MC3T3-E1 Cell Infiltration, Proliferation and
Survival

The efficiency of initial cell seeding decreased with increasing porogen used to
fabricate the PLGA microsphere scaffolds (Figure 3-7). Of the 4 x 104 MC3T3 cells
initially seeded onto each scaffold, approximately 3.3 x 104 cells adhered to the control
scaffolds, and only 2.5 x 104 cells adhered to the scaffolds with increased porosity (i.e.,
40% NaCl/60% PLGA by dry weight). However, after 5 days of culture in osteogenic
media, the DNA concentration, which is proportional to cell number, was not
significantly different in control scaffolds and scaffolds with increased porosity (i.e., 20%
NaCl/80% PLGA and 40% NaCl/ 60% PLGA by dry weight). By 2 weeks of culture,
cell number and proliferation in the scaffolds with increased porosity exceeded that of
control scaffolds (Figure 3-8). The limitation of cell culture on scaffolds was seen by 3
weeks of culture, as the capacity of the scaffolds to support cell proliferation began to
decrease. The effects of scaffold porosity on cell viability were examined on the surface
of the scaffolds, as well as the interior, of the scaffolds. At 4, 7, and 14 days of cultures,
cell-scaffold constructs were bisected, and live/dead assays were performed.
Representative fields from the center of the scaffold (approximately 5 mm depth) taken
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by confocal microscopy are shown in Figure 3-9. After 4 days of culture, there was not a
significant difference in live : dead cell ratio between the control scaffolds and scaffolds
with increased porosity. By 14 days of culture, we observed a significant difference in
live cells present in the interior region of scaffolds with increased porosity versus control
scaffolds. In 20% NaCl/80% PLGA and 40% NaCl/ 60% PLGA scaffolds, the cells
displayed a robust and healthy morphology, with extended processes. In contrast, the
cells in the center of the control scaffolds were mostly dead by 14 days and displayed a
round morphology appearance.

Figure 3-7. Effect of increasing porosity on cell-seeding efficiency on scaffolds (*p <
0.05).
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Figure 3-8. Effect of increasing porosity on proliferation of murine pre-osteoblast
pre
cells (MC3T3-E1)
E1) seeded on PLGA control and optimally porous scaffolds at 5, 14,
and 21 days (*p < 0.05).
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Figure 3-9. Effect of increasing porosity on cell viability in the interior of the
PLGA microsphere scaffolds at 4, 7, and 14 days (scale = 200 mm).

3.3.4.1.2. MC3T3-E1 Cell Localization and Expression

Through a modified paraffin-embedding and sectioning procedure, we were able
to study the cellular localization and expression of the MC3T3 cells cultured on our
PLGA microsphere scaffolds. In Figure 3-10, PLGA scaffolds with increasing porosity
(i.e., 20% NaCl/ 80% PLGA and 40% NaCl/ 60% PLGA; images of 40% NaCl/ 60%
PLGA scaffolds are not shown) promote cell infiltration into the interior of the scaffolds.
After 28 days of culturing MC3T3 cells on the scaffolds, hematoxylin staining
highlighted cells densely located on the top of control scaffolds and not in the center of
the control scaffolds (Figure 3-10A).

On the other hand, scaffolds with increased
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porosity displayed cell localization on the surface, as well as increased cell infiltration
and survival in the center of the scaffold (Figure 3-10 B, C). Likewise, we found cells
expressing osteopontin and collagen type I only on the surface of the control scaffolds
(Figure 3-10 D, G). PLGA scaffolds with increased porosity displayed cells expressing
osteopontin and collagen type I at the top, as well as the center of the scaffold (Figure
3-10 E, F, H, I).

Figure 3-10. MC3T3-E1 cellular localization and expression on control and
optimally porous PLGA scaffolds. Hematoxylin staining of control (A) and
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optimally porous scaffolds [top (B) and center (C)], osteopontin
immunohistochemistry of control (D) optimally porous scaffolds [top (E) and center
(F)], and collagen type I immunohistochemistry of control (G) and optimally porous
scaffolds [top (H) and center (I)]. Arrows indicate cell staining. Scale on all images
= 200 µm.

3.3.4.1.3. MC3T3-E1 Cell Mineralization

After 28 days following seeding and culturing MC3T3 cells on scaffolds, we
performed Alizarin Red Staining to detect calcium mineralization. Scaffolds with
increased porosity visually appeared to have higher mineralization potential than control
scaffolds (Figure 3-11). Control scaffolds displayed mineralization limited to the top
surface, and not in the center and bottom. On the other hand, scaffolds with increased
porosity showed Alizarin red staining throughout the entire scaffold (i.e. top and bottom
surfaces, and middle of construct). To compare and quantify the mineralization that was
occurring throughout the scaffolds versus mineralization occurring only in the center of
the scaffolds, we cultured MC3T3 cells on cylindrical scaffolds that were taller (scaffold
size 10 mm height, 5 mm diameter), so that we were able to manually dissect 2 mm off
the top and bottom scaffold surfaces (Figure 3-12). Alizarin Red staining quantification
confirmed the increase in mineralization in scaffolds with increasing porosity. 20%
NaCl/80% PLGA scaffolds displayed the highest significant difference in mineralization
compared to control.

Although mineralization in 40% NaCl/ 60% PLGA scaffolds

displayed higher mineralization potential than control scaffolds, it was not as high as 20%
NaCl/ 80% PLGA (Figure 3-12 A). After manually removing the top 2 mm and bottom 2
mm surfaces of the tall cylindrical scaffolds, we quantified the mineralization in the
center portions of the scaffolds. Mineralization increased significantly in the center of
the scaffolds with increasing porosity after 28 days in culture (Figure 3-12 B).
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Figure 3-11. Mineralization potential of control and optimally-porous PLGA
microsphere scaffolds. Alizarin red staining was performed 28 days after MC3T3E1 cells had been cultured on scaffolds. Red staining in images signifies
mineralization or calcium deposition. Optimally porous scaffold displayed
mineralization on throughout the scaffold (i.e., top and bottom surfaces, and cross
section), while control scaffold mineralization is limited to only the top surface of the
scaffold. Scale bar = 1000 µm.
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Figure 3-12. Effects of porosity on mineralization (A) throughout the entire scaffold,
and (B) in the center of the scaffold. After 28 days of cell culture on scaffolds,
Alizarin Red staining was performed on the entire cell-scaffold construct and
quantified. Two millimeters from the top and bottom surfaces of the scaffolds were
manually removed as shown in (C), and Alizarin red staining was performed to
analyze the mineralization in the center of the constructs (B) ( * signifies p < 0.05).
Photographs of control scaffolds (0% NaCl/100% PLGA) seeded without cells and
with MC3T3-E1 cells, and optimally-porous scaffolds (20% NaCl/80% PLGA
scaffolds) seeded with MC3T3 cells. Mineralization in control scaffold is limited to
the top of the scaffold, whereas mineralization of optimally-porous scaffolds extends
significantly lower than control scaffolds (Scale bar = 5 mm).

3.3.4.1.4. Oxygen Tension Levels in Scaffold’s Interior
Regions

Oxygen tension measurements demonstrated a significant gradient between the
media surrounding the cultured constructs and the interior regions of the constructs in all
experimental groups after 3 weeks in vitro. Oxygen tension in the peri-construct region
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for all experimental scaffold groups was not statistically different from each other, and
averaged 6.67% ± 1.11%.

Oxygen tension in the interior of the cell-seeded scaffolds

was directly related to the concentration of porogen used to fabricate the scaffolds.
Specifically, increases in the scaffold’s porosity facilitated and enhanced oxygen
diffusion to the construct’s interior region, and thus, decreasing the oxygen tension
gradient from the scaffold’s exterior to interior (Figure 3-13). The peri-construct –
interior construct oxygen gradient was most significantly seen in control scaffolds, where
the oxygen gradient in the interior of cell-seeded control (0% NaCl/100% PLGA
scaffolds) scaffolds conditions dropped below 1%. Optimally-porous scaffolds (20%
NaCl/80% PLGA scaffolds) displayed similar oxygen tension gradients as compared to
macro-porous scaffolds (40% NaCl/60% PLGA scaffolds).
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Figure 3-13. The effect of porosity on oxygen tension gradient from the exterior to
interior of PLGA
GA microsphere scaffolds after 3 weeks in vitro.. Oxygen tension of
ambient air is 21%, and average oxygen tension of cell culture med
media
ia is 6.67% –
1.11%.

3.3.4.2.
MSC Performance on Optimally-Porous
Porous PLGA
Scaffolds
3.3.4.2.1. MSC Viability

In vitro culture of mesenchymal stem cells (MSCs) on optimally-porous
optimally
microsphere scaffolds resulted in enhanced cell survival throughout the entire construct,
compared to that of control scaffolds over long-term 21 day culture. As seen in Figure
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3-14, optimally-porous scaffolds cultured with MSCs displayed significantly more live
cells (i.e., live cells are stained green with calcein AM, dead cells are stained red with
ethidium bromide) in the interior of the construct, whereas control constructs displayed
significant cell death in the interior regions of the construct after 21 days in vitro. This
observed increasing cell survival trend can be attributed to the increased oxygen tension
levels, as well as more normal pH levels in the interior of the scaffolds, as compared to
that of control scaffolds after 21 day in vitro.

Figure 3-14. MSC viability in interior of control and optimally-porous scaffolds at 7
and 21 days in vitro. Live cells fluoresce green (i.e., calcien-AM), and dead cells
fluoresce red (i.e., ethidium bromide).
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3.3.4.2.2. Oxygen Tension Levels and pH in Scaffold’s
Interior Regions

The observed increasing cell survival trend can be attributed to the increased
oxygen tension levels, as well as more normal pH levels in the interior of these scaffolds,
as compared to that of control scaffolds after 21 day in vitro. With both, oxygen tension
and pH levels, there was a positive correlation with the percentage of porogen used
during fabrication (i.e., porosity) (Figure 3-15A). For instance, in respect to oxygen
tension levels in the scaffold’s interior regions, the control scaffolds displayed the lowest
oxygen tension levels (0.51% ± 0.47%), whereas 60% PLGA/ 40% NaCl scaffolds
displayed the highest oxygen tension levels (4.11% ± 0.48%). However, there was no
statistically significant difference in oxygen tension levels in the interior regions of
scaffolds fabricated with 20% NaCl, 30% NaCl, or 40% NaCl.

Although the oxygen

tension levels in the interior regions of all scaffold groups (0%-40% NaCl) was
significantly less than the oxygen tension levels in the media surrounding the scaffold
(6.52% ± 0.61%).
Like oxygen tension levels, there was a positive relationship between the
percentage of porogen used during fabrication and pH levels in the interior of the
scaffolds (Figure 3-15B). pH levels are critical to cell survival, as too acidic or basic
conditions is harmful to the cell. The media surrounding the construct (i.e., peri-cellular
region) had a pH of 7.61 % ± 0.08%. Only scaffolds fabricated without NaCl (i.e.,
control scaffolds), and scaffolds with 10% NaCl displayed a significant difference in pH
levels in the scaffold’s exterior regions compared to that in the exterior regions of the
scaffold (i.e., pH gradient from scaffold’s exterior to interior regions) (i.e., 6.83%±
0.06% and 6.99% ± 0.06%, respectively).
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Figure 3-15.. Comparison of oxygen tension and pH levels in interior of control and
macro-porous
porous PLGA microsphere scaffolds at 21 days in vitro.

3.4.

Discussion

Large area or critically sized bone defect repair via scaffold-based
based bone tissue
engineering requires a mechanically
mechanically-stable scaffold that supports osteogenesis entirely.
For this, it is critical to develop a scaffold that allows for oxygen diffusion, and thus, cell
survival and proliferation in the scaffold’s interior regions. In the present study, we have
developed a novel biodegradable scaffold for bone regeneration that encompasses the
previously mentioned requirements, and demonstrated their ability to promote uniform
osteogenesis in vitro.
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Figure 3-16. The pros and cons of scaffolds with low and high porosity, and the
requirement to design scaffolds with optimal porosity and mechanical properties
(i.e., optimally porous scaffolds) for homogeneous and enhanced bone regeneration.

Appropriate scaffold porosity and accessible volume are critical for obtaining
effective osteogenesis in large area bone repair. As seen in Figure 3-16, deviations from
the moderate porosity range display positive and negative tradeoffs. Scaffolds with
decreased average pore size are associated with an increase in surface area, and thus, cell
seeding efficiency.

Such scaffolds with relatively lower porosity exhibit higher

mechanical strength, a critical factor in clinical applications (140). However, these
scaffolds are also associated with significant drawbacks, including decreased mass
transport of oxygen and nutrients, and decreased vascularization, which in turn, results in
decreased osteoblast survival and bone regeneration (16, 17, 141, 142). On the other
hand, scaffolds with high porosity are not as mechanically strong and display decreased
cell seeding efficiency, but are associated with higher mass transport of oxygen and
nutrients, facilitating enhanced bone regeneration (21). With respect to dynamic bone
remodeling, increased osteoclast number and size in scaffolds with high porosity may
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result in increased bone matrix strength via increases in bone remodeling (143). Also,
studies have identified scaffolds with increased pore sizes to allow for the most efficient
vascularization (78, 144). Thus, scaffold porosity is a crucial parameter to consider when
fabricating scaffolds.
For bone tissue engineering applications, PLGA scaffolds developed via
microsphere sintering techniques have a unique advantage as they display mechanical
properties in the range of human cancellous bone (31), an essential aspect of scaffolds to
ensure proper support at the defect site upon implantation. These cancellous bonemechanically compatible scaffolds are attractive since bone has the special ability to
undergo remodeling and optimize its mechanical function for its particular skeletal
location, and thus, can be effectively used for regeneration in either cancellous or cortical
bone sites (55). Our group has fabricated and extensively investigated PLGA 85/15,
PLGA-nano hydroxyapatite composites, and PLGA-chitosan blend microsphere scaffolds
for bone regeneration (31-33, 145). PLGA 85/15 based microsphere scaffolds have
supported bone forming cell proliferation, differentiation and mineralization in vitro and
bone formation in vivo (32). However, these PLGA microsphere scaffolds lack the
necessary porosity for sufficient cell in-growth, and thus, result in surface-limited
osteogenesis in vitro and in vivo (Figure 3-17).

Figure 3-17. Schematic illustration of surface-limited and large-area bone
regeneration in a biodegradable scaffold. Scaffolds with a limited pore size and
reduced oxygen diffusion through their pore structure result in bone cell survival
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and growth limited to the scaffold surface, and thus surface-limited bone
regeneration (B), while optimally porous scaffolds with increased oxygen levels in
the scaffold interior allow for bone regeneration throughout the scaffold thickness,
which, in turn, can support large-area bone regeneration both in vitro and in vivo
(C). (A) is showing the cross-sectional surface of a scaffold.
To effectively increase microsphere scaffold porosity, we have used microsphere
sintering followed by a porogen leaching method. In this method, we combined PLGA
microspheres with a porogen (i.e., NaCl particles), thermally sintered, and then leached
out the porogen by soaking the constructs in water. Scaffold porosity and mechanical
properties can be tuned according to the clinical requirement by controlling the size and
amount of the porogen added during the fabrication process. Through this method, we
have improved PLGA microsphere performance and its ability to support osteoblast cell
survival, proliferation and mineralization throughout the construct, and yet retained
mechanical compatibility for effective bone regeneration.
As we increase the dry weight ratio of NaCl:PLGA used during the fabrication
process of PLGA microsphere scaffolds, the porosity and accessible volume increases
significantly (Table 3-). High accessible volume within scaffolds is a crucial parameter
that influences the efficiency of nutrient, gas, and waste exchange within the scaffolds, as
well as cell migration needed to promote tissue regeneration. Furthermore, it facilitates
angiogenesis allowing for blood vessel in-growth, and thus, increases supply of oxygen
and nutrients to the center of the construct. However, with increases in pore volume,
mechanical integrity is sacrificed (Figure 3-6). Scaffolds with a higher ratio of NaCl than
that in 40% NaCl/60% PLGA scaffolds were not mechanically stable.

Scaffolds

fabricated with an intermediate concentration of NaCl (i.e., optimally-porous scaffolds;
20% NaCl/80% PLGA scaffolds) were significantly more mechanically robust than those
fabricated with 40% NaCl/60% PLGA.
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Optimally-Porous
Scaffold (20%
NaCl/80% PLGA 85/15)
~ 31 % pore volume is
~ 12 % pore volume is
with pore sizes ≥ 200 µm with pore sizes ≥ 200 µm
338.4 ± 114.5 MPa
237.4 ± 46.5 MPa
11.4 ± 1.73 MPa
4.19 ± 0.99 MPa
Control Scaffold
PLGA 85/15

Accessible Pore Volume
Mechanical Properties
•Compressive Modulus
•Compressive Strength
Cell Seeding Efficiency
Cell Proliferation

81.30%

63.70%

1.87 fold increase from
5-14 day in vitro

2.98 fold increase from 514 day in vitro

Mineralization

Surface limited

Osteoconductivity

Surface limited

Homogeneous throughout
entire scaffold
Homogeneous throughout
entire scaffold (i.e., top,
center, bottom)
•35.5% more
mineralization in entire
scaffold
•79.2% more
mineralization in
scaffold’s interior
Fully osteoconductive

Oxygen in Scaffold Interior

0.69% ± 0.60%

3.13 ± 0.91%

Cell Viability and
phenotypic expression

Periphery limited

Table 3-1. Porosity, mechanical performance, and osteoconductivity comparison
between control and optimally-porous PLGA microsphere scaffolds.
In addition to decreasing mechanical strength, scaffolds with increased porosity
display a lower cell seeding efficiency, as these scaffolds are less efficient in retaining
cells during the cell seeding process (Figure 3-7). Despite the decrease in initial cell
number seeded on the scaffolds with increased porosity, cell numbers on these scaffolds
reached that of control scaffolds by 5 days in culture, and surpassed it by two weeks in
culture (Figure 3-8). We demonstrated that scaffolds with increasing accessible pore
volume corresponding specifically to pore sizes in the range of 200 to 400 µm (i.e., the
critical pore size range for neovascularization of engineered bone constructs), resulted in
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decreasing gradient of oxygen and pH from the exterior to interior regions of the MSCseeded constructs after 21 days in vitro. For instance, scaffolds fabricated with 80%
PLGA microspheres and 20% NaCl (by weight) demonstrate 30.6% of its accessible pore
volume to pore sizes of 200 µm, 12.5% of its accessible pore volume to pore sizes of 300
µm, and 6.0% of its accessible pore volume to pore sizes of 400 µm, in contrast to 12.3%,
2.0% and 0.9% of that in scaffolds that did not undergo porogen leaching. Scaffolds
fabricated with greater than 20% NaCl porogen further demonstrated increasing
accessible pore volume, however significantly lower mechanical strength.

Further, we

demonstrated that increasing accessible pore volume corresponded to increasing oxygen
tension and more normal pH levels in the interior of the scaffolds, allowing for enhanced
MSC-derived osteoblasts survival throughout the construct after long-term 21 day
culture. Thus, scaffolds with larger porosity have a better potential to support cell
proliferation in vitro, likely due to uniform oxygen tension and near-neutral pH
throughout the entire construct.
Increased cell survival and activity (i.e., osteopontin and Collagen Type 1
expression) was confirmed in the interior of scaffolds with increased porosity, compared
to that of control scaffolds over a long-term culture. However, there appears to be an
important relationship between mineralization potential and surface area of scaffold,
since macro-porous scaffolds (i.e., 40% NaCl/60% PLGA scaffolds) did not display as
high of mineralization as for optimally-porous scaffolds. Per these attributes, optimallyporous scaffolds display the highest performance in supporting cell infiltration,
proliferation, and mineralization throughout the entire construct in vitro (Table 3-2).
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Our optimally-porous scaffolds stand superior to other methods currently utilized
to increase cell proliferation and mineralization throughout BTE constructs in vitro. For
instance, bioreactor culture methods are popular alternative methods utilized to increase
cell infiltration and proliferation throughout constructs (146-148).

However, unlike

bioreactor culture methods, which are complex in nature and only effective in vitro,
optimally-porous scaffold development is simple and effectively allows for enhanced
oxygen tensions throughout the constructs both in vitro and in vivo. In addition, the
increased porosity in optimally-porous scaffolds are expected to improve vascularization
and osteoclast participation, and hence, bone remodeling by closely mimicking the native
bone repair process (143). Lastly, studies have citied a significant enhancement in bone
regeneration when adding growth factors (i.e. BMP-2) to BTE constructs (149-151).
However, functional bone regeneration may only occur when the entire construct,
including the interior, supports cell survival and proliferation (i.e., fully osteoconductive).
The combination of growth factors with an appropriate scaffold, such as our optimallyporous scaffold, that is fully osteoconductive and may support vascularization
throughout, will lead to optimal bone regeneration in large area bone defects.
In this study, by controlling scaffold pore size and pore volume, we effectively
designed oxygen tension controlled matrices. Increasing the amount of porogen resulted
in a systematic increase in not only porosity, but also available oxygen tension
throughout the matrix.

The enhanced survival, proliferation, differentiation and

mineralization of pre-osteoblasts may be attributed to the increase in available oxygen
tension. However, this increased cell performance may be cell type specific, as other cell
types, such as chrondrocytes, display enhanced performance in scaffolds with low
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porosity (152). Thus, the proposed optimally-porous scaffolds with improved oxygen
availability and bone compatible mechanical properties are desirable for large area bone
regeneration. Oxygen tension control via scaffold porosity optimization may provide
opportunities in designing next generation scaffold systems most effective for large area/
critical sized bone defect repair.

3.5.

Conclusions

Large area or critically sized bone defects pose a serious challenge in orthopaedic
surgery, as all current treatment options present with shortcomings.

Bone tissue

engineering offers a more promising alternative treatment strategy. However, this
approach requires mechanically-stable scaffolds that support homogenous bone formation
throughout the scaffold thickness. Despite advances in scaffold fabrication, current
scaffold-based techniques are unable to support uniform, three-dimensional bone
regeneration, and are limited to only the scaffold surface in vitro and in vivo. This is
mainly due to inadequate scaffold pore sizes (<200 µm) and accessible pore volume, and
the associated limited oxygen diffusion and vascular invasion. In this study, we have
adopted a method combining microsphere sintering and porogen leaching techniques to
fabricate scaffolds with increased accessible pore volume. Of the scaffolds developed,
optimally-porous PLGA microsphere scaffolds were selected as most advantageous, since
they retain mechanical strength in the range of human cancellous bone, and display
significantly higher accessible pore volume, which is attributed to an increased
percentage of larger pores (i.e., size range 200-600 µm). Unlike control scaffolds with
limited pore size and accessible pore volume, optimally-porous scaffolds displayed
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increased oxygen diffusion, pre-osteoblast cell infiltration, proliferation, and survival
throughout the entire scaffold.

Furthermore, optimally-porous PLGA microsphere

scaffolds displayed enhanced and homogenous mineralization in vitro. Since these newly
designed optimally-porous scaffolds are weight-bearing, fully osteoconductive and have
the ability to support vascularization, they may serve as effective scaffolds for large area
bone defect repair/regeneration.

In addition, this study demonstrates the ability to

modulate scaffold porosity and in turn, develop oxygen tension controlled matrices that
are effective for large area bone regeneration.
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4.

IDENTIFICATION OF EFFECTIVE AND

CLINICALLY-RELAVENT PROGENITOR CELLS FOR
ENHANCED VASCULAR AND BONE REGENERATION

4.1.

Introduction

Insufficient neo-vascularization currently represents a critical roadblock to
successfully engineering bone (35, 110, 142). The incorporation of endothelial cells into
engineered bone constructs has been offered as a promising and efficient approach to
enhance vascularization and in turn, promote successful bone formation at the graft site
(40, 41, 106, 153). Though many previous pre-vascularization studies have used human
umbilical vein endothelial cells (HUVECs) and mature endothelial cells obtained via
sacrification of blood vessels, they are not clinically applicable and have demonstrated
significant apoptosis upon transplantation (154). Endothelial progenitor cells (EPCs),
however, represent an exciting alternative to mature endothelial cells as they display high
angiogenic, proliferative and survival potential in situ.

Further, EPCs have been

successfully isolated from a number of sources (i.e., peripheral blood, bone marrow,
umbilical cord blood), and may be expanded to achieve adequate cell numbers for tissue
engineering applications without loosing their endothelial cell phenotype (122). Isolation
of EPCs from peripheral blood eliminates donor site morbidity risks, and thus, may
represent an ideal autologous cell source for the promotion of vascularization in tissue
engineering applications.
In the present study, we have isolated EPCs from two clinically-relevant sources
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for bone tissue engineering applications, peripheral blood and bone marrow (PB-EPCs
and BM-EPCs, respectively). In attempt to identify a superior source for EPC isolation,
we, for the first time, investigated the differential phenotypic expression of PB-EPCs and
BM-EPCs, and their potential for angiogenesis in vitro. We also assessed their ability to
enhance osteogenic differentiation of mesenchymal stem cells in vitro, and their
enhancement of key angiogenic and osteogenic markers. This investigation presents a
landmark study as it identifies the ideal isolation source for EPCs, making steps closer to
achieving clinical success in bone regeneration and repair.

4.2.

4.2.1.

Materials and Methods

Isolation of Rabbit Mesenchymal Stem Cells

(MSCs)

Mononuclear cells were isolated via layering over a Percoll density gradient, and
centrifuging at 600 rpm for 20 min at room temperature. The mononuclear cell fraction
was seeded and expanded in Dulbecco's Modified Eagle Medium (DMEM, Invitrogen)
supplemented with 10% FBS and 1% Penicillin/Streptomycin (P/S, Gibco) at 37oC and
5% CO2. Passages 3-5 were used for experimentation.
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4.2.2.

Isolation of Rabbit Endothelial Progenitor Cells

(EPCs)
4.2.2.1.
Bone Marrow-Derived Endothelial
Progenitor Cells (BM-EPCs)
Mononuclear cells from the bone marrow of New Zealand White rabbits were
isolated via layering over a Percoll density gradient, and centrifuging at 600 rpm for 20
min at room temperature. The mononuclear cell fraction was re-suspended in endothelial
cell growth medium (EGM2, Lonza; composed of endothelial cell basal medium-2
(EBM-2), 10% FBS, 1% P/S and EGM-2-SingleQuots growth factors and supplements),
immediately seeded on dishes coated with 1 mg/cm2 of rabbit type I collagen (C5608,
Sigma), and cultured at 37oC and 5% CO2. Non-adherent cells were removed after 4-7
days with gentle washes of PBS. Culture medium was changed every three days. After 3
weeks of passaging and expanding on collagen-coated plates, approximately 30 million
cells were achieved. Cells were cyropreserved for subsequent experiments. At this point,
collagen coating was no longer required.

Cells isolated 3-4 weeks post-isolation

(passages 5-8) were used for experiments.

4.2.2.2.
Peripheral Blood-Derived Endothelial
Progenitor Cells (PB-EPCs)
Peripheral blood (50 mL) was collected via cardiac bleeding protocol (approved
by the University of Connecticut Health Center Animal Care and Use Committee) from
New Zealand White rabbits (Figure 4-1). Isolation of mononuclear cell fraction, and
subsequent cell culture was performed following procedures described in Section 4.2.2.1.
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Similar numbers of PB-EPCs (30 x 106 total cells) were achieved after 3 weeks of
culture, at which point PB-EPCs obtained a cobblestone-like morphology, and collagen
coating the cell culture plates was no longer required. Cells isolated 3-4 weeks postisolation (passages 5-8) were used for experiments.

Figure 4-1. (A) Isolation of rabbit peripheral blood via cardiac exsanguination (i.e.,
terminal bleeding). (B) Image of Percoll solution layered on top of peripheral blood
in 50 milliliter centrifuge tubes prior to centrifugation. (c) Image of peripheral
blood separated by Percoll density gradient after centrifugation. At this stage, the
mononuclear fraction may be easily isolated.

4.2.3.

Isolation of Rabbit Vascular Smooth Muscle Cells

Methods for the isolation of rabbit smooth muscle cells (SMCs) from the aorta
were adapted from methods described by Sreejayan et al. (155). Passages 2-4 were used
for experimentation.

4.2.4.

Culture of Human Umbilical Vein Endothelial Cells

HUVECs (CRL-2873, ATTC) were cultured in EGM2 on 150 mm cell culture
plates at 37°C and 5% CO2.
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4.2.5.

Flow Cytometry

Samples were incubated with the following primary antibodies anti-human CD31
(M0823), anti-human vWF (sc-59957), anti-human CD34 (sc-7045), anti-rabbit CD44
(MCA806G), and anti-rabbit CD45 (MCA808G), subsequently an appropriate
fluorochrome-conjugated secondary antibody: mouse anti-goat IgG-PE (sc-3752) or goat
anti-mouse IgG-PE (sc-3738). Samples were analyzed using a BD Biosciences LSR II
using FACSDiVa software. PE was excited by the 488 nm laser and detected using a
575/25 bandpass filter. Live/Dead® Fixable Far Red Dead Cell Stain was excited by the
633 nm laser and detected using a 660/20 bandpass filter. Data was analyzed using
FlowJo software v.8.7.3 (TreeStar).

4.2.6.

Western Blot Analysis

Western blot analysis was performed on cell lysates as described by Lo et al.
using the following primary antibodies, alpha-smooth muscle actin (ab7817), transgelin
(sc-18513), smoothelin (sc-20479) (156).

4.2.7.

Matrigel 2D Assay

Cell suspensions containing 150,000 cells in 150 µl of DMEM were seeded in
triplicates on Matrigel coated glass bottom culture dishes, and plates were incubated for 6
hours at 37°C and 5% CO2. Samples were then incubated with calcein-AM, and imaged
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using confocal microscopy. For quantification, in ten random fields per sample, a pattern
recognition values were determined following the manufacturer’s guidelines (ECM625,
Millipore). Number of branch points and the number of tubular structures were counted
under a phase contrast microscope. Results are expressed as mean ± standard deviation.

4.2.8.

Co-Culture of MSCs and EPCs

Gene expression of osteogenic MSCs with PB-EPCs or BM-EPCs cultured
simultaneously (i.e., co-culture) was examined. Prior to co-culture, MSCs were cultured
in osteogenic media (DMEM, 10% FBS, 10 nM dexamethasone, 50 µg/ml ascorbic acid,
10 mM β-glycerophosphate) for 7 days. Then, MSCs were co-cultured with either PBEPCs or BM-EPCs at various co-culture ratios in a 1-to-1 mixture of osteogenic and
angiogenic medium on cell culture plates (not collagen coated). The following twelve
sample groups were studied: PB-EPCs alone; BM-EPCs alone; MSCs:PB-EPCs coculture ratios of 1:4, 1:2, 1:1, 2:1, and 4:1; and MSCs:BM-EPCs co-culture ratios of 1:4,
1:2, 1:1, 2:1, and 4:1.

Specific test conditions for cellular expression studies are

described in the following Section 2.10, 2.11 and 2.12.

4.2.9.

Analysis of Co-Culture Systems

4.2.9.1.

Matrigel 3D Assay

Cells were encapsulated in Matrigel (106 cells/mL Matrigel) and cultured in a 1to-1 mixture of osteogenic and angiogenic medium for 7 days in 48 well cell culture
plates. The following twelve sample groups were studied: PB-EPCs alone; BM-EPCs
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alone; MSCs:PB-EPCs co-culture ratios of 1:4, 1:2, 1:1, 2:1, and 4:1; and MSCs:BMEPCs co-culture ratios of 1:4, 1:2, 1:1, 2:1, and 4:1. Three-dimensional samples (10 mm
diameter, 2 mm height) were paraffin-embedded, sectioned and then stained with
hematoxylin and eosin. Four samples per group were embedded, and three sections per
sample were stained (one from top, middle and bottom; approximately 200 µm apart from
each other). Stained sections were analyzed under the light microscope Olympus BX50
with Olympus DP70 camera. Twelve images viewed under 10X magnification, and the
number of branches were counted for each sample.

4.2.9.2.

Alkaline Phosphatase Activity

Alkaline Phosphatase (ALP) Substrate Kit (172-1063) was used in accordance to
manufacturer’s instructions.

ALP levels were normalized to total protein levels as

determined using BCA Protein Assay Kit.

4.2.9.3.

Gene Expression (RT-PCR)

For each cell culture condition (n=3), a total of 40,000 cells were plated on a 24
well-cell culture plate. For co-culture samples, 1 milliliter of a 1-to-1 mix of endothelial
and osteogenic media was added. For single cell type cultures (i.e., EPCs or MSCs), 1
milliliter of endothelial or osteogenic media was added, respectively. At the appropriate
time points, total RNA was isolated using the Qiagen RNeasy Mini Kit, and converted
into cDNA via Clontech Sprint RT Complete cDNA synthesis kit. For quantitative real
time PCR, BioRad iCycler Thermal Cycler Base and BioRad iQ Supermix, BMP-2
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(Oc03824113_s1), BMP4 (Oc03233792_m1), thrombomodulin (Oc03822979_s1),
KDR/FLK (Oc03395666_m1), collagen type 1 alpha 1 (Oc03396074_g1), VEGFA (Oc03395999_m1), and GAPDH (Oc03823402_g1) gene probes (Applied Biosciences,
Carlsbad, CA) were used. Threshold cycle values of target genes was standardized
against GAPDH expression and normalized to the expression in the control culture.

4.2.10.

Statistical Analysis

For Matrigel 2D and 3D Assay analysis, ALP and gene expression quantification
a two-way analysis of variance (ANOVA) was preformed to compare data. Error is
reported in figures as the standard deviation (SD) and significance was determined using
a probability value of P<0.050.
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4.3.
4.3.1.

Results
Cell Morphology and Expression of Isolated BM-

EPCs and PB-EPCs

Figure 4-2. Endothelial cell phenotype and immunostaining of CD31 and vWF. (D,
E) HUVECs and PB-EPCs stained positive for CD31 and vWF. (F) BM-EPCs did
not stain positive for CD31, but did stain positive for vWF.
Rabbit EPCs isolated either from bone marrow (BM) or peripheral blood (PB) by
density gradient and cultured on collagen type 1-coated cell culture plates exhibited
distinct morphology and cellular expressions of key endothelial cell markers (Figure 4-2).
Initially, both PB-EPCs and BM-EPCs displayed a spindle-like morphology. However,
after two to three weeks of culture post-isolation, PB-EPCs formed colonies that
exhibited a pronounced endothelial “cobblestone” morphology, which was also observed
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by human umbilical vein endothelial cells (HUVECs), a commonly studied vascular
endothelial cell line. BM-EPCs did not form colonies of cobblestone-like cells by this
time, and continued to have colonies composed of spindle-shaped cells. HUVECs were
used in these experiments to study the characteristics of a mature, homogenous vascular
endothelial cell line.

Figure 4-3. Flow cytometry analysis of CD31, vWF, VEGF-R2, CD34, and CD45 on
(A) HUVECs, (B) PB-EPCs, and (C) BM-EPCs; and CD44, CD34, and CD45 on (D)
MSCs. Blue lines indicate fluorescence signals of isotypic controls, and red lines
indicate fluorescence signals of the specific antigens. Plots are depicted with % of
Maximum Counts (%Max) on y-axes, and the PE fluorescence intensity for the
indicated markers is shown (bi-exponential scale) on x-axes.
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Like HUVECs, PB-EPCs are strongly positive for CD31 and von Willebrand
factor, common endothelial cell markers (Figure 4-3A, B). BM-EPCs, however, did not
express CD31 (Figure 4-3C). All endothelial cell types (i.e., HUVECs, PB-EPCs, BMEPCs) display a low signal for CD34 and CD45 (Figure 4-3). MSCs stained positive for
CD44, and negative for CD34 and CD45 (Figure 4-3D). Lack of CD45 signal indicates
no/minimal hematopoietic cell contamination.

Figure 4-4. Gene expression of key bone and vascular markers (i.e., BMP-2, COL I,
BMP-4, VEGF, VEGF–R2 and thrombomodulin) in PB-EPCs and BM-EPCs 4
weeks post-isolation.

Furthermore, four weeks post-isolation, PB-EPCs also demonstrated markedly
higher gene expression levels of key vascular markers important to angiogenesis and
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osteogenesis. The following genes displayed significantly higher regulation in PB-EPCs
in comparison to that of BM
BM-EPCs, BMP-2, collagen type 1 (COL1), VEGF, BMP4,
VEGF-receptor 2 (VEGF-R2/KDR),
R2/KDR), thrombomodulin (THRMB) (Figure 4-4).
4
VEGFR2 is a well-documented marker of EPCs, as they have been shown to respond to
angiogenic factor, VEGF, for proliferation and migration.

On the other hand,

interestingly, BM-EPCs expressed high levels of established smooth muscle markers (i.e.,
smooth muscle actin- alpha (SMA
(SMA-α), smoothelin, transgelin), whereas PB-EPCs did not
(Figure 4-5C-E). MSCs expressed SMA-α, but lacked smoothelin and transgelin.

Figure 4-5. Protein expression of isolated cell populations.

4.3.2.

2D In Vitro Angiogenesis Characteristics of BM-

EPCs and PB-EPCs
PB-EPCs and BM-EPCs
EPCs significantly differed in their angiogenic ability to form
tubular networks. PB-EPCs,
EPCs, like HUVECs, uniformly participated in elaborate network
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formations (Figure 4-6 A, B), whereas a significantly lower percentage of BM-EPCs
demonstrated network formation, and instead, the majority of BM-EPCs showed only the
ability to stretch on Matrigel (Figure 4-6 C, D). Also, PB-EPCs formed significantly
more branch points and higher total tube length than BM-EPCs; however, both form
significantly less than HUVECs (Figure 4-6 G).

Figure 4-6. Two-dimensional angiogenesis assay showing network formation by (A)
HUVECs, (B) PB-EPCs and (C) BM-EPCs, (D) SMCs, and (E) MSCs. Scale bar =
500 µm. (E) Numerical pattern recognition values were assigned to each pattern,
such that a numerical value is associated with a degree of angiogenesis progression
(i.e., 0 = cells isolated or in a sheet-like monolayer, 1 = cells begin to migrate and
align themselves, 2 = capillary tubes visible but no sprouting, 3 = sprouting of new
capillary tubes visible, 4 = closed polygons form, 5 = complex mesh like structures
develop). Examples of branch point (white arrow), tube length (white line), and
polygon shape (white outlined hexagon) on indicated on (B). Comparison of
number of (F) formed branch points, (G) average tube length and (H) total tube
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length formed by PB-EPCs
EPCs and BM
BM-EPCs. (E-H)
H) Values are expressed as arbitrary
units. Significance is signified as * (p<0.01).
4.3.3.

3D In Vitro Network Formation in Matrigel

After 1 week in 3D Matrigel culture, PB-EPCs began to organize into elongated
structures that connected to each other and formed a 3D network (Figure
Figure 4-7A). In
contrast, BM-EPCs did not fo
form extensive 3D networks (Figure 4-7B, C). Co-seeding
PB-EPCs and MSCs promoted the degree of network formation. Specifically,
significantly more luminal structures were present in groups seeded with MSCs:PB-EPCs
MSCs:PB
ratios of 1:4 compared to PB
PB-EPC alone. A direct relationship was observed between
branch points and PB-EPCs:MSCs
EPCs:MSCs co-culture ratio.

Figure 4-7. Capillary network formation of (A) PB-EPCs and (B) BM-EPCs
BM
in
Matrigel. (C) PB-EPCs formed significantly higher branching points after 7 days
cultured in Matrigel in vitro. Significance is signified as * (p<0.01).
(p<
(D-I)
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Hematoxylin/eosin staining of capillary network formation of various co-culture
ratios of MSCs and PB-EPCs (MSCs:PB-EPCs), specifically (D) 1:4, (E) 1:2, (F) 1:1,
(G) 2:1, (H) 4:1. (I) Scoring of the branch points formed with different MSC:EPC
ratios in 3D culture, data presented as mean ± SD. Scale bar = 250 µm.

4.3.4.

ALP Activity of BM-EPCs and PB-EPCs Co-Cultured

with MSCs
Alkaline phosphatase (ALP) activity in co-cultures of MSCs with either PB-EPCs
or BM-EPCs was studied as an early marker of osteogenic differentiation. After 14 days
of culture, PB-EPCs displayed significantly higher ALP activity than BM-EPCs, though
both less than that of MSCs (Figure 4-8).

ALP activity levels were also enhanced in

MSC:PB-EPC co-cultures, in comparison to MSCs or PB-EPCs cultured alone.

ALP

activity increased as the MSC fraction of the co-culture increased, however this trend was
not observed in MSC:BM-EPC co-cultures.
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Figure 4-8. Comparison of ALP activity of MSCs co-cultured with PB-EPCs or
BM-EPCs at various ratios. ALP activity of MSCs, PB-EPCs, and BM-EPCs alone
under the same conditions are displayed in dashed lines, whereas MSC:PB-EPC and
MSC:BM-EPC co-cultures at different ratios are displayed as the blue and red line,
respectively.

4.3.5.

Effect of MSC:EPC Co-Culture Ratios on Vascular

and Osteogenic Gene Expression

Gene expression of critical angiogenic and osteogenic markers are higher in PBEPCs than BM-EPCs (dashed lines) after 7 days in vitro (Figure 4-9A-F). BMP-2 and
BMP-4 expression levels display a direct relationship with the MSC fraction in the coculture ratios of both MSC:PB-EPC and MSC:BM-EPC, such that BMP-2 and BMP-4
expression significantly increased as the MSC fraction in the co-culture increased
(Figure 4-9A, B). For example, co-cultures with a 4:1 MSC:EPC ratio displayed the
highest levels of BMP-2 and BMP-4. On the other hand, COL1 expression was also only
enhanced in MSC:PB-EPC co-cultures, in comparison to MSCs and EPCs cultured alone;
this trend was not observed in MSC:BM-EPC co-cultures (Figure 4-9C).

Gene

expression of vascular markers, VEGF, VEGF-R2 and thrombomodulin, decreased with
increasing MSC fraction in both MSC:PB-EPC and MSC:BM-EPC co-culture ratios
(Figure 4-9D-F).
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Figure 4-9. Comparison of (A) BMP-2, (B) COL1, (C) BMP-4, (D) VEGF, (E)
VEGF-R2, and (F) thrombomodulin in co-cultures with MSCs and either PB-EPCs
or BM-EPCs at different ratios. Gene expression normalized to GAPDH levels is
plotted on the y-axis, and various ratios of MSCs co-cultured with EPCs on the xaxis. Gene expression of MSCs, PB-EPCs, and BM-EPCs alone under the same
conditions of the MSC:EPC co-cultures after 7 day in vitro are presented as mean
and displayed in dashed lines, whereas MSC:PB-EPC co-cultures and MSC:BMEPC co-cultures at different ratios are displayed as the blue and red line,
respectively.
4.3.6.

Time Course of BMP-2 and VEGF Expression of

MSC:PB-EPC Co-Cultures
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Figure 4-10. Time course of (A) BMP-2 and (B) VEGF expression in co-cultures
co
of
MSCs and PB-EPCs at different ratios at day 2, 7, and 14 in vitro. Dashed lines
indicate gene expression of either MSCs or PB-EPCs cultured alone under the same
conditions as the co-cultures.
tures.
MSC:PB
coBMP-2 gene expression was significantly up-regulated in MSC:PB-EPC
cultures over the course of 14 days in vitro (Figure 4-10A), in respect to BMP-2
expression in MSC alone. After 2 and 7 days in vitro, BMP-2 expression was enhanced
in only 1:1, 2:1 and 4:1 MSC:PB
MSC:PB-EPC co-culture ratios, in comparison to MSCs and PBEPCs cultured alone.

However, after 14 days, all MSC:PB-EPC co-culture
culture ratios

displayed significantly enhanced expression of BMP-2 to the expression of that in each
cell type cultured alone.
MSC:PB
VEGF gene regulation followed an inverse pattern of BMP-2 in MSC:PB-EPC
co-culture. VEGF expression decreased as MSC fraction increased in MSC:PB-EPC
MSC:PB
coculture, and was also significantly enhanced in co-culture compared to when cultured
alone (Figure 4-10B). VEGF expression was enhanced in co-culture as early as day 2,
with MSC:PB-EPC ratios of 1:1, 1:2 and 1:4 being significantly enhanced in comparison
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to the cells alone. At day 7 and 14, VEGF expression was enhanced in all co-culture
ratios in relation to its expression in the cells alone.

4.4.

Discussion

Despite the recent exponential growth of EPC literature, critical details remain
unclear. In this study, we determined the best clinically-relevant cell source for EPC
isolation. Past studies investigated whether adult peripheral blood (PB) or fetal cord
blood (CB) offer the best source for EPC isolation. Many reported that CB represent a
superior EPC cell source, as CB-EPCs had greater isolation efficiency, higher ex vivo cell
number expression, and longer stability of vascular networks in vivo, in comparison to
PB-EPCs (104). Though interesting, CB-ECPs are presently not clinically relevant, as
most patients do not have access to this. With this, we sought to explore not only more
clinically-relevant cell sources, but also investigate more widely reported sources in bone
tissue engineering studies. We have isolated, characterized and compared EPCs from
rabbit peripheral blood and bone marrow (PB-EPCs and BM-EPCs, respectively).
Though the investigated cells were isolated from rabbits, the same cell populations may
be isolated from humans for their potential clinical use for bone repair and regeneration
(104, 157). PB-EPCs have proven to be a superior endothelial cell population, in contrast
to BM-EPCs, a population in which the majority of bone tissue engineering studies
involving EPCs have previously reported on.
Differences in isolation and cultivation procedures of EPCs make it difficult to
directly compare published studies on the outcomes of EPC functionality. For this reason,
we have isolated and cultured EPCs isolated from peripheral blood and bone marrow in a
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similar manner, and as previously described by numerous studies (158). The PB-EPC
population that has been characterized in our studies has also been referred to as late
EPCs, outgrowth endothelial cells (OECs) and endothelial colony–forming cells (ECFCs)
in other published studies (158-160). BM-EPCs did not express endothelial marker
CD31, as confirmed by flow cytometry and western blot analysis.
Bone formation is a complex process, and one of the most important heterotypic
cross-talks in this process is the one between endothelial cells and osteoblasts (39, 161).
The underlying cellular regulatory mechanisms for this cross-talk have pointed to
paracrine signaling based on angiogenic growth factors, such as VEGF and PDGF, and
also direct cellular communication via gap junctions (162).

Therefore, we also

investigated how the addition of isolated EPCs contributes to osteogenic differentiation
and bone-forming capacity of rabbit mesenchymal stem cells (MSCs) for bone tissue
engineering purposes, a popular approach actively being investigated in vivo by many
other groups (40, 42, 47, 153).

In co-culture, rabbit MSCs and PB-EPCs display

significantly enhanced expression of key vascular and osteogenic markers.

The

expression of the key markers were also significantly higher in MSC/PB-EPC co-culture
than that in co-cultures of MSCs and BM-EPCs. As early as 1 week in co-culture,
expression of bone markers COL1, BMP-2, and BMP-4, and angiogenic markers VEGF,
VEGF-R2, and thrombomodulin were enhanced beyond expression levels of MSCs and
PB-EPCs cultured alone.
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Figure 4-11.. Schematic illustrati
illustration
on of possible EPC differentiation mechanism.
The putative BM-EPCs,
EPCs, which were isolated precisely as many tissue engineering
researchers have previously described, did not exhibit the typical endothelial phenotype
as expected of EPCs. Instead, putative BM-EPCs exhibited more of a smooth musclelike phenotype, with limited angiogenic potential similar to the smooth muscle cells
isolated from rabbit aorta, as compared to HUVECs and PB-EPCs. Further, putative
BM-EPCs express high levels of smooth muscle markers, whereas PB-EPCs
EPCs do not.
Plausible explanations for these observations involve the committed lineage stages of
BM-EPCs and PB-EPCs isolated from bone marrow and peripheral blood, as illustrated
in Figure 4-11. It has been established that EPCs originate from the bone marrow, and are
derived from a vascular progenitor cell population, which also has the ability to give rise
to smooth muscle progenitor cells (SMPCs) (163). As EPCs become mobilized from the
bone marrow into circulation in the peripheral blood, they begin to express more
124

endothelial cell markers, and begin to lose their stem cell-like properties and become less
plastic. Thus, the transition from the bone marrow to the peripheral blood marks a
certain degree of maturation or committed-ness of EPCs to the endothelial cell lineage.
EPCs and SMPCs have previously been shown to have the ability to trans-differentiate
from one lineage to the other via an endothelial-to-mesenchymal transition-like process
mediated by TGFβ-RI (164). Thus, BM-EPCs, which may harbor more stem cell-like
properties and more easily trans-differentiate into SMPCs, are marked by the waning of
endothelial markers and functionality. Whereas, PB-EPCs are likely to be in a more
committed stage in their differentiation process, and do not give rise to smooth muscle
progeny spontaneously.
Supporting our study, Fedrovich et al. observed early BM-EPCs (i.e., BM-EPCs
cultured for approximately 1 week in endothelial growth media) to express CD31 only
transiently, and lose CD31 expression as culture time increased (43). BM-EPCs also
displayed transient endothelial cell phenotype, including isolectin B4 binding and
acetylated LDL-incorporation. Also, it is important to note that in other previous studies
that report their isolated BM-EPCs to be CD31 positive, they may have studied their BMEPCs at this early stage. Also, many other studies have not specified whether their BMEPCs express CD31, they only provide their isolation protocol.
These putative BM-EPC may possibly be more appropriately referred to as
smooth-muscle like progenitor cells; however, although not a superior endothelial
progenitor cell source, this population may still serve as an important option for enhanced
vascularization and/or bone formation in engineered bone tissue. Firstly, there is an
established cooperation between endothelial cells and perivascular cells (i.e., smooth

125

muscle cells located at the periphery of capillaries) that is fundamental for vascular
maturation (35).

Also, perivascular cells have been shown to differentiate into

osteoblasts, and contribute to bone formation in vivo (165). Lastly, bone tissue
engineering studies have reported positive results when implanting not only PB-EPCs,
but also BM-EPCs, at a bone defect site, for enhanced vascularization and bone
formation in vivo.

Thus, given these established relationships between EPCs,

perivascular cells and MSC derived-osteoblasts, future studies should upgrade co-culture
systems, and perhaps explore tri-cultures involving these three cell types (i.e., PB-EPCs,
putative BM-EPCs and MSC derived-osteoblasts) for further enhancement of bone
formation and vascular networks in vivo.

4.5.

Conclusions

For tissue engineering applications, effective bone regeneration requires rapid
neo-vascularization of implanted grafts to ensure the survival of cells in the early postimplantation phase. Incorporation of autologous endothelial progenitor cells (EPCs) for
the promotion of primitive vascular network formation ex vivo has offered great promise
for improved graft survival, enhanced rate of vascularization and bone regeneration in
vivo. For clinical usage, identification of an optimal EPC isolation source from the
patient is critical. We have, for the first time, characterized and directly compared EPCs
from rabbit peripheral blood and bone marrow (PB-EPCs and BM-EPCs, respectively).
PB-EPCs outperformed BM-EPCs on all measures.

PB-EPCs displayed typical

endothelial cell markers, such as CD31, as well as high angiogenic potential in three-
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dimensional

extracellular

matrix

in

vitro.

Furthermore,

PB-EPCs

cultured

simultaneously with mesenchymal stem cells, displayed significantly enhanced
expression levels of key osteogenic and vascular markers, including alkaline phosphatase,
bone morphogenetic protein 2, and vascular endothelial growth factor. On the contrary,
putative BM-EPCs did not express CD31, and instead, expressed key smooth muscle
markers. BM-EPCs further failed to display vasculogenic activity. Hence, the highly
angiogenic peripheral blood derived-EPCs may serve as an ideal cell population for
enhanced vascularization and success of engineered bone tissue.

127

5.

EVALUATION OF PRE-VASCULARIZED

OPTIMALLY-POROUS SCAFFOLDS FOR ENHANCED
NEO-VASCULARIZATION AND BONE FORMATION IN
VIVO

5.1.

Introduction

Many cellular-based bone tissue engineering approaches involve the utilization of
bone marrow derived mesenchymal stem cells (MSCs) as osteo-progenitor cells to
promote and accelerate bone regeneration.

In this approach, MSCs are seeded on

scaffolds for colonization and implantation at a defect site. However, upon implantation,
colonized cells in the interior regions of scaffolds with depth dimensions greater than
one-millimeter experience limited oxygen and nutrient availability, since they are
dependent on post-implantation vascularization that may occur on the order of days to
weeks. Due to limited nutrient delivery and waste products removal via diffusion and
proper functional vascularization, cell viability, and in turn, bone regeneration and host
integration is severely hindered.
Efficient methods to establish near-immediate neovascularization in bone tissue
engineered constructs are essential.

In vitro pre-vascularization of bone tissue

engineering constructs with endothelial progenitor cells (EPCs) have gained significant
attention in this respect (48).

EPCs, which may be easily isolated from the patient’s

peripheral blood, demonstrate high proliferative potential for ex vivo expansion, as well
as the ability to enhance and accelerate neovascularization in vivo (166). Moreover,
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when co-implanted with MSCs at a bone defect site enhanced neovascularization and
bone formation is observed.

This enhancement is a result of synergistic communication

(i.e., “cross-talk”) between MSCs and EPCs (167, 168), where MSCs have been shown to
release angiogenic factor VEGF (169, 170), and EPCs have been shown to release
osteogenic factor, such as BMP-2 and BMP-4 (171, 172).

Although this pre-

vascularization approach with EPCs and MSCs has been examined and proven effective,
the ideal cell ratio that would potentially yield functional bone grafts has not yet been
investigated.
In this study, we investigated a two-pronged approach for enhanced neovascularization and bone formation in vivo. We utilized our optimally-porous scaffolds
with tunable, increased porosity, especially in the range of 300-400 um, which has been
cited as the critical pore size range for neo-vascularization (16).

These scaffolds

demonstrate enhanced performance, specifically in respect to increased oxygen tension
levels, near-normal pH levels, and increased cell viability in the interior regions of the
constructs after long-term in vitro culture with MSCs. Moreover, we investigated the
effectiveness of various co-culture ratios of MSCs and EPCs on these scaffolds in
promoting neo-vascularization and bone formation in vivo.

5.2.

Materials and Methods

5.2.1.

In Vitro Culture of Cell-Seeded Optimally-Porous

Scaffolds
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Optimally porous scaffolds (20% NaCl/80% PLGA scaffolds; 10 mm diameter, 2
mm height) were seeded with a total of 250,000 cells/scaffold and cultured in a 1-to-1
mix of endothelial and osteogenic media for 2 days 37oC and 5% CO2. Prior to culture on
scaffolds, MSCs were cultured in osteogenic media (DMEM, 10% FBS, 10 nM
dexamethasone, 50 µg/ml ascorbic acid, 5 mM β-glycerophosphate) on tissue culture
plate (TCP) for 7 days. Various cell conditions seeded on scaffolds were examined: (1)
MSC-derived osteoblasts, (2) EPCs, (3) co-culture of 4 parts MSC-derived osteoblasts to
1 part EPC (4:1), (4) co-culture of 1 part MSC-derived osteoblasts to 1 part EPC (1:1),
and (5) co-culture of 1 part MSC-derived osteoblasts to 4 parts EPC (1:4).

5.2.2.

In Vitro Performance Evaluation of Cell-Seeded

Optimally-Porous Scaffolds

Expression of other osteogenic markers, RunX2 and Collagen Type I, and
vasculogenic markers, CD31 and vWF, was analyzed by immuofluorescence. After 2
days in vitro, cell-seeded constructs were fixed in 10% formalin for 1 hour at room
temperature, rinsed with PBS, and permeabilized with 0.25% Triton X-100 for 10
minutes. Constructs were rinsed with PBS, blocked in 10% normal goat serum for 1
hour, and then incubated with the following primary antibodies for 1 hour: anti-RunX2
antibody (Abcam, ab76956, 1:50), anti-Collagen I antibody (Abcam, ab34710, 1:100),
anti-CD31 antibody (Abcam, ab28364, 1:50), anti-Von Willebrand Factor antibody
(Abcam, ab6994, 1:1000), Anti-β-Tubulin (Millipore 05-661, 1:200). Samples were then
washed and labeled with the corresponding secondary antibody: anti-mouse IgG
secondary antibody-FITC (sc-2099, Santa Cruz) or anti-rabbit IgG secondary antibody130

FITC (sc-53805, Santa Cruz) diluted 1:100 in 1% BSA/PBS for 40 min at room
temperature. Finally, cell nuclei were counterstained using propidium iodide (81845,
Sigma, St. Louis, MO). Stained constructs were examined via confocal microscopy
(Zeiss LSM Confocor 2).

5.2.3.

In Vivo Performance Evaluation of Cell-Seeded

Optimally-Porous Scaffolds
First, to evaluate the most effect ratio of mesenchymal stem cells (MSCs) and
peripheral-blood derived endothelial progenitor cells (PB-EPCs) seeded on our
optimally-porous scaffolds for the promotion of vascularization in vivo, we utilized a
SCID mouse subcutaneous implant model. Second, we evaluated the performance in
respect to vascularization and bone regeneration potential of our optimally-porous
scaffolds seeded with the most appropriate cell progenitor ratio and implanted in a rabbit
ulnar bone defect model (Figure 5-1).

Figure 5-1. Study plan for evaluating the vascular and bone regeneration potential
of optimally-porous scaffolds seeded with clinically-relevant progenitor cells in vivo.
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5.2.3.1.
5.2.3.1.1.

SCID Mouse Subcutaneous Implant Model
Construct Implantation

To evaluate the in vivo performance of various combination of peripheral blood
(PB)-derived EPCs (PB-EPCs) and MSC-derived osteoblasts, we implanted the 5
construct conditions described in Section 5.2.1 after 2 days in vitro to ensure proper cell
adherence (Figure 5-2). As a negative controls, we used an acellular optimally-porous
scaffolds. Male Fox Chase (CB17) SCID (severe combined immunodeficiency) (Charles
River Laboratories, Wilmington, MA, USA) mice were anaesthetized with isoflurane in
the induction chamber at a range of 3-5%. The animals were maintained on 2-4%
isoflurane with the nose cone between placement of implants in separate subcutaneous
dorsal pockets (2 implants/ animal; 3 animals/condition).

The animals were post-

operatively treated with the analgesic buprenorphine (0.05mg/kg, subcutaneous).

All

animal experiments were approved by the University of Connecticut Health Center
Animal Care and Use Committee (protocol 2009-593).
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Figure 5-2. Implantation of constructs in a dorsal subcutaneous SCID mouse
model. (A, B) An incision with approximately the same length as the construct’s
diameter is created in the dorsum of the mouse, (C) the construct is implanted
subcutaneously, and (D) the skin at the implantation site is stapled closed.

5.2.3.1.2. Histological Staining and Analysis

The implanted constructs were retrieved 8 weeks after implantation to analyze the
blood vessel formation and bone formation. Samples were fixed overnight in 10%
formalin and processed for paraffin sections. Histological staining was performed with
Masson’s Trichrome Staining (Sigma, HT15) on 5 µm thick paraffin sections according
to the manufacturer’s protocol.

Stained sections were analyzed under the light

microscope Olympus BX50 with Olympus DP70 camera.
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For collagen quantification,

we utilized the RBG plug-in in ImageJ (National Institutes of Health), and specifically,
collagen, which stains blue via Masson’s Trichrom Staining, was quantified.

Ten

random images under 40X magnification were analyzed per sample (3 samples/group;
thirty total images per group) in ImageJ using the RBG Measure Plug-in
(http://rsb.info.nih.gov/ij/plugins/color-histogram.html) to measure the Collagen stained
blue with Trichrome Stain. Images were opened in Image J and converted to RBG Color
(Image > Type > RBG Color), then the background was subtracted (Process > Subtract
Background > Light Background), the RBG was measured on the selected region of
interest (ROI).

For vessel quantification, we analyzed and counted vascular structures

in ten random images taken under 20X magnification for each group.

5.2.3.1.3. Immunohistochemical Analysis

To

confirm

vascularization

and

bone

formation,

we

performed

immunohistochemical analysis for endothelial markers CD31 and vWF, and bone
markers RunX2 and Collagen Type I, respectively. We immune-stained sections of the
group containing the scaffold seeded with 1 part MSC-derived osteoblasts and 1 part EPC
(1:1). We used paraffin-embedded mouse limbs (post-natal day 1) as a positive control.
Briefly, rehydrated sections were exposed to heat-mediated antigen target retrieval
(Target Retrieval Solution, Dako S1700) for 5 minutes at 98oC, then blocked in 10%
normal goat serum in PBS for 1 hour at room temperature. Sections were then incubated
with the following primary antibodies overnight at 4oC: anti-RunX2 antibody (Abcam,
ab76956, 1:50), anti-Collagen I antibody (Abcam, ab34710, 1:100), anti-CD31 antibody
(Abcam, ab28364, 1:50), anti-Von Willebrand Factor antibody (Abcam, ab6994, 1:1000),
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Anti-β-Tubulin (Millipore 05-661, 1:200). Samples were then washed and labeled with
the corresponding secondary antibody: anti-mouse IgG secondary antibody-FITC (sc2099, Santa Cruz) or anti-rabbit IgG secondary antibody-FITC (sc-53805, Santa Cruz)
diluted 1:100 in 1% BSA/PBS for 40 min at room temperature. Finally, sections were
mounted with Propidium Iodide/Anti-fade Solution (S7112, Millipore), and examined via
confocal microscopy (Zeiss LSM ConfoCor2, 20X magnification).

5.2.3.2.

Rabbit Ulnar Defect Model

5.2.3.2.1. Construct Implantation

Optimally porous scaffolds (20% NaCl/80% PLGA scaffolds; 15 mm height, 5
mm diameter) were seeded with a total of 500,000 cells/scaffold and cultured in a 1-to-1
mix of endothelial and osteogenic media for 2 days 37oC and 5% CO2. Prior to culture on
scaffolds, MSCs were cultured in osteogenic media (DMEM, 10% FBS, 10 nM
dexamethasone, 50 µg/ml ascorbic acid, 5 mM β-glycerophosphate) on tissue culture
plate (TCP) for 7 days. Various cell conditions seeded on scaffolds were examined: (1)
MSC-derived osteoblasts, (2) EPCs, (3) co-culture of 1 part MSC-derived osteoblasts to 1
part EPC (1:1), (4) acellular (i.e., scaffold alone).
New Zealand white rabbits (4-5 kg weight) were anesthetized via an
intramuscular injection of a mixture of ketamine (50mg/kg), xylazine (6mg/kg), and
acepromazine (1mg/kg) (Figure 5-3). The right forelimb of the rabbit were shaved, and
prepped with betadine and 70% ethanol. A longitudinal incision was made to expose the
mid-diaphysis of ulna. A segment of the ulna measuring 15 millimeters in length was

135

removed using a bone saw. The scaffolds weree implanted into the defect site and the
wound was closed by suturing muscles and skin in layers (Figure 5-4). After 12 weeks
post-implantation, animals were sacrificed and ulnar bone was excised, fixed in 10%
formalin for 24 hours, and then transferred to 70% ethanol until further analysis.

Instru
Figure 5-3. Preparation for rabbit ulnar bone defect model (A) Instruments
utilized during implantation of constructs in a critical
critical-size
size ulnar bone defect in a
rabbit. The rabbit is prepared pre
pre-surgery.
surgery. The rabbit is (B) intubated, (C) hooked
up to a heart monitor,, and (D) closely monitored during the operation. (F) The
rabbit’s right arm is prepared, cleansed with betadine and ethanol and stabilized.
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Figure 5-4.. Steps involved in implantation of a construct into a rabbit ulnar bone
b
defect model. (A) An incision is made in the right arm of the rabbit, (B, C) the
surrounding muscle is dissected to expose the u
ulnar
lnar bone. (D) A saw is used to make
the first cut into the bone.. (E) The length of the construct is marked off on the back
b
of a sterile wooden stick, and (F, G) is used to measure the length of the bone defect.
(H) A second cut is made in the bone, and the 15 millimeter bone piece is removed.
(I) The bone and construct are equivalent in length. (J) The construct is secured
sec
in
the defect, and (K) the surrounding muscle layer is sutured, and (L) then the
surrounding skin is sutured.

5.2.3.2.2. X-Ray Analysis

Bone formation on each rabbit ulnar explant was analyzed at 18 kV for 10 seconds using
the Faxitron X-ray machine, and the Faxitron DX-Beta SR v1.4 software.

5.2.3.2.3. MicroCT Analysis

MicroCT provides an efficient method to measure the distribution and density of
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mineralized tissue throughout the scaffold. Limbs harvested at week 12 were imaged
using cone beam micro-focus
focus X-ray computed tomography to render three-dimensional
three
models for direct quantitation of sample bone density and volume, and to provide a threedimensional reconstruction of the defect (µCT40, Scanco Medical AG, Bassersdorf,
Switzerland).

Segmentation of bone and scaffold provided direct volumetric

quantification of bone formation into the depths of the scaffold, as well as the analysis of
the structural integrity of new bone and biodegradable scaffold.

Mass was calibrated to

a stepped hydroxyapatite phantom (Scanco, Item # KP-03-03) units of mg of HA per
cubic cm (mg HA/cm3) (Figure
Figure 55-5).

Figure 5-5. Image of the stepped hydroxyapatite phantom used for calibration of
mass during MicroCT analysis.
Serial tomographic images were acquired at 55 kV and 145 µA with a 300 msec
integration time. A set length of 11 millimeters was analyzed within the defect.
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Measurements include volumetric basis, but accurate measures are based on mass, which
captures all mineral including what is not taken into account in volume measurements of
repairing bone with low density regions. Mass is calibrated to a stepped hydroxyapatite
phantom, units of mg of HA per cubic cm (mg HA/cm3). Since the bone remodeling is
significant, such that formation/resorption/remodeling are not distinguishable and
includes regions of high and low density, to measure all formation, the total mass of all
bone (radius, callus, everything) was measured within the set length. We also measured
and subtracted off the mass of the radius in the intact limb within the matching region of
each experimental limb.

5.2.3.2.4. Histological Staining and Analysis

Limbs were embedded in methyl methacrylate using a slow methylmethacrylate
(sMMA) processing, infiltration and embedding techniques as described by Kecena et al.,
and then sectioned at 7 µm thickness with a Reichert Jung Polycut E microtome and a
Tungsten carbide D profile knife (Dornt Hart), and mounted onto glass slides. These
sections were then be stained with hematoxylin and eosin to evaluate cellular events, von
Kossa to evaluate all the mineralized tissue at the site, and with Goldner’s Trichrome to
evaluate the osteoid, or new unmineralized bone being deposited at bone forming sites.
All staining was performed according to protocols described by Kecena et al. (173).
5.2.4.

Statistical Analysis

For vascular and bone quantification analysis (i.e., histology and MicroCT), a
two-way analysis of variance (ANOVA) was preformed to compare data.
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Error is

reported in figures as the standard deviation (SD) and significance was determined using
a probability value of p < 0.05.

5.3.
5.3.1.

Results
Cell-Seeded Constructs In Vitro Evaluation

Cell-seeded macro-porous scaffolds were evaluated after 2 days in culture (i.e.,
pre-implantation stage) (Figure 5-6). Each macro-porous scaffolds was seeded with a
total of 250,000 cells, and the following cellular conditions were examined in vitro to
confirm cell performance, phenotype and survival at the pre-implantation stage: (1)
MSC-derived osteoblasts, (2) EPCs-, and (3) co-culture of MSC-derived osteoblasts and
EPCs at a 1:1 ratio. As seen in Figure 3, MSC-derived osteoblasts maintained their
differentiation as demonstrated by positive immune-staining of bone markers collagen
type 1 (Col1) and RunX2, which was observed in MSC-derived osteoblast – seeded
constructs, as well as co-culture seeded constructs. Furthermore, EPCs maintained the
endothelial cell phenotype as demonstrated by the positive immune-staining of vascular
endothelial markers CD31 and von Willebrand Factor (vWF), which was observed in
EPC – seeded constructs, as well as co-culture seeded constructs.
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Figure 5-6. Immunofluorescence staining of endothelial markers CD31 and vWF,
osteogenic markers RunX2 and Collagen type I, and tubulin on MSC, EPC and coco

culture of MSC:EPC (1:1) constructs pre
pre-implantation.

5.3.2.

Cell-Seeded
Seeded Constructs In Vivo Evaluation

5.3.2.1.

SCID Mouse Subcutaneous Implantation

Two day pre-cultured
cultured in vitro constructs were implanted for 8 weeks
subcutaneously in SCID mice, at which point they were harvested for histological
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analysis.

Constructs of various MSC-derived osteoblast: EPC (OB:EPC) co-culture

ratios were evaluated, and constructs of each cell type seeded alone served as controls, as
well as acellular constructs.

Constructs were paraffin-embedded, sectioned and

processed for immunostaining and Masson’s Trichrome staining (Figure 5-7)).

Figure 5-7.. Masson’s Trichrome Staining on (A) acellular, (B) MSC-seeded,
MSC
(C)
EPC-seeded,
seeded, (D) 4 MSC: 1 EPC – seeded, (E) 1 MSC: 1 EPC –seeded,
seeded, and (F) 1
MSC: 4 EPC- seeded constructs 8 weeks post-implantation.
We analyzed and quantified collagen formation histologically (Figure
Figure 5-8B).
Specifically, we performed a colormeric quantification analysis (RBG plugin, ImageJ,
NIH) on Masson’s Trichrome stained paraffin-embedded sections of the constructs. Since
the Masson’s Trichrome staining procedure results in blue-stained collagen and bone, we
utilized the RBG Measure Plug-in tool in Image J to measure the blue-staining
collagen/bone. In this manner, we observed significant collagen formation in constructs
cultured with MSC-derived
derived osteoblasts, as well as with co-cultured MSC-derived
MSC
osteoblasts and EPCs at all examined ratios (i.e., 4:1, 1:1, 1:4) compared to aceullar
142

constructs after 8 weeks in vivo.

However, in comparison to collagen formation in

constructs seeded with MSC-derived osteoblasts, only constructs seeded with co-cultured
MSC-derived osteoblasts and EPCs at ratios of 4:1 and 1:1 demonstrated significant
collagen formation. On the other hand, subcutaneous implantation of acellular and EPCseeded constructs resulted significant adipose tissue formation, instead of collagen
formation.
Vascular formation analysis throughout the constructs was also performed on the
Trichrome-stained sections. Implantation of EPCs significantly enhanced vascularization
throughout the constructs.

As seen in Figure 5-8, constructs seeded with EPCs

demonstrated significantly more vascularization than constructs that were initially
implanted without cells. However, constructs co-seeded with MSC-derived osteoblasts
and EPCs at ratio of 1:1 (1 OB: 1 EPC) demonstrated the highest level of vascularization.
Implantation of constructs co-seeded with MSC-derived osteoblasts and EPCs at ratio of
1:4 did result in significant vascularization compared to acellular constructs, however
lower than that of EPC-seeded and 1:1 (1 OB: 1 EPC) –seeded constructs. It is important
to note that significant adipose tissue formation was observed in implanted acellular
constructs and constructs seeded with EPCs or higher level of EPCs in co-culture (1 OB:
4 EPC).

Qualitative assessment of vascular, collagen and adipose tissue formation is

shown in Figure 8.

Thus, 1 OB: 1 EPC constructs showed the highest level of

vascularization and collagen formation. Vessel formation was confirmed via CD31 and
von Willabrand Factor (vWF) immunostaining, and bone formation was confirmed via
Collagen type 1 (Col1) and RunX2 immunostaining (Figure 5-9).
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Figure 5-8. (A) Quantification of In Vivo Vascularization. (** Significance
compared to Negative (p < 0.05), # Significance compared to EPC (p < 0.05)). (B)
Quantification of collagen staining. (** Significance compared to Negative (p <
0.05); # Significance compared to MSC (p < 0.05)).

Figure
5-9.
Immunofluores
cence staining
of endothelial
markers CD31
and vWF, and
osteogenic
markers
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RunX2 and Collagen type I on (A) construct pre-seeded with MSC:EPC (1:1), and
(B) mouse limb post-natal day 1 (positive control).

5.3.2.2.
Rabbit Ulnar Critical Size Bone Defect
Implantation
A 15 millimeter bone defect was created in the ulnar bone of New Zealand White
rabbits (4-5 kilograms), and an optimally-porous construct (cylinder of 5 millimeter
diameter, and 15 millimeter height) was inserted into the bone defect. The construct was
previously seeded with 250,000 mesenchymal stem cells (MSCs), endothelial progenitor
cells (EPCs), or a 1-to-1 ratio of MSCs and EPCs (125,000 MSCs and 125,000 EPCs), or
no cells (i.e., acellular construct to serve as a negative control), and cultured for 2 day in
a 1-to-1 mix of osteogenic and endothelial growth media. We examined 6 rabbits for
each group (i.e., 4 groups; acellular, MSC, EPC, 1 MSC:1 EPC). As seen in Figure 5-10,
x-ray analysis was utilized immediately post-operation to confirm a bone defect of 15
millimeters was created.
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Figure 5-10. Radiograph of rabbit (A) sham (i.e., no defect) arm, and (B) right arm
(with defect) immediately post-implantation.

Rabbits were monitored closely for their recovery and performance. Several days
to one week post operation, all rabbits were sitting up, walking, eating, drinking, and
performing as expected for post-operation.

Rabbits were fully functioning in their

movements (i.e., walking, running, jumping), and applying weight on their forearms
(including their arm that operated on) at 6 and 12 weeks post-operation. After 12 weeks,
all rabbits were sacrificed for analysis and evaluation of bone and vascular regeneration
at the bone defect.
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Figure 5-11. Representative cross-section MicroCT image of remodeled bone in the
middle of the rabbit ulnar bone defect. U = ulnar bone, R = radius bone. Scale bar
= 5 mm.

MicroCT analysis was utilized to evaluate bone regeneration at the defect site.
As seen in Figure 5-11, significant remodeling and callus formation was observed in

most bone specimens, such that formation, resorption, and/or remodeling are not
distinguishable, and includes regions of high and low density. Therefore, in order
to measure all bone formation, the total mass of all bone (i.e., ulnar, radius, callus)
within the set length was measured. In addition, the mass of the radius in the
intact limb also measured. To quantify the mass and bone volume within the ulnar
defect, the mass of the intact radius was subtracted off the mass of the matching
region of each experimental limb.

Limited bone regeneration was observed in the acellular group, which confirmed
this model as a critical-sized bone defect (Figure 5-12).

The MSC and EPC group

displayed higher levels of bone regeneration than the acellular group (Figure 5-13).
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However, the rabbit group that received constructs seeded with 1-to-1 ratio of MSCs and
EPCs displayed significantly higher levels of bone regeneration than that of the acellular
group. As seen by the longitudinal sections in Figure 5-12, the 1 MSC: 1 EPC group
displayed complete bone bridging throughout the thickness of the defect, whereas the
other groups did not.

Furthermore, as seen in Figure 5-14, the highest amount of

regenerated bone volume and mass was observed in the 1:1 MSC:EPC group.

Figure 5-12. MicroCT analysis of ulnar bone defect 12 weeks post-implantation.
Representative scout view images (i.e., radiographs), three-dimensional
reconstructed images, and longitudinal section images are shown for each group
(i.e., Acellular, MSC-seeded, EPC-seeded, and a 1:1 ratio of MSC:EPC seeded
construct). Scout views were utilized to determine the region of interest (ROI) for
bone mass and volume quantification. Scale bar = 5 millimeters.
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Figure 5-13. (A) Bone Volume and (B) Mass with the ulnar bone defect. * indicates
p < 0.05.

Figure 5-14. Representative histological images of Von Kossa –stained crosssections (top two rows) and longitudinal sections (bottom two rows). Images were
taken under low magnification to view the entire defect area in the section. Images
displayed under 4X represent regions of interest (highlighted in red box) under low
magnification. Scale bar (low magnification) = 2 millimeters. Scale bar (4X
magnification) = 500 µm.
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Histological analysis of Von Kossa stained sections confirmed the findings from
MicroCT analysis (Figure 5-14). The acellular group displayed a lack of mineralized
tissue within the defect, whereas the cell-seeded groups with MSCs and EPCs showed
increased bone mineralization located at the bony edges of the bone defect. Moreover,
the 1:1 MSC:EPC –seeded construct group displayed the highest amount of the bone
mineralization not just localized to the bony edge of the defect, and instead there are
signs of attempted bony bridging. Quantative analysis of the Von Kossa stained sections
demonstrated a significant increase in mineralized bone area in MSC- and EPC- seeded
groups compared to acellular constructs, however their levels are not significantly
different from each other. The co-culture 1:1 MSC:EPC- seeded group displayed the
most significant increase in mineralized bone area compared to the acellular group
(Figure 5-14, Figure 5-15).
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Figure 5-15.. Quantification of mineralized bone area formed within the rabbit
ulnar defect. Three regions on Von Kossa stained sections were analyzed from 3
samples in each group under low magnification with a thresholding analysis tool
from ImageJ software. ** indicates p < 0.05, ## indicates p < 0.001
0.001.
Similar trends were observed with unmineralized bone formation with Goldner’s
Trichrome staining (Figure
Figure 55-16, Figure 5-17).

Green staining represents collagen

deposition, with the increased intensity being mineralized collagen formation.

Red

staining represents fibrous tissue formation. The acellular group showed limited collagen
deposition, and increased levels of adipose tissue deposition (Figure 5-16).
). The MSCand EPC- seeded groups displayed mineralized bone formation within the defect, as well
as some unmineralized bone formation. However, the 1:1 MSC:EPC- seeded group
displayed the highest levels of mineralized and unmineralized bone formation within the
bone defect (Figure 5-16, Figure 55-17, Figure 5-18). In addition, the 1:1 MSC:EPCseeded group displayed the highest and most significant levels of vascularization,
vascularization with
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the MSC- and EPC- seeded groups also displaying increased vascularization compared to
the acellular group (Figure 5-19).

Figure 5-16. Representative histological images of Goldner’s Trichrome –stained
longitudinal sections imaged under low, 4X, 10X, 20X and 40X magnification.
Images shown for 4X magnification were taken from the region of interest
highlighted in the low magnification image. Images shown for 10X, 20X, and 40X
magnification are representative images of each group. Scale bar for low
magnification images = 5 mm; Scale bar for 4X magnification images = 500 µm;
Scale bar for 10X images = 500 µm; Scale bar for 20X images = 250 µm; 40X images
= 100 µm.
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Figure 5-17. Labeled Goldner’s Trichrome stained sections imaged under (A) 20X
(scale bar = 250 µm), and (B) 40X (scale bar = 100 µm). M = microsphere scaffold,
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C = unmineralized collagen, BV = blood vessel, O = osteoblast, Os = osteoid, B =
mineralized bone.

Figure 5-18. Quantification of collagen formation within the rabbit ulnar defect.
Ten regions on Trichrome stained sections were analyzed for the intensity of
collagen (green color) from 3 samples in each group under 20X magnification with a
color (RBG) histogram anal
analysis
ysis tool from ImageJ software (arbitrary scale of 0 to
255, with 255 representing the highest green intensity).
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Figure 5-19.. Quantification of vessels within the rabbit ulnar defect. Vessels were
counted in five regions on Trichrome stained sections under 10X magnification for 3
samples in each group.

5.4.

Discussion

Insufficient vascularization of bone tissue engineered constructs hinders optimal
bone regeneration. Here, we have demonstrated a two-pronged approach for enhanced
vascularization, specifically involving the development of oxygen tension controlled
constructs that allow for enhanced cell viability, as well as the optimal ratio of clinicallyrelevant cells for in vitro pre
pre-vascularization, and enhanced ectopic bone and vascular
formation in vivo.
In this study, we have utilized a previously described fabrication of porogen
leaching and microsphere sintering to develop poly(lactic-co-glycolic acid)
acid (PLGA)
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microsphere scaffolds that demonstrate tunable oxygen tension and pH levels in the
scaffold’s interior regions after long term in vitro cell culture.

Specifically, by adding

NaCl crystals to a mixture of PLGA microspheres, and leaching out the NaCl via soaking
in water after thermal sintering the molded mixture, we developed biodegradable
scaffolds with increased pore sizes and accessible pore volume, while retaining
mechanical strength in the range of human cancellous bone.
With our newly-designed oxygen tension controlled matrices, we set forward to
investigate the most effective cell ratio of MSC-derived osteoblasts and EPCs for in vitro
pre-vascularization, and subsequent neo-vascularization and bone formation in vivo. We
investigated the following MSC-derived osteoblasts/EPC ratios: 1 part MSC-derived
osteoblasts to 4 parts EPC (1:4), 1 part MSC-derived osteoblasts to 1 part EPC (1:1), and
4 parts MSC-derived osteoblasts to 1 part EPC (4:1). We confirmed the maintenance of
endothelial cell markers (i.e., CD31 and von Willabrand Factor (vWF)) by EPCs, and
osteogenic cell markers (i.e., collagen type 1 and RunX2) by MSCs, cultured alone and in
co-culture via immunofluoresence. After 2 days in vitro, the constructs of the various
cells ratios, as well as the cell types alone, were implanted subcutaneously in SCID mice.
Constructs seeded with MSC-derived osteoblasts and EPCs at a ratio of 1:1 demonstrated
not only the highest level of vascularization throughout the implant construct, but also
collagen formation after 8 weeks in vivo. Though constructs seeded with EPCs alone, as
well as in co-culture with MSC-derived osteoblasts (ratio of 1:4) also demonstrated
significant vascular formation throughout the construct compared to acellular constructs,
it was significantly less than that of constructs seeded with the cells at a 1:1 ratio. In
addition, significant collagen formation was observed throughout all the constructs that
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were seeded with both cells types at all ratios (1:4, 1:1, 4:1), as well as constructs seeded
with MSC-derived osteoblasts. However, again, constructs seeded with MSC-derived
osteoblasts and EPCs at a ratio of 1:1 resulted in the highest levels of collagen formation.
Vascular and bone formation in vivo was confirmed through immunostaining of
endothelial markers CD31 and vWF, as well as osteogenic markers collagen type 1 and
RunX2, respectively.

Implanted acellular constructs demonstrated significant adipose

tissue formation, as well as constructs seeded with only one cell type (i.e., EPCs-alone,
MSC-derived osteoblasts- alone), as well co-culture ratio 1:4.
With this, we selected the ratio of 1:1 MSC:EPC as the most effective progenitor
cell ratio, and pursued a load-bearing bone defect model. We evaluated the performance
of 4 different groups, acellular scaffold constructs (i.e., negative control), MSC-seeded
scaffold constructs, EPC-seeded scaffold constructs, and a co-culture of MSCs and EPCs
at a ratio of 1:1. The co-culture group outperformed, and displayed the most significant
increase in bone formation and vascularization with the bone defect as confirmed by
MicroCT, and histological analysis. Furthermore, this group displayed the least amount
of adipose and fibrous tissue formation, as compared to the acellular group, and MSCand EPC- seeded group.

5.5.

Conclusions

The fundamental implications of this study are apparent, and will lay the
groundwork for future bone tissue engineering studies. We have developed oxygen
tension-controlled matrices allowing for enhanced in vitro cell viability, as well the
identified of the most effective cell ratio of MSC-derived osteoblasts to EPCs, two easily
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accessible autologous cell sources.

Though many studies have investigated co-

implantation of MSC-derived osteoblasts and EPCs for effective neo-vascularization and
bone formation, we were the first to examine the proper ratio of these two cell types.
Further, we utilized both, optimally-porous oxygen tension-controlled matrices and the
optimal ratio of effective progenitor cells for the enhanced repair and regeneration of a
critically-sized load-bearing bone defect in rabbits.
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6.

CONCLUSIONS AND FUTURE DIRECTIONS

Large area or critically-sized bone defects represents a major clinical problem in
orthopaedic and cranio-/maxillo- facial surgery (127). Large area bone defects may
result from trauma, tumor resection, revision surgery and developmental deformities, and
are unable to heal spontaneously (4). Repair of large defects require bone grafts/graft
substitutes that can physically support bone regeneration, while providing surface area for
cell attachment and tissue growth. Current treatment options for large area bone defects
include bone grafts, distraction osteogenesis, demineralized bone matrix, and porous
hydroxyapatite; all of which have been associated with significant challenges and
complications (5-10).

Thus, there is a warranted search for better bone replacement

methods to overcome the drawbacks of the currently used bone graft materials.
Bone tissue engineering research has revealed tremendous potential for the
treatment of bone defects. The bone tissue engineering paradigm classically involves the
combination of one or more of the following components: a mechanically-compatible
scaffold, effective cell populations and/or growth factors. However, central necrosis or
lack of bone tissue formation due to the lack of or insufficient vascularization of bone
constructs is a well-recognized obstacle to the success of complete bone regeneration and
host integration in bone tissue engineering (35).
In the present study, we have demonstrated a two-pronged approach involving the
development of optimally-porous constructs that allow for enhanced cell viability, as well
as the identification of effective clinically-relevant cells for enhanced bone formation and
vascularization.

Again, in the first component of our approach, we developed a novel

optimally-porous biodegradable scaffold for bone regeneration and vascularization. We
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fabricated poly(D,L-85 lactide-co-15 glycolide) (PLGA) microsphere scaffolds with
increased porosity via the combination of thermal sintering and porogen (i.e., NaCl
particles) leaching. Specifically, we combined PLGA microspheres with NaCl, thermally
sintered, and then leached out the NaCl by soaking the constructs in water. Through this
method, scaffold porosity and mechanical properties may be tuned according to the
clinical requirement by controlling the size and amount of the porogen added during the
fabrication process.
Through this method, we have improved PLGA microsphere scaffold
performance and its ability to support osteoblast cell survival, proliferation and
mineralization throughout the construct, and yet retained mechanical compatibility for
effective bone regeneration. We determined PLGA microsphere scaffolds fabricated
with 20% NaCl to be optimally-porous.

Although optimally-porous scaffolds displayed

decreased mechanical strength as compared to the control scaffolds (i.e., fabricated
without porogen), the mechanical strength of these scaffolds remained within the
mechanical constraints of human cancellous bone. However, unlike control scaffolds
with limited pore sizes and accessible pore volume, optimally-porous scaffolds displayed
significantly more pores sizes in the range of 200-400 µm, which has been previously
cited as a critical pore size range for vascularization in bone tissue engineering
constructs. Optimally-porous scaffolds also displayed increased oxygen levels and nearnormal pH levels. These scaffolds proved to be fully osteoconductive as they supported
pre-osteoblast cell infiltration, proliferation, and survival throughout the entire scaffold in
vitro. Furthermore, optimally-porous PLGA microsphere scaffolds displayed enhanced
and homogenous mineralization in vitro.
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In addition, we demonstrated the ability to modulate scaffold porosity and in turn,
develop oxygen tension controlled matrices that may be effective for large area bone
regeneration.

Specifically, increasing the concentration of porogen during scaffold

fabrication resulted in a systematic increase in not only porosity, but also available
oxygen tension throughout the matrix.

The enhanced survival, proliferation,

differentiation and mineralization of pre-osteoblasts may be attributed to the increase in
available oxygen tension. Thus, the proposed optimally-porous scaffolds with improved
oxygen availability and bone compatible mechanical properties are desirable for large
area bone regeneration. Oxygen tension control via scaffold porosity optimization may
provide opportunities in designing next generation scaffold systems most effective for
large area/ critical sized bone defect repair.
As for the second component of our two-pronged approach, we aimed to identify
effective clinically relevant cell populations for enhanced bone formation and
vascularization.

We examined endothelial progenitor cells (EPCs) as an effective

endothelial population since they have been previously proven to promote vascularization
and in turn, promote successful bone formation at the graft site. Additionally, EPCs
display high angiogenic, proliferative and survival potential in situ.
We have, for the first time, sought to identify the ideal isolation source for EPCs,
either bone marrow or peripheral blood (BM-EPCs or PB-EPCs), that would yield the
most effective EPC cell population for enhanced vascularization and bone formation.
PB-EPCs outperformed BM-EPCs on all measures.

PB-EPCs displayed typical

endothelial cell markers, such as CD31, as well as high angiogenic potential in threedimensional

extracellular

matrix

in

vitro.
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Furthermore,

PB-EPCs

cultured

simultaneously with mesenchymal stem cells (MSCs), displayed significantly enhanced
expression levels of key osteogenic and vascular markers, including alkaline phosphatase,
bone morphogenetic protein 2, and vascular endothelial growth factor. On the contrary,
BM-EPCs did not express CD31, and instead, expressed key smooth muscle markers.
BM-EPCs further failed to display vasculogenic activity. Therefore, we identified the
highly angiogenic peripheral blood derived-EPCs (PB-EPC) as an ideal autologous cell
population since their isolation does not risk donor site morbidity, and importantly, they
effectively result in enhanced vascularization and success of engineered bone tissue
regeneration.
With the fabrication of newly-designed optimally-porous scaffolds and
identification of effective progenitor cells, we set forward to investigate the most
effective cell ratio of MSC-derived osteoblasts and EPCs for in vitro pre-vascularization,
and subsequent neo-vascularization and bone formation in vivo.

We determined that

constructs seeded with MSC-derived osteoblasts and EPCs at a ratio of 1:1 demonstrated
not only the highest level of vascularization throughout the implant construct, but also
collagen formation 8 weeks post-implantation in a mouse subcutaneous model. Vascular
and bone formation in vivo was confirmed through immunostaining of endothelial
markers CD31 and vWF, as well as osteogenic markers collagen type 1 and RunX2,
respectively. With this, we selected the ratio of 1:1 MSC:EPC as the most effective
progenitor cell ratio, and pursued a load-bearing, critical-sized bone defect model. We
evaluated the performance of 4 different groups, acellular scaffold constructs (i.e.,
negative control), MSC-seeded scaffold constructs, EPC-seeded scaffold constructs, and
a co-culture of MSCs and EPCs at a ratio of 1:1. The co-culture group outperformed, and
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displayed the most significant increase in bone formation and vascularization with the
bone defect as confirmed by MicroCT, and histological analysis. Furthermore, this group
displayed the least amount of adipose and fibrous tissue formation, as compared to the
acellular group, and MSC- and EPC- seeded group.
As a whole, this investigation presents a landmark study, and may lay the
groundwork for future bone tissue engineering studies to make steps even closer to
achieving clinical success in bone regeneration and repair. We have developed optimallyporous and oxygen tension-controlled scaffolds allowing for enhanced in vitro cell
viability, as well the identified of the most effective cell ratio of MSC-derived osteoblasts
to EPCs, two easily accessible autologous cell sources. Further, we utilized both,
optimally-porous oxygen tension-controlled matrices and the optimal ratio of effective
progenitor cells for the enhanced repair and regeneration of a critically-sized load-bearing
bone defect in rabbits. Future studies should focus on adopting the fundamental concepts
presented in this investigation (i.e., scaffold and autologous cell population) into a even
more clinically-tailored concept. For example, more effective cell isolation, seeding and
culturing methods need to be used in order to streamline the engineering process, and
decrease the safety risks associated with the handling the constructs during the preimplantation period. Bioreactors that can combine all three steps may be used for this
purpose, and may drive the way for safer and more effective bone tissue engineering. In
addition, the incorporation of immunomodulatory strategies may be used to modulate the
host’s foreign-body response (i.e., fibrous tissue encapsulation), an event that is often
observed to be an inhibitory factor for optimal tissue regeneration and integration.
In conclusion, bone tissue engineering research has recently gained significant
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momentum and revealed tremendous potential for the treatment of bone defects, and
prospects for achieving clinically successful bone regeneration are extremely optimistic.
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7.

APPENDIX 1 – Protocols

Fabrication of PLGA Microspheres

7.1.
7.1.1.

Materials
•

Poly(D,L-85 Lactide-co-15 glycolide) (PLGA) (Lakeshore
Biomaterials; Birmingham, AL)

7.1.2.

•

Poly (vinyl alcohol) (PVA) (Sigma)

•

Methylene chloride (CH2Cl2) (Sigma)

Protocol

85:15 PLGA polymer was dissolved in organic solvent, Methylene Chloride at
4:1 ratio and vortexed until it dissolved. The mixture was then slowly added to
a 1% poly (vinyl alcohol) solution while stirring at 250 rpm and left stirring
over night at 300 rpm. The microspheres were then vacuum dried for 24 hours
then sieved to obtain 425-600 µm size range and kept in desiccator until
needed.

Fabrication of Optimally-Porous PLGA

7.2.

Microsphere Scaffold
7.2.1.

Materials
•

PLGA microspheres (425-600 µm diameter)

•

Porogen, NaCl crystals (200-300 µm diameter)
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•

Steel mold to fabricate disc-shaped (10 mm diameter, 2 mm
height) or cylinder-shaped (5 mm diameter, 15 mm or 10 mm
height) scaffolds

•

7.2.2.

Oven set to 100oC

Protocol

Control scaffolds were fabricated by packing approximately 0.15 g of PLGA
microspheres (425-600 µm diameter) into each compartment within the steel
mold.

Scaffolds with increased porosity were fabricated by mixing PLGA

microspheres (425-600 µm diameter) and NaCl crystals (200-300 µm diameter) at
specific weight ratios (i.e., PLGA:NaCl ratios include 90:10, 80:20, 70:30, 60:40,
50:50), which was then packed in the the steel mold in a similar manner as
described with the control scaffolds.

The mold was then subjected to heat

treatment of 100°C for 1 hour to form three-dimensional scaffolds. The mold was
then allowed to cool to room temperature before the scaffolds were removed from
the mold. Scaffolds were then soaked in water for 2 hours in order to leach out
the NaCl. Scaffolds were then stored in a desiccator until further use.

Mechanical Testing

7.3.
7.3.1.

Materials
•

Pre-fabricated PLGA microsphere scaffolds (10 mm height x 5
mm diameter)

•

Instron model 5544
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Computer with installed Merlin data analysis software

•

7.3.2.

Protocol

Cylindrical scaffolds (n = 6) with 2:1 aspect ratio (10 mm length and 5 mm
diameter) were used for mechanical characterization. Compressive testing will
carry out using an Instron model 5544 with a cross head speed of 2 mm/min
maintained until the sample failed. We followed the standard protocol of
ASTM 1621.37. The compressive modulus and maximum compressive
strength of scaffolds were determined using the Merlin data analysis software.
Compressive strength was defined as the maximum stress magnitude.
Apparent modulus was measured as the tangential slope of the linear region of
the effective stress–strain curve at 50% of compressive strength magnitude.

7.4.
7.4.1.

MicroCT Analysis
Materials
•

Pre-fabricated PLGA microsphere scaffolds (2 mm height x 10
mm diameter)

•

Cone-beam micro- focus X-ray computed tomography
(mCT40; Scanco Medical AG)

a.

PROTOCOL

Scaffold specimens were imaged using cone-beam micro- focus X-ray
computed tomography (CT) to render three- dimensional (3D) models for
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direct quantitation of porosity (mCT40; Scanco Medical AG). Serial
tomographic images were acquired at 45kV and 177mA, collecting 2000
projections per rotation at 300 millisecond integration time. Threedimensional 16-bit grayscale images were reconstructed using standard
convolution back-projection algorithms with Shepp and Logan filtering, and
rendered within a 12.3-mm field of view at a discrete density of 4,629,630
voxels/mm3 (isometric 6 mm voxels). Segmentation of solid scaffold from
open porosity was performed in conjunction with a con- strained Gaussian
filter to reduce noise, applying a threshold of - 220 Hounsfield units (water =
0, air = - 1000). Direct measurements of internal porosity included volume
fraction, size, connectivity, accessible internal pore volume, and accessible
solid surface area of the scaffold (as a function of pore dimension). The
accessible volume and surface parameters provide direct measurements of the
pore volume and the surface available to cell infiltration as a function of
minimum pore dimension, using a distance transformation algorithm similar
to that used by Moore et al.

7.5.

Scanning Electron Microscopy (SEM) Using the

FEI Strata 400s Dual Beam FIB
7.5.1.

Materials
•

PLGA microsphere scaffolds

•

Gold/palladium
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7.5.2.

Protocol

The morphology of the PLGA microsphere scaffolds was analyzed using the
FEI Strata 400s Dual Beam FIB. The surface characterization of both
microspheres and scaffolds was done in the SEM mode (2KeV). Samples
were prepared by coating with gold/palladium (1-2 minutes) and examined
under SEM.

7.6.
7.6.1.

7.6.2.

Scaffold Sterilization
Materials
•

70% ethanol

•

PBS

•

UV radiation

Protocol

Scaffolds were sterilized by immersing in 70% ethanol for 30 minutes.
Scaffolds were then washed three times in sterile PBS before exposing
them to UV radiation, 30 minutes each side of scaffold. Scaffolds were
then placed in 24 well plates and let to dry for few minutes.

7.7.

Cell Culture
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7.7.1.

Cell Types

7.7.1.1.
MC3T3 Pre-Osteoblast Cells
Pre-osteoblastic MC3T3-E1 cells were obtained from American
Type Culture Collection (ATCC, Manassas, VA).

Cells from

Passage 18-23 were used for experiments.

7.7.1.2.
7.7.1.2.1.

Rabbit Mesenchymal Stem Cells (MSCs)
Materials

•

Betadine Solution

•

100% Ethanol

•

Phosphate Buffered Saline (PBS) Solution

•

Isolation Medium (a-MEM + 10% Fetal Bovine Serum
+ 1% Pen/Strep)

•

Growth Medium (a-MEM + 15% Fetal Bovine Serum +
1% Pen/Strep)

•

Lymphoprep (1.077 g/mL)

•

Sterile Drapes and Sponges

•

Scalpel

•

Sterile Petri Dishes (100 x 15 mm)

•

Sterile Disposable Syringes with Luer Lock Sterile
Needles (16-, 18- and 21-G)

•

Sterile glass beaker (100 mL)
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7.7.1.2.2. Protocol

The isolated long bones of New Zealand white rabbits were
placed in a beaker containing 100% EtOH for 5 minutes, and
then in individual 50 mL centrifuge tubes containing isolation
media. The bones were kept on ice until ready for marrow
isolation. The long bones were removed from media and place
into a 100 mm sterile Petri dish in a sterile cell culture hood.
The bones were rinsed with PBS, and any adherent muscle or
soft tissues were removed from the long bones using scalpel
and scissors. The long bones were rinsed again with PBS and
transferred to a clean 100 mm sterile Petri dish.

The

metaphyses (flared ends of long bone) of each bone were
removed using a bone cutter to expose the marrow cavity. The
long bone pieces were placed into individual sterile 50 mL
polystyrene test tubes, and 5 milliliters of isolation medium
(containing 1250 U heparin) was used to flush the marrow
contents repeatedly using a 5 mL syringe containing a 21gauge
needle. The marrow contents were centrifuged at 1000 x g
(2400 rpm) for 5-10 minutes at 4°C.

The supernatant

(containing mainly bone marrow fat and isolation medium) was
removed, and the cell pellet was re-suspended in 5 mL of
isolation medium, and then 5 ml of Lymphoprep was added to
a new 15 milliliter sterile centrifuge tube, and the cell
suspension was layered onto the Lymphoprep layer and
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centrifuged at 400 x g (1500 rpm) for 30-40 min at 18-20°C.
Centrifugation resulted in 4 different layers: (i) the bottom is
predominately red blood cells/granulocytes, (ii) above is a clear
Ficoll layer, (iii) above this is a slightly pink hazy layer
containing the majority of the mononuclear cells, and (iv) the
uppermost is predominantly plasma, platelets and PBS. The
uppermost layer was aspirated taking care to avoid disturbing
the mononuclear layer. The mononuclear layer and two-thirds
of the Ficoll layer was transferred to new 50-ml tubes, and
centrifuged at 600-750 rpm for 10 minutes at 18-20°C. The
supernatant was aspirated and the pellet was washed twice with
PBS, and then centrifuged at 500 g for 5 minutes. The cells
were resuspended in growth medium, and then plated at an
appropriate seeding density on TCPS culture flasks, and
cultured at 37°C in 5% CO2. Non-adherent cells were removed
after 24 hours by washing with PBS.

The basal media was

changed subsequently every 4 days, until culture reached 90%
confluency (2 weeks).

MSCs were recovered using 0.25%

Trypsin-EDTA and re-plated at a density of 5,000-6,000 cells
per cm2 of surface area as passage 1 (P1) cells.

7.7.1.3.
Rabbit Bone Marrow-Derived Endothelial
Progenitor Cells (BM-EPCs)
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7.7.1.3.1.

Materials

•

Betadine Solution

•

100% Ethanol

•

Phosphate Buffered Saline (PBS) Solution

•

Sterile Drapes and Sponges

•

Scalpel

•

Sterile Petri Dishes (100 x 15 mm)

•

Sterile Disposable Syringes with Luer Lock

•

Sterile Needles (16-, 18- and 21-G)

•

Sterile glass beaker (100 mL)

•

Lymphoprep (1.077 g/mL)

•

Endothelial Growth Media-2 (EGM-2, Lonza)

•

150 mm plates coated with Rabbit Type 1 Collagen (1
µg/cm2)

•

1 plate / 50 ml of collected blood

•

0.25% Trypsin/EDTA

7.7.1.3.2. Protocol

Bone marrow from the long bones of New Zealand White
Rabbits (4-5 kg) were be isolated, mixed with an equal volume
of PBS and centrifuged on a Lymphoprep (1.077 g/ml) gradient
for 400 x g (1500 rpm) for 30-40 min at 18-20°C.

The

mononuclear fraction was isolated, and then washed three
times with PBS. The mononuclear fraction was cultured on
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150 mm culture dishes coated with 1 µg/cm2of rabbit type I
collagen in EGM-2 Endothelial Medium (EGM-2) at 37oC and
5% CO2. After 4 days of culture, non-adherent cells were
removed by washing with PBS, and a fresh medium was
applied. When cells reached about 90% confluency, cells were
trypsinized, and passaged. The cells at passage 2-4 were used
for cell characterization and construct engineered bone.

7.7.1.4.
Rabbit Peripheral Blood-Derived Endothelial
Progenitor Cells (PB-EPCs)
7.7.1.4.1.

•

Materials

Anesthesia (ketamine (90-120 mg/kg body wt) and
xylazine (5-10 mg/kg body wt) given via intramuscular
injection)

•

BD Vacutainer Chemistry Tubes - 10 mL Plasma Tubes
with Spray-Coated Sodium Heparin (BD, #02-689-6)

•

BD Vacutainer Tube Holder (BD, #22-289-953)

•

BD Vacutainer Blood Collection Needles 21 x 1-1/2 in.
(BD, #266521)

•

70% ethanol

•

Lymphoprep

•

Phosphate Buffered Saline (PBS) Solution (1x)

•

Endothelial Growth Media-2 (EGM-2, Lonza)
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•

150 mm plates coated with Rabbit Type 1 Collagen (1
µg/cm2)

•

1 plate / 50 ml of collected blood

•

0.25% Trypsin/EDTA

7.7.1.4.2. Protocol

Peripheral blood was obtained via terminal exsanguination of a
New Zealand White rabbit (4-5 kg).

The rabbits were

anesthetized with intramuscular ketamine (90-120 mg/kg body
wt) and xylazine (5-10 mg/kg body wt). The rabbit was
positioned in dorsal recumbency, and chest area was wiped
with 70% ethanol. An incision overlying the thoracic cavity
was made to expose the heart. Blood collection was performed
by puncturing the heart with a 21 guage needle connected to a
Vacutainer blood collection system. Once blood withdrawal
was complete, sodium pentobarbital is injected intracardiac at
100 mg/kg to ensure death.
Rabbit peripheral blood mononuclear cells (PBMNCs) was
isolated from ~200 ml of peripheral blood by density gradient
centrifugation with Lymphoprep separation solution (d=1.077
g/ml). Specifically, 15 milliliters of Lymphoprep was added to
each 50-ml centrifuge tube. Then, an equal amount of PBS
was added to the peripheral blood, and 35 milliliters of
blood/PBS solution was slowly pipetted into each 50-ml
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centrifuge tube containing Lymphoprep, and then centrifuged
at 400 g or 20 min at room temperature. This resulted in four
visible

layers

after

centrifugation:

(i)

the

bottom

is

predominately red blood cells, (ii) above is a clear Lymphoprep
layer, (iii) above this is a slightly pink and hazy layer
containing the majority of the mononuclear cells, and (iv) the
uppermost is predominately PBS. The uppermost layer was
aspirated taking care to avoid disturbing the mononuclear
layer. The mononuclear layer and two-thirds of the Ficoll layer
was transferred to new 50-ml tubes, and PBS was added to fill
each tube and spin at 1500 g for 5 min to pellet cells. The pellet
was washed once with PBS, resuspend in EGM-2 media, and
then plated mononuclear cells from each 50 ml collected blood
onto one 100 mm collagen-coated plate.

The cells were

cultured at 37oC and 5% CO2 for 4 days, and then nonadherent cells removed by washing with PBS two times. The
culture was maintained for another 4–5 weeks, and media was
be changed every 3 days. After reaching about 80%
confluence, cells were trypsinized and seeded into 150 mm
culture plate coated with rabbit Type I collagen for expansion.
EPCs from passage 2– 4 were used for experiments.
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7.7.1.5.

Rabbit Vascular Smooth Muscle Cells (SMCs)

7.7.1.5.1.

Materials

•

Betadine Solution

•

Isopropyl Alcohol

•

100% Ethanol

•

Phosphate Buffered Saline (PBS) Solution

•

Sterile Drapes and Sponges

•

Scalpel, forceps

•

Sterile Petri Dishes (100 x 15 mm)

•

Sterile glass beaker (100 mL)

•

DMEM + 3X Penicillin/Streptomycin

•

0.25% Trypsin/EDTA

•

7

milliliters

of

digesting

solution

DMEM+PenStrep

containing

15

(Worthington),

200

U/mL

(10mL

U/mL

collagenase

of

Elastase
Type

2

(Worthington), and 1.7 mg/mL of bovine serum
albumin (BSA))
•

0.22-um

low-protein

retention

filter

(Millipore,

Billerica, MA))

7.7.1.5.2.

Protocol

In a New Zealand white rabbit, the thoracic aorta was isolated
from its origin just above the heart to the iliac bifurcation, and
then transferred to a 50 ml test tube containing DMEM + 3x

177

penicillin/ streptomycin 37 °C. The vessels were rinsed three
times with DMEM + 3X Pen/Strep at 37°C, and then the
connective tissues and adventitia was gently removed from the
aorta using forceps. The aorta was washed in DMEM with 3X
Pen/Strep at 37°C by repeatedly pipetting out with a widemouthed, glass pipet to ensure the removal of blood within the
aorta. The aorta was chopped into small pieces, and then was
added

to

7mL

DMEM+PenStrep

of

digesting

containing

solution
15

U/mL

(10mL

of

Elastase

(Worthington), 200 U/mL collagenase Type 2 (Worthington),
and 1.7 mg/mL of bovine serum albumin (BSA).

This

solution was filtered through a 0.22-um low-protein retention
filter (Millipore, Billerica, MA)) and incubated at 37 °C for
about 60–75 min with gentle shaking. The completion of
digestion is indicated by homogenization of the aorta in the
digestion media. The solution was then spun at 1000 g for 5
min, and then the supernatant was gently discarded.

The

pellet was washed by swirling gently (slight dissociation) with
5 milliliter glass pipette three times with DMEM/PenStrep (5
milliliters). The supernatant containing single cells was spun
at 100 g for 30 seconds, and then the cells were plated on
culture dishes containing cell culture media, and culture at 5%
CO2 and 95% air.
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7.7.1.6.
Human Umbilical Vein Endothelial Cells
(HUVECs)
HUVECs were obtained from American Type Culture Collection
(#RL-2873, ATCC, Manassas, VA). Cells from Passage 4-6 were
used for experiments.

7.7.2.

Cell Culture Mediums

7.7.2.1.
Basal Growth Medium
Basal growth medium for MC3T3 cells, MSCs and SMCs is
DMEM

supplemented

with

10%

FBS

and

1%

penicillin/streptomycin.

7.7.2.2.

Osteogenic Medium

7.7.2.2.1. MC3T3 Cells

Cells were cultured in DMEM supplemented with 10% FBS,
1% penicillin-streptomycin, 3mM β-glycerophosphate and 10
µg/ml ascorbic acid.

7.7.2.2.2. Mesenchymal Stem Cells

For osteogenic differentiation, the culture medium (DMEM,
10% FBS, 1% Penicillin/Streptomycin) was supplemented with
10-8 M dexamethasone, 10mM β-glycerophosphate, and 50
µg/ml ascorbic acid.
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7.7.2.3.
Endothelial Growth Medium
BM-EPCs, PB-EPCs and HUVECs were cultured in EGM-2 media
(CC-3162, Lonza).
(EBM2)

EGM-2 includes endothelial basal medium

supplemented

with

10%

FBS,

1%

Penicillin/Streptomycin, and EGM2 Singlequots (hEGF,VEGF,
hFGF-B,

R3-IGF-1,

ascorbic

acid,

heparin,

gentamicin–

amphotericin-B.

7.7.2.4.
1-to-1 Mix of Osteogenic And Endothelial
Medium
7.7.2.4.1. Co-Culture of Mesenchymal Stem Cells and Endothelial
Progenitor Cells

Co-cultures of MSCs and EPCs were cultured in a 1-to-1 mix
of osteogenic and endothelial medium (i.e., 1 part osteogenic
media (DMEM, 10% FBS, 1% Penicillin/Streptomycin, 10-8 M
dexamethasone, 10 mM β-glycerophosphate, and 50 ug/ml
ascorbic acid) and 1 part endothelial media (EGM-2 media,
10% FBS, 1% Penicillin/Streptomycin, EGM2 Singlequots)).

7.7.3.

Cryopreservation Of Cells

7.7.3.1.

Materials
• Dimethyl sulfoxide (DMSO, Sigma-Aldrich, D4540)
•

Cryogenic vials

•

0.25% Trypsin-EDTA (Sigma-Aldrich, T4049)

•

15ml centrifuge tube
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•

70% isopropyl alcohol (inside the cryogenic storage
container)

•

PBS Phosphate-Buffered Saline (Gibco)

•

Cryogenic storage container

7.7.3.2.
Protocol
To cryopreserve cells for later use, the cells were trypsinized and
transferred to a 15 milliliter centrifuge tube, and centrifuged at 500
rpm for 10 minutes. The cells were resuspended in 5 milliliters of
media, and counted using trypan blue and a hemacytometer for a
viable cell count. In each cryopreservation 1.5 milliliter tube, 0.4 ml
FBS, 0.1 ml DMSO, and 1x106 cells/0.5 ml media was added to create
a cell suspension of 1x106 cells per milliliter. The cells were then
immediately transferred to cyrogenic storage container at -80°C
overnight, before permanent storage in liquid nitrogen.

7.8.

Cell Seeding on Scaffolds and Culture

Conditions
After cell trypsinization, a cell suspension was uniformly seeded onto the
scaffolds. The disc-shaped scaffolds were placed flat on the culture plate, and a 20 µL
cell suspension was uniformly added to the top of the scaffold. The cylindrical
scaffolds were placed along the length of the scaffold on the culture plate, and a 40
µL cell suspension was added to the lengthwise surface as the scaffold was slowly
rotated (i.e., along the long axis of the scaffold) to maintain uniform cell seeding. The

181

cell-seeded scaffolds were incubated for 2 hour at 37°C to allow for cell adhesion
onto the scaffolds before 1 milliliter of media was added.

Cell culture was

maintained for pre-determined time-points in an incubator at 37°C, 5% CO2, and 95%
humidified air.

7.9.
7.9.1.

7.9.2.

Cell Seeding Efficiency
Materials
•

Cell suspension

•

Hemocytometer

•

Trypan blue

•

Light microscope

Protocol

After 6 hours of cell seeding, scaffolds were transferred to new wells. Cells at
the bottom of the original wells were trypsinized, resuspended, and counted
with a hemocytometer. The cell-seeding efficiency (i.e., the number of cells
that adhered to the scaffolds) was determined by the difference between the
number of cells initially seeded and the number of cells that were counted at
the bottom of the well.

7.10.
7.10.1.

Cell Proliferation (PicoGreen Analysis)
Materials
•

DNA solution in 1% Triton X100 solution
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•

Quant-iTTM PicoGreen® dsDNA Assay Kit (Molecular
Probes, #P7589)

7.10.2.

•

PicoGreen dsDNA quantitation reagent (Component A)

•

Buffer, 20X TE (Component B)

•

Lambda DNA standard (Component C)

•

Sterile, distilled, DNase-free water

Protocol

To quantitate dsDNA (double stranded DNA), we utilized the Quant-iTTM
PicoGreen® dsDNA Assay Kit. PicoGreen dsDNA quantitation reagent is an
ultrasensitive fluorescent nucleic acid stain for quantitating dsDNA in
solution. To prepare sample, the experimental DNA solution was diluted in
TE to a final volume of 1.0 milliter in test tubes. 1.0 mL of the aqueous
working solution of the Quant-iTTM PicoGreen® reagent was added to each
sample, and then incubated for 2-5 minutes at room temperature in the dark.
The standards were prepared as indicated below. The fluorescence of the
unknown samples and standards were measured using the TECAN at a
wavelength of 523 nm. The fluorescence value of the reagent blank was
subtracted from that of each of the samples. The DNA concentration of the
sample was determined from the standard curve generated in DNA Standard
Curve.

High Range Standard curve for λDNA:
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(µL) Volume

Volume (µL) Volume
2µg/µL of

of

TE (µL)

1X

Final concentration
of of λDNA

λDNA

(diluted B)

diluted A

0

1000

1000

0ng/uL (blank)

1

999

1000

1 ng/µL

10

990

1000

10 ng/µL

25

975

1000

25 ng/µL

50

950

1000

50 ng/µL

100

900

1000

100 ng/µL

250

750

1000

250 ng/µL

500

500

1000

500 ng/µL

1000

0

1000

1000 ng/µL

7.11.
7.11.1.

Alkaline Phosphatase Assay
Materials
•

Sample in 1% Triton X100

•

BioRad

Alkaline

Phosphatase

Substrate

Kit

(Bio-Rad

Laboratories, Inc)
•

Diethanolamine Buffer (5X) (make 1X soln from 5X soln: 1ml
5X soln: 4ml H2O=1X)

•

Note: to make 0.4 N sodium hydroxide solution (dissolve 2.0g
sodium hydroxide in 125 ml of DDI water)
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•

p-Nitrophenylphosphate, 5mg each, tablets

•

For every 5 ml of the 1X solution, add 1 tablet to be completely
dissolved

b.

PROTOCOL

Alkaline phosphatase activity of cells cultured on microsphere scaffolds were
measured as an early marker for osteogenic phenotype using an alkaline
phosphatase (ALP) substrate kit (Bio-Rad, Hercules, CA). In this assay, the
early phenotypic marker ALP, from osteoblasts in culture, converts pnitrophenyl phosphate (p-NPP) into p-nitrophenol (p- NP). The rate of p-NP
formation is directly proportional to the ALP activity and can be measured
colorimetrically. At pre-determined timepoints, the cell-scaffold constructs
were washed twice with PBS to remove any unattached cells. These scaffolds
were then frozen in a −70°C with 1 mL of 1% Triton X100. At the end of the
cell study, samples from all time points were subjected to three freeze−thaw
cycles and collected the cell lysate for ALP assay. For a volume of 100 µL of
cell lysate, a 400 µL of p-NPP substrate solution and buffer mixture was
added and incubated at 37 °C for 30 min. The reaction was stopped by adding
500 µL of 0.4 N NaOH. Subsequently, the ALP induced p-NP production can
be estimated by measuring the absorption at 405 nm the TECAN. The results
of ALP activity will be normalized by the total protein or DNA (i.e., BCA
assay or DNA Picogreen Assay) from each individual sample.
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7.12.
7.12.1.

Bicinchoninic Acid (BCA) Total Protein Assay
Materials
•

BCA Protein Assay Reagent (Bicinchoninic Acid) (Peirce, #
23225)
o Kit Contents: BCA Reagent A, 2 x 500 mL; BCA
Reagent B, 25 mL; Albumin Standard Ampules,
2mg/mL, 10 x 1mL

•
7.12.2.

1% Triton X100 (Sigma-Aldrich, # X100-100ML)

Protocols

In order to normalize specific protein levels of cells cultured on scaffolds, we
determined total protein levels via the Bicinchoninic Acid Assay (BCA) total
protein assay. At each time point, the media was aspirated off, and the
scaffolds were washed once with PBS. The cells were lysed with 1% Triton
X100 (1 milliliter/sample), and two freeze-thaw cycles. The working reagent
was prepared by mixing 50 parts of BCA reagent A with 1 part of BCA
reagent B. In a 48 well plate, 100 µl of each unknown sample or standard
(i.e., diluted with 1% Triton X100 solution) was pipetted, and then 800 µl of
the working reagent was added to each well, and mixed thoroughly. The plate
was covered and incubated at 37oC for 30 minutes, and then the absorbance
was measured at 550 nm on Tecan.

Diluted albumin (BSA) standards:
Vial

Volume

of Volume & Source Final
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BSA

diluent (µ
µl)

of BSA

concentration

A

450

150 µl of stock

500 µg /ml

B

300

300 µl of A

250 µg /ml

C

300

300 µl of B

125 µg /ml

D

360

240 µl of C

50 µg /ml

E

300

300 µl of D

25 µg /ml

F

320

80 µl of E

5 µg /ml

G

400

0

0 = blank

7.13.
7.13.1.

Alizarin Red Mineralization Assay
Materials
•

4 M Alizarin Red, pH 4.23: add 1.369g of powder dye to 100
ml of DDI water, use 1N NaOH to adjust pH.

•

10% (w/v) Cetylpyridinium Chloride (CPC), pH 7.0: add 10g
to 100ml of 10mM Sodium Phosphate Na2PO4. Use 1N HCl to
adjust pH

•

10 mM Na2PO4: dissolve 0.142 in 100 mL

•

70% Ethanol

•

PBS w/o Ca or Mg
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7.13.2.

Protocol

Mineralized matrix synthesis was evaluated using Alizarin Red staining
method for calcium deposition. This colorimetric analysis is based on
solubility of the red matrix precipitate with cetylpyridinium chloride (CPC) to
yield a purple solution. At predetermined time points, cell-scaffold constructs
were rinsed free of media with DDI water and fixed for 1 hour with 70%
ethanol at 4°C. Ethanol was removed and constructs were air-dried for 5 –10
minutes. The samples were washed one time with DDI water, and then
covered with 500 µL alizarin red dye for 10 minutes at room temperature.
Samples were then washed with DDI water 5 or more times until no color can
be washed out. Next, 1 milliliter of 10% CPC was added on cellularized
scaffolds and incubated at room temperature for 30 minutes at which point the
color will be stable. The absorbance was read on a plate reader at 562 nm
using TECAN. Samples can be diluted 1:10 in additional CPC if necessary (if
the machine reads “OVER” you can dilute).

7.14.

7.14.1.

Histology

Paraffin-Embedding & Sectioning

7.14.1.1.
•

Materials
Formalin-fixed samples

•

Ethanol (70%, 95%, 100%)

•

Histoclear (National Diagnostics, #HS-200)
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•

Paraplast (Fisher, #23-021-401)

7.14.1.2.
Protocol
After 24 hours of formalin fixation, samples were processed
through the following steps for paraffin-embedding:

7.14.2.

Solution

Time (min)

70% ethanol

20 min

95% ethanol

20 min

95% ethanol

20 min

100% ethanol

20 min

100% ethanol

20 min

100% ethanol

20 min

Histoclear

30 min

Histoclear

30 min

Paraffin

30 min

Paraffin

30 min, 65OC

Poly(Methylmetharylate) (PMMA) Slow Embedding

& Sectioning
7.14.2.1.
•

Materials
Formalin-fixed samples

•

Ethanol (70%, 95%, 100%)

•

Toluene

•

Methylmethacrylate (MMA)
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•

Dibutyl

phthalate

(DP)

containing

increasing

concentrations of the catalyst benzoyl peroxide (BP)
•

Tungsten carbide knife

•

Chromalum-gel coated slides

7.14.2.2.
Protocol
The formalin-fixed bones were stripped of soft tissue and placed
directly in 70% ethanol at 4°C for at least 24 hours. (Bones can be
stored for up to one month at 4°C in 70% ethanol). After 24 hours,
bones were processed in a tissue processor and dehydrated and
cleared according to the following schedule:
Solution

Time(hr)

70% ethanol

1.5

95% ethanol

1.5

95% ethanol

2.0

100% ethanol

3.0

100% ethanol

4.0

100% ethanol

4.0

100% ethanol:toluene (50:50)

4.0

Toluene

3.5

Toluene

2.0

Toluene

2.0
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Bones were subjected to alternating cycles of pressure and
vacuum on the tissue processor in each solution above. Following
dehydration and clearing, bones were infiltrated with a mixture of
85% methylmethacrylate (MMA) and 15% dibutyl phthalate (DP)
containing increasing concentrations of the catalyst benzoyl
peroxide (BP) as follows: MMA I (3 days): 85% MMA, 15%DP;
MMA II (3 days): 85% MMA, 15% DP, 1% BP; MMA III (3
days): 85% MMA, 15% DP, 2.5% BP. Each MMA solution was
stirred at least two hours prior to use. All infiltration was carried
out at 4°C.
Bases for embedding were prepared in 20 ml scintillation
vials containing 3 ml of MMA III polymerized in a 37°C radiant
heat oven. Once infiltration was complete, bones were placed on a
pre-polymerized base of MMA III, covered with freshly made
MMA III, capped tightly and allowed to sit at room temperature
overnight. The next day, the bones were placed in a 37°C radiant
heat oven for four days. Once polymerization was completed,
glass vials were removed from the oven, incubated at -20°C for
one hour and glass was removed by breaking.
Specimen blocks were then trimmed and sanded on a
Buehler Mataserve Grinder-Polisher (Buehler, Lake Bluff, IL) with
60 or 240 grit grinding paper (Carobinmet Special Silicon Carbide
Grinding Paper, Buehler) for course grinding and polishing,
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respectively. Prepared bone blocks were clamped directly into
Reichert-Jung Polycut E Microtome block holder, and trimmed
using a tungsten-carbide knife, D-profile (Delaware Diamond
Knives, Wilmington, DE).

The block face and knife were

moistened with 40% EtOH to facilitate sectioning. Once the area
of the ulnar bone was reached, 7 µm sections were carefully
removed from the knife blade with fine foreceps. Sections were
placed on a 95% ethanol that was on chrome-alum-gel coated
slides, and teased and flattened using a very fine paintbrush.
Sections were covered with a strip of clear plastic and remaining
wrinkles and excess ethanol were removed by rolling over the
plastic with a small roller. Slides were stacked and pressure was
applied using a paper clamp. Sections mounted on chrome-alumgel coated slides were incubated overnight at 37oC to adhere
sections to slide.

The sections for VonKossa staining were

mounted on the Silane-Plus coated slides, and sections for
Trichrome and H&E staining were mounted on charged slides.
Sections were adhered to the slides by overnight incubation at
60°C.

7.14.3.

Histological Staining
Hematoxylin & Eosin Stain

7.14.3.1.

7.14.3.1.1. Materials

•

For paraffin-embedded sections: Xylene/Histoclear
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•

For sMMA-embedded sections: Cellsolve (ethylene glycol
monomethyl ether acetate, Fisher Scientific)

•

Ethanol (100% and 95%)

•

dH2O

•

Hematoxylin (Fisher, #67-650-09)

•

Bluing Solution (Fisher, #67-690-02)

•

Eosin (Fisher, #23-245-658)

•

Mounting Media (Thermo Scientific, #22-110-610)

7.14.3.1.2. Protocol

Solution

Time

Xylene/Histoclear/Cellsolve

25 min

Xylene/Histoclear/Cellsolve

25 min

100% ethanol

5 min

100% ethanol

3 min

95% ethanol

5 min

95% ethanol

3 min

dH2O

2 min

Hematoxylin

1 min

Running tap H2O

Until clear

Bluing Solution

1 min

Running tap H2O

Till clear
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dH2O

2 min

95% Ethanol

2 min

Eosin

30 sec

dH2O

2 min

95% ethanol

3 min

95% ethanol

5 min

100% ethanol

3 min

100% ethanol

5 min

Xylene/Histoclear

3 min

Xylene/Histoclear

5 min

Mounting Media

Coverslip

7.14.3.1.3. Results

7.14.3.2.

•

Nuclei -------------------------------- blue

•

Cytoplasm --------------------------- pink

Masson’s Tri-Chrome Stain

7.14.3.2.1. Materials

•

For paraffin-embedded sections: Xylene/Histoclear

•

For sMMA-embedded sections: Cellsolve (ethylene glycol
monomethyl ether acetate, Fisher Scientific)

•

Ethanol (100% and 95%)

•

dH2O

•

Masson’s Trichrome Staining Kit (Sigma-Aldrich #HT15)
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o Biebrich Scarlet-Acid Fuchsin Solution (0.9%)
o Phosphotungstic Acid Solution (10%)
o Phosphomolybdic Acid Solution (10%)


Prepare

Working

Phosphotungstic/

Phosphomolybdic Acid Solution by mixing
1 volume of Phosphotungstic Acid Solution,
and 1 volume Phosphomolybdic Acid
Solution, with 2 volumes of deionized water.
Discard after one use.
o Aniline Blue Solution (2%)
•

Bouin’s Solution (Sigma-Aldrich, # HT10-1-32)

•

Weigert’s Iron Hematoxylin solution

•

1% Acetic Acid

•

Mounting Media (Thermo Scientific, #22-110-610)

7.14.3.2.2. Protocol

Solutions

Time

Xylene/Histoclear/Cellsolve

25 min

Xylene/Histoclear/Cellsolve

25 min

100% ethanol

5 min

100% ethanol

3 min

95% ethanol

5 min

95% ethanol

3 min

dH2O

2 min
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Bouin’s Solution

15 min, 56oC

Running tap H2O

Until clear

Weigert’s

Iron

Hematoxylin 5 min

Solution
Running tap H2O

Till clear

dH2O

2 min

Biebrich Scarlet-Acid Fucshin

5 min

dH2O

2 min

Phosphotungstic/Phosphomolybdic 5 min
Acid Solution
Aniline Blue Solution

5 min

Acetic Acid

2 min

dH2O

2 min

95% ethanol

3 min

95% ethanol

5 min

100% ethanol

3 min

100% ethanol

5 min

Xylene/Histoclear

3 min

Xylene/Histoclear

5 min

Mounting Media

Coverslip

* Unless indicated otherwise, the step was performed at
room temperature.
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7.14.3.2.3. Results

•

Collagen fibers---------------------------- blue

•

Nuclei-------------------------------------- black

•

Cytoplasm, fibrin, erythrocytes ----------- red

Von Kossa Stain

7.14.3.3.

7.14.3.3.1. Materials

•

For paraffin-embedded sections: Xylene/Histoclear

•

For sMMA-embedded sections: Cellsolve (ethylene glycol
monomethyl ether acetate, Fisher Scientific)

•

1% Aqueous Silver Nitrate Solution

•

5% Sodium Carbonate-Formaldehyde

•

0.1% Nuclear Fast Red Solution

•

Ethanol (100% and 95%)

•

dH2O

•

Mounting Media (Thermo Scientific, #22-110-610)

7.14.3.3.2. Protocol

Solution

Time

Xylene/Histoclear/Cellsolve

25 min

Xylene/Histoclear/Cellsolve

25 min

100% ethanol

5 min

100% ethanol

3 min
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95% ethanol

5 min

95% ethanol

3 min

dH2O

2 min

1% silver nitrate solution

30 min; dark

Running tap H2O

Until clear

5%

sodium

carbonate- 2 min

formaldehyde
Running tap H2O

Till clear

dH2O

2 min

Methyl green pyronin

20 min

dH2O

2 min

95% ethanol

3 min

95% ethanol

5 min

100% ethanol

3 min

100% ethanol

5 min

Xylene/Histoclear

3 min

Xylene/Histoclear

5 min

Mounting Media

Coverslip

7.14.3.3.3. Results

•

Calcium salts ---------- black or brown-black

•

Osteoid ----------------------red or light pink
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7.15.
7.15.1.

Immunohistochemistry
Materials
•

Histoclear or Xylene

•

Ethanol (100%, 95%)

•

Distilled water

•

Dako Target retrevial (S1700, Dako)

•

Hydrogen Peroxide (216763, Sigma-Aldrich)

•

Phosphate buffered saline 1X (Sigma)

•

Bovine Serum Albumin (BSA) (A9418-5G, SigmaAldrich)

•

Primary Antibody

•

Secondary Antibody (HRP-conjugated or fluorescent)

•

Normal

Goat

Serum

(NGS)

(S-1000,

Vector

Laboratories)
•

Blocking Solution (10 mL PBS, 0.05 g BSA)

•

Primary/Secondary Antibody Solution (10 mL PBS,
0.05 g BSA, 300 ul Normal Goat Serum, and 1o
Antibody)

•

TBS plus 0.025% Triton X-100

•

DAB Substrate Kit, 3,3’-diaminobenzidine (SK-4100,
Vector)

•

PAP pen (#ab2601, Abcam)

•

Mounting Media (Thermo Scientific, #22-110-610)
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•
7.15.2.

Coverslips

Protocol

Immunohistochemistry is the localization of antigens or proteins in tissue
sections by the use of labeled antibodies as specific reagents through antigenantibody interactions that are visualized by a marker such as fluorescent dye
or enzyme. Before proceeding with the staining protocol, the slides were
deparaffinized and rehydrated, since incomplete removal of paraffin can cause
poor staining of the section. The slides were placed in Histoclear for 5
minutes, and this was repeated two times. The slides then underwent serial
dehydration. The slides were placed in 100% ethanol for 10 minutes (2
times), and then 95% ethanol for 10 minutes (2 times). The slides were
transferred to distilled water for 5 minutes (2 times), and then antigen retrevial
(Dako Target retrevial) was performed for 5 minutes at 98oC. This step serves
to break the methylene bridges and expose the antigenic sites in order to allow
the antibodies to bind. The slides were then washed 2 times for 5 minutes each
in TBS and 0.025% Triton X-100 with gentle agitation. The slides were
blocked in 10% normal serum with 1% BSA in TBS for 2 hours at room
temperature. The slides were then drained for a few seconds (do not rinse)
and then wiped around the sections with tissue paper. The primary antibody
diluted in TBS with 1% BSA was applied, and incubated overnight at 4°C.
The slides were rinsed 2 times for 5 minutes each in TBS and 0.025% Triton
with gentle agitation. If an HRP conjugate was used for detection, the slides
were incubated in 0.3% H2O2 in TBS for 15 minutes. For enzymatic detection
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(HRP conjugates), HRP-conjugated secondary antibody was applied to the
slide diluted to the concentration recommended by the manufacturer in TBS
with 1% BSA, and incubated for 1 hour at room temperature. For fluorescent
detection, fluorophore-conjugated secondary antibody was applied to the slide
diluted to the concentration recommended by the manufacturer in TBS with
1% BSA, and incubated for 1 hour at room temperature. The slides were
rinsed 3 times for 5 minutes each with TBS. If using fluorescent detection,
the procedure ended at this step and the slides were coversliped with mounting
medium. If visualizing the protein with a chromogen, the slides were
developed with a chromogen (i.e., 3,3'- Diaminobenzidine (DAB)) for 10
minutes at room temperature. The slides were rinsed in running tap water for
5 minutes, and then counterstained with hematoxylin. The slides were then
dehydrated, cleared and mounted with coverslips.

7.16.

Immunocytochemistry

7.16.1.

Materials

7.16.2.

Histoclear or Xylene
•

Ethanol (100%, 95%)

•

Distilled water

•

Dako Target retrevial (S1700, Dako)

•

Hydrogen Peroxide (216763, Sigma)

•

Phosphate buffered saline 1X (Sigma)

•

Bovine Serum Albumin (BSA) (A9418-5G, Sigma)
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•

Primary Antibody

•

Secondary Antibody (HRP-conjugated or fluorescent)

•

Normal Goat Serum (S-1000, Vector Laboratories)

•

Blocking Solution (10 mL PBS, 0.05 g BSA)

•

Primary/Secondary Antibody Solution (10 mL PBS,
0.05 g BSA, 300 ul Normal Goat Serum, and 1o
Antibody)

•

TBS plus 0.025% Triton X-100

•

DAB Substrate Kit, 3,3’-diaminobenzidine (SK-4100,
Vector)

7.16.3.
To

•

PAP pen (#ab2601, Abcam)

•

Mounting Media (Thermo Scientific, #22-110-610)

•

Coverslips

Protocol

examine

cell

expression

of

specific

proteins,

we

performed

immunocytochemistry. First, cells were removed from cell culture, washed
briefly with PBS, and then covered to a depth of 2-3 mm with 2-4%
formaldehyde in PBS for 15 minutes at room temperature. The fixative was
aspirated, and then the cells were rinsed three times in PBS for 5 minutes
each. To permeabilize the cells, the cells were covered with ice-cold 100%
methanol, and incubated in methanol for 10 minutes at –20°C. The specimens
were then incubated with 10% normal blocking serum in PBS for 20 minutes
to suppress non-specific binding of IgG. Blocking serum ideally should be
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derived from the same species in which the secondary antibody is raised. The
specimens were then incubated with primary antibody for 60 minutes.
Optimal antibody concentration should be determined by titration;
recommended range is 0.5–5.0 µg/ml in PBS with 1.5% normal blocking
serum. The specimens were then washed with three changes of PBS for 5
minutes each, and then incubated for 45 minutes with fluorochromeconjugated secondary antibody diluted to 1–5 µg/ml in PBS with 1.5%–3%
normal blocking serum. The specimens were then washed with three changes
of PBS, and incubated with DAPI to stain the nuclei.

The cells were then

covered in multi-well plate with aqueous mounting medium, and viewed
under a fluorescence microscope.

7.17.
7.17.1.

Live/Dead Cell Viability Analysis
Materials
•

Phosphate buffered saline 1X (Sigma)

•

Live/Dead®

Viability/Cytotoxicity

Kit

(#L3224,

Invitrogen)
•

Glass Bottom Dishes, 35 mm uncoated (P35G-1.0-14C, MatTek)

7.17.2.

Protocol

To examine cell viability, we utilized the Live/Dead Viability Kit, which
contains calcein AM and ethidium homodimer-1. Membrane-permeant calcein
AM is cleaved by esterases in live cells to yield cytoplasmic green
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fluorescence, and membrane-impermeant ethidium homodimer-1 labels
nucleic acids of membrane-compromised cells with red fluorescence. The
sample was rinsed with PBS two times, and incubated with Live/Dead
solution (10 milliliters PBS, 4 µl ethidium bromide, 1.25 µl calcien AM) for 1
hour.

The samples were rinsed with once with PBS, and viewed under

fluorescent microscope or confocal microscope (requires sample to be on
Glass Bottom Dishes).

7.18.
7.18.1.

Gene Expression Analysis
RNA Extraction

7.18.1.1.

Materials
• Qiagen RNeasy Mini Kit
o RNeasy Mini Spin Columns (pink)
o Collection Tubes (1.5 ml)
o Collection Tubes (2 ml)
o Buffer RLT (Add 10 µl β-ME per 1 ml Buffer
RLT)
o Buffer RW1
o Buffer RPE (concentrate; add 4 volumes of
ethanol (96–100%) as indicated on the bottle to
obtain a working solution.)
o RNase-Free Water
•

QIAshredder Spin Columns
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•

14.3 M β-mercaptoethanol (β-ME)

•

Sterile, RNase-free pipette tips

•

96–100% ethanol

7.18.1.2.
Protocol
We used Qiagen RNeasy Mini Kit to extract and purify RNA from
cells cultured on scaffolds. First, to directly lyse cells, 0.5 milliliters
of Buffer RLT was added, and then pipetted the lysate directly into a
QIAshredder spin column placed in a 2 ml collection tube, and
centrifuged for 2 min at full speed. 1 volume of 70% ethanol was
added to the homogenized lysate, mixed well by pipetting, transferred
to an RNeasy spin column placed in a 2 ml collection tube, and
centrifuged for 15 seconds at ≥8000 x g (≥10000 RPM). The flowthrough was discarded. If the sample volume exceeded 700 µl,
successive aliquots was centrifuged in the same RNeasy spin column.
The flow-through was discarded after each centrifugation, and 700 µl
Buffer RW1 was added to the RNeasy spin column and then
centrifuged for 15 seconds at ≥8000 x g (≥10000 rpm RPM to wash
the spin column membrane. The flow-through was discarded, and 500
µl Buffer RPE was added to the RNeasy spin column, and then
centrifuged for 15 seconds at ≥8000 x g (≥10000 RPM) to wash the
spin column membrane. The flow-through was discarded, and 500 µl
Buffer RPE was added to the RNeasy spin column, and centrifuged for
2 minutes at ≥8000 x g (≥10000 RPM) to wash the spin column
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membrane.

The RNeasy spin column was placed in a new 2 ml

collection tube, and centrifuged at full speed for 1 minute.

The

RNeasy spin column was placed in a new 1.5 ml collection tube, and
30–50 µl RNase-free water was added directly to the spin column
membrane, and centrifuged for 1 minute at ≥8000 x g (≥10000 RPM)
to elute the RNA. We used the NanoDrop machine to measure the
RNA concentration in each sample. 3 µg of RNA per sample was used
to carry out gene quantification analysis.

7.19.

Quantitative Polymerase Chain Reaction (Q-

PCR)
7.19.1.

Materials
•

Clontech Sprint RT Complete cDNA synthesis kit
(Clontech; Mountain View, CA)

•

BioRad MyiQ2 Two-Color Real-Time PCR Detection
System

•

2x iQ real-time PCR Supermix (BioRad; Hercules, CA)

•

TaqMan® Gene Expression Assay Probes (Applied
Biosystems; Carlsbad, CA)

•

Microseal 96-Well PCR Plates (BioRad; Hercules, CA)

•

iQ real-time PCR Supermix

•

TaqMan® Gene Expression Assay probe (Applied
Biosystems)
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7.19.2.

Protocol

For cDNA synthesis, 2 µg total RNA was used as a template for
Clontech Sprint RT Complete cDNA synthesis kit (Clontech;
Mountain View, CA) in a total volume of 20 µl. For quantitative real
time PCR, BioRad MyiQ2 Two-Color Real-Time PCR Detection
System, 2x iQ real-time PCR Supermix (BioRad; Hercules, CA),
TaqMan® Gene Expression Assay Probes (Applied Biosystems;
Carlsbad, CA) were loaded in Microseal 96-Well PCR Plates (BioRad;
Hercules, CA).

Each well contained 10 µl of iQ real-time PCR

Supermix, 1 ul of TaqMan® Gene Expression Assay probe and 9 µl of
diluted cDNA.

Threshold cycle values of target genes was

standardized against GAPDH expression and normalized to the
expression in the control culture. The –fold change in expression was
calculated using the ∆∆Ct comparative threshold cycle method.

7.20.
7.20.1.

Angiogenic Potential Assays
2D Matrigel Assay

7.20.1.1.

Materials
• BD Matrigel Basement Membrane Matrix High
Concentration (354248, BD Biosciences)
•

Serum-free DMEM

•

Endothelial Growth Media-2 (EGM-2) (Lonza)

207

•

Glass Bottom Dishes, 35 mm uncoated (P35G-1.0-14C, MatTek)

•

Live/Dead®

Viability/Cytotoxicity

Kit

(#L3224,

Invitrogen)
•

Phosphate buffered saline 1X (Sigma)

7.20.1.2.
Protocol
To evaluate the angiogenic potential of endothelial cells, we cultured
the cells on Matrigel, a solid gel of basement proteins prepared from
the Engelbreth Holm-Swarm (EHS) mouse tumor. Cells with high
angiogenic potential will rapidly align and form hollow tube-like
structures. For this, we diluted the Matrigel (stock concentration 20
mg/ml) to 10 mg/ml with serum-free DMEM, and evenly coated glass
bottom 35 mm cell culture dishes with 75 µl of diluted Matrigel, and
incubate for 30 minutes at 37oC. 300 µl cell suspension containing
80,000 cells was plated, and incubated for 5-6 hours. The cells were
stained

with

microscropy.

Live/Dead

staining,

and

imaged

via

confocal

The following criteria were quantified: pattern

recognition, branch point counting, average and total capillary tube
length. For pattern recognition quantification, we assigned numerical
values for specific visual patterns (see below) (adapted from Millipore,
In Vitro Angiogenesis Assay Kit).
Value

Pattern
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Individual cells, well separated

0

Cells begin to migrate and align themselves 1

7.20.2.

Capillary tubes visible. No sprouting.

2

Sprouting of new capillary tubes visible.

3

Closed polygons begin to form.

4

Complex mesh like structures develop

5

3D Matrigel Assay

7.20.2.1.

Materials
• BD Matrigel Basement Membrane Matrix High
Concentration (354248, BD Biosciences)
•

48 well cell culture plate

•

Cell culture media

7.20.2.2.
Protocol
Matrigel was thawed overnight at 4oC on ice. Matrigel was handled
with pre-cooled pipettes, tips, and tubes when preparing for useage,
since Matrigel will gel rapidly at 22oC to 35oC.

Cells were

encapsulated in Matrigel (106 cells/mL Matrigel) by mixing a 1x106
cell suspension in chilled media (750 µl) with 750 µl of Matrigel (20
mg/ml), to make a final concentration of 10 mg/ml of Matrigel. 500 µl
of this Matrigel/cell suspension mixture was seeded into each well in a
48-well plate. 3 samples per group were seeded, and cultured in a 1209

to-1 mixture of osteogenic and angiogenic medium for 7 days in 48
well cell culture plates. The following twelve sample groups were
studied: PB-EPCs alone; BM-EPCs alone; MSCs:PB-EPCs co-culture
ratios of 1:4, 1:2, 1:1, 2:1, and 4:1; and MSCs:BM-EPCs co-culture
ratios of 1:4, 1:2, 1:1, 2:1, and 4:1. Three-dimensional samples (10
mm diameter, 2 mm height) were paraffin-embedded, sectioned and
then stained with hematoxylin and eosin. Four samples per group
were embedded, and three sections per sample were stained (one from
top, middle and bottom; approximately 200 µm apart from each other).
Stained sections were analyzed under the light microscope Olympus
BX50 with Olympus DP70 camera. Twelve images viewed under 10X
magnification, and the number of branches were counted for each
sample.

7.21.
7.21.1.

Flow Cytometry
Materials
•

1x106 cell suspension (for each marker of interest)

•

BD

Cytofix/Cytoperm™

BD

Cytofix/Cytoperm™

Fixation/Permeabilization Solution Kit (#554714, BD
Bioscience)
•

BD Pharmingen™ Stain Buffer (FBS) (#554656, BD
Bioscience)
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•

BD Perm/WashTM buffer (#554723, BD Bioscience)

•

Live/Dead Fixable Stain in Far Red (#L10120,
Invitrogen)

7.21.2.

•

Primary antibody

•

Fluorochrome-conjugated secondary antibody

Protocol

Flow cytometry (FCM) is a technique that may be used for counting and
examining surface and intracellular proteins on cells.
7.21.2.1.
Surface Staining Cells
To examine one cell surface marker, a sample of cells in suspension
containing at least 1 × 106 cells was centrifuged. The supernatant was
discarded, and the cells were washed once with 1 milliliter of Staining
Buffer, and the resuspended in 1 milliliter of Staining Buffer
containing 1 µL of the reconstituted fluorescent reactive dye. The
suspension was incubated at room temperature or on ice for 30
minutes, protected from light, and then washed with 1 milliliter of
Staining Buffer and resuspended in 50 µl of Staining Buffer. The cell
suspension of ~106 cells in 50 µl of Staining Buffer was then stained
with the appropriate amount of a primary antibody specific for 30
minutes at 4°C.

The excess antibody was washed off following

staining, and 1.5-2 milliliters of Staining buffer was added to each
tube, and centrifuged 5 minutes at 2000 RPM. The supernatant was
aspirated, and 100 µl of staining buffer was added to each tube, and
then 0.5-1 µg of the fluorochrome-conjugated secondary antibody. The
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sample was vortexed and incubated for 15-30 minutes in a covered ice
bucket.

To wash off excess antibody following staining, 1.5-2

milliliters of staining buffer was added to each tube and then
centrifuged in tabletop microfuge for 5 minutes at 2000 RPM. The
supernatant was aspirated off, and the cells were resuspended in 250 µl
for tubes of Fixation/Permeabilization solution for 20 min. at 4°C.
(Note: Cell aggregation is avoided by vortexing prior to the addition of
the Fixation/Permeabilization solution.) The cells were washed two
times in 1× BD Perm/WashTM buffer (e.g., 1 milliliters /wash for
staining in tubes) and pellet. (NOTE: BD Perm/WashTM buffer must
be maintained in washing steps to keep cells permeabilized.)
Resuspend in Staining Buffer prior to flow cytometric analysis.

7.21.2.2.
Intracellular Staining Cells
A sample of cells in suspension (> 1 × 106 cells) was centrifuged, and
the supernatant was discarded. The cells were washed once with 1
milliliter of Staining Buffer. The cells were resuspended in 1 milliliters
of Staining Buffer containing1 µL of the reconstituted fluorescent
reactive dye, and then incubated at room temperature or on ice for 30
minutes, protected from light. The cells were washed with 1 milliliters
of

Staining

Buffer,

and

then

resuspended

in

250

µl

Fixation/Permeabilization solution for 20 minutes at 4°C. The cells
were washed two times in 1× BD Perm/WashTM buffer (e.g., 1
milliliters/wash for staining in tubes) and pellet.
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(NOTE: BD

Perm/WashTM buffer must be maintained in washing steps to keep
cells permeabilized.) The cells were resuspended in 50 µl of BD
Perm/WashTM Buffer, and then stained the ~106 cells in 50 µl of BD
Perm/WashTM buffer with the appropriate amount of a primary
antibody specific for 30 min at 4°C. To wash off excess antibody
following staining, 1.5-2 milliliters of BD Perm/WashTM buffer was
added to each tube, and then centrifuged for 5 minutes at 3000-4000
RPM for intracellular staining. The supernatant was aspirated off, and
100 µl of BD Perm/WashTM buffer was added to each tube with 0.5-1
µg fluorochrome-conjugated secondary antibody. The sample was
vortexed and incubated for 15-30 minutes in a covered ice bucket. To
wash off excess antibody following staining, 1.5-2 milliliters of BD
Perm/WashTM buffer was added to each tube, and centrifuged in a
tabletop microfuge for 5 minutes at 2000 RPM (or 3000-4000 RPM
for intracellular staining). The sample was then resuspended in 400 µl
Staining Buffer prior to flow cytometric analysis.

7.22.
7.22.1.

Western Blot Analysis
Materials
•

CellLytic M buffer and Protease Inhibitor (Sigma)

•

4-15% Tris-HCl Ready Gels

•

Laemmli Sample Buffer

•

Mini-PROTEAN Tetra System

213

•

10x Tris/Glycine/SDS Buffer

•

Precision Plus Protein Dual Color Standard

•

10x Tris/Glycine Buffer

•

Mini Trans-Blot Electrophoresis Transfer Cell

•

Blot Papers

•

0.2 µm Nitrocellulose Membrane

•

TBS-T solution (10x Tris-Buffered Saline, 0.1%
Tween-20)

7.22.2.

•

10% milk/TBS-T solution

•

Primary and secondary antibodies

•

Super Signal West Pico Chemiluminescent Substrate

•

CL-XPosure Film

Protocol

CellLytic M buffer and Protease Inhibitor (Sigma; St. Louis, MO) were
added to cells and then incubated at 4°C for 30 minutes. Cells were removed
by mechanical scrapping and spun down at 10,000 rpm for 5 minutes. Protein
concentrations were measured using BCA Protein Assay Kit and the
absorbance of the samples were measured at 562 nm after 30 minute
incubation at 37°C. Each sample was prepared with Laemmli Sample Buffer
and samples were boiled for 5 minutes. 25 µg of each sample were run on 415% Tris-HCl Ready Gels for western blot protein electrophoresis.

Mini-

PROTEAN Tetra System, 10x Tris/Glycine/SDS Buffer, Precision Plus
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Protein Dual Color Standard were used and gels were run at a constant 100
volts. Gels were transferred at a constant 100 Volts for 2 hours using 10x
Tris/Glycine Buffer, Mini Trans-Blot Electrophoresis Transfer Cell, Blot
Papers and 0.2 µm Nitrocellulose Membrane. Membranes were blocked for 2
hours at 4°C in 10% milk/TBS-T solution (10x Tris-Buffered Saline, 0.1%
Tween-20).

Membranes were washed with TBS-T solution after each

incubation. Membranes were incubated overnight with primary antibodies
diluted in 5% milk/TBS-T solution at 4°C. Membranes were incubated for 45
minutes with secondary antibody diluted in 5%milk/TBS-T solution at 4°C
and then washed three times with TBS-T. Super Signal West Pico
Chemiluminescent Substrate was used for detection, and CL-XPosure Film
was used for exposure of the membranes. All reagents and materials for
western blot analysis were purchased from BioRad (Hercules, CA) unless
otherwise indicated.

7.23.
7.23.1.

Animal Models
SCID Mouse Subcutaneous Implant Model

Fox Chase CB17 SCID® (Severe Combined Immunodeficiency) male
mice (Charles River Laboratories, Cambridge, MA), ages 50–56 days were
used for the mouse subcutaneous implant model. Prior to surgery, animals
were given 0.05-0.1 mg/kg Buprenorphine subcutaneous for pre-operative
analgesia. Animals were anesthetized with an intraperitonial injection of a
mixture of ketamine (90-120 mg/kg body wt) and xylazine (5-10 mg/kg body
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wt) given IP. After the animals were fully anesthetized, the surgical site on
animals (dorsum) was shaved and cleaned with 70% ethanol, betadine and
again with 70% ethanol. Two subcutaneous pouches were created bilaterally
of the dorsal side (i.e., both the sides of the spine) by making incisions
approximately 2.5 cm long using blunt dissection techniques, and a sterile
polymer scaffold will be inserted into each pouch.
Post-surgery, animals were kept in recovery cages placed on heating pads
and under warm light to maintain body temperature, which was monitored
with a rectal thermometer every 15-20 minutes until recovery. The animals
were administered Buprenorphine (0.05-0.1 mg/kg SQ) twice per day 8-10
hours apart for up to 48 hours and then as needed to minimize pain post
surgery. The following signs of pain were monitored: lack of grooming,
sitting haunched up in a corner of the cage, rapid and shallow breathing,
reaching less frequently for food and water. Furthermore, the surgical wounds
were evaluated daily during the first postoperative week for the presence of
infection or dehiscence.

At pre-determined time-points, animals were

sacrificed by CO2 narcosis followed by cervical dislocation.

7.23.2.

New Zealand White Rabbit Ulnar Critical-Size Bone

defect Model
New Zealand White male rabbits (4-5 kg) from Millbrook Breeding Labs
(Amherst, MA, USA) were used to perform the rabbit ulnar critical-size bone
defect model. Animals were housed with ad libitum access to food and water
prior to surgery. A dose of 0.01-0.05 mg/kg buprenorphine was given IM
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approximately 1 hour prior to, 5-10 mg/kg Xylazine given IM 10 min prior
to, and 33 – 35 mg/kg Ketamine IM. Sedation was confirmed through ear/toe
pinch. Sedation was maintained during surgery with 0.5-2% isoflurane.
Sterile surgical technique and sterile fields was maintained at all times
prior to and during surgery. Briefly, protective lubricant was applied to eyes
of the rabbit, and an ear catheter was placed for administration of IV fluids
(i.e., Normosol R, Lactated Ringers) during anesthesia at approximately
10ml/kg/hr. Rabbits were then intubated. Once intubated, isoflurane 0.5-2%
was initiated and maintained through the surgical procedure. The surgical site
on the animal was shaved, cleaned with 70% ethanol, betadine, and 70%
ethanol again, and then placed on a sterile drape and the area around the
surgical site covered with sterile drapes. The surgeon wore a sterile gown, and
gloves and will wear a face mask, eye shield, and cap. The instruments were
autoclaved at 121oC for 15 minutes to ensure sterility. Instruments were
opened within the sterile field. Between surgeries on different animals,
unused, sterile instruments were used. A surgical hypothermia unit that uses
circulating warm water was placed under the rabbit during surgery.
Under sterile conditions, a lateral incision approximately 2.5 centimeters
long was made and the tissue overlying the ulna was dissected. A 1.5 cm
segmental osteoperiosteal defect was created in the middle of the ulna using
an oscillating saw. The defect was filled with the construct, and the soft
tissues was closed in layers, using resorbable sutures to close muscle tissue.
The skin was approximated and closed using 3-0 absorbable sutures.
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Subcuticular suturing with buried knots will be employed to minimize or
prevent chewing of the surgical area, along with surgical glue. The overlying
skin was also be closed with non-degradable sutures.
After the surgical procedure was complete, animals were kept in the
recovery room. Pain will be will be monitored through frequent observations:
grinding of teeth, lack of grooming, sitting hunched up in a corner of the cage,
rapid and shallow breathing, reaching less frequently for food and water.
When the animal was ready to be extubated, a 25mcg fentanyl patch was
applied to a shaved area over the dorsal neck/interscapular region. The patch
was maintained at therapeutic levels for 72 hours, at which time it was either
be removed or replaced. If there was an unexpected time lapse, then another
dose of buprenex was administered to fill the gap until patch fentanyl is
absorbed (which may take up to 8 hours). All animals were weighed once per
week. Animals were housed with access to food and water ad libitum. Post op
analgesia was considered for up to 5-6 days if needed. Animals were given
hay cubes, bunny blocks, and fresh produce to stimulate appetite or for
environmental enrichment.
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8.

APPENDIX 2 - List Of Publications
8.1.

RESEARCH PAPERS:

Amini AR, Adams D, Laurencin CT, Nukavarapu SP. Optimally Porous and
Biomechanically Compatible Scaffolds for Large Area Bone Regeneration.
Tissue Engineering. 2012 Apr 16. [Epub ahead of print].

Amini AR, Laurencin CT, Nukavarapu SP. (2012)

Differential analysis of

peripheral blood- and bone marrow-derived endothelial progenitor cells for
enhanced vascularization in bone tissue engineering. J Orthop Res. 2012 Feb 29.
[Epub ahead of print].

Nukavarapu SP, Amini AR. (2011) Optimal scaffold design and effective
progenitor cell identification for the regeneration of vascularized bone. Conf Proc
IEEE Eng Med Biol Soc. 2011: 2464-7.

Latres E, Amini AR, Amini AA. et al. (2005) Insulin-like Growth Factor (IGF-1)
Inversely Regulates Atrophy-induced Genes via the Phosphatidylinositol 3Kinase/Akt/Mammalian Target of Rapamycin (PI3K/Akt/mTOR) Pathway.
Journal of Biological Chemistry. 280 (4): 2737-44.

8.2.

REVIEW ARTICLES:
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Amini AR, Laurencin CT, Nukavarapu SP. Bone Tissue Engineering: Recent
Advances and Challenges. Crit Reviews BME. [in review].

Amini AR, Wallace JS, Nukavarapu SP. (2011) Short-term and long-term effects
of orthopedic biodegradable implants. J Long Term Eff Med Implants. 21(2):93122.

8.3.

BOOK CHAPTERS:

Igwe J, Amini AR, Mickael P, Nukavarapu SP, Laurencin CT. Nanostructured
scaffolds for Bone Tissue Engineering. In: Zilberman M, editor. Studies in
Mechanobiology,

Tissue

Engineering

and

Biomaterials.

Verlag

Berlin

Heidelberg: Springer; 2011.

8.4.

ABSTRACTS:

Amini AR, Laurencin CT, Nukavarapu SP. Development and Evaluation of
Optimized Scaffolds Pre-seeded with Effective Progenitor Combination for
Vascularized Bone Regeneration.

Orthopaedic Research Society (ORS)

Conference. San Francisco, CA. February 4-7, 2012.

Igwe J, Amini AR, Nukavarapu SP. Fabrication and Evaluation of a Novel
Scaffold System with High-Density Cell Seeding for Bone Regeneration: An
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Investigation of Cell Density Enhanced Osteogenic Expression. Orthopaedic
Research Society (ORS) Conference. San Francisco, CA. February 4-7, 2012.

Amini AR, Laurencin CT, Nukavarapu SP. Comparative Analysis of Endothelial
Progenitor Cells Isolated from Peripheral Blood and Bone Marrow for Enhanced
Vascularization in Bone Tissue Engineering Applications. Tissue Engineering
and Regenerative Medicine Society (TERMIS) Conference.

Houston, TX.

December 11-14, 2011.

Mikael PE, Amini AR, Igwe J, Nukavarapu SP. Carbon Nanotubes composite
scaffolds for Bone Tissue Engineering: Mechanical and In Vivo Investigation.
Biomedical Engineering Society (BMES) Conference. Hartford, CT. October 1215, 2011.

Nukavarapu SP, Amini AR. Optimal Scaffold Design and Effective Progenitor
Cell Identification for the Regeneration of Vascularized Bone.

33rd Annual

International Conference of the IEEE Engineering in Medicine and Biology
Society. Boston, MA. August 30-September 3, 2011.

Amini AR, Laurencin CT, Nukavarapu SP. Design and Characterization of Fully
Osteoconductive Scaffolds for Homogeneous and Enhanced Bone Regeneration.
Society for Biomaterials Conference. Orlando, Florida. April 13-16, 2011.
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Amini AR, Mikael P, Adams D, Laurencin C, Nukavarapu S. Design and
Characterization of Fully Osteoconductive Scaffolds for Homogeneous and
Enhanced Bone Regeneration. Orthopaedic Research Society (ORS) Conference.
Long Beach, California. January 13-16, 2011.
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